GESTATIONAL DIABETES A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright ©2004 by ICON Group International, Inc. Copyright ©2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Gestational Diabetes: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83956-5 1. Gestational Diabetes-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on gestational diabetes. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON GESTATIONAL DIABETES .......................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Gestational Diabetes ................................................................... 25 E-Journals: PubMed Central ....................................................................................................... 66 The National Library of Medicine: PubMed ................................................................................ 67 CHAPTER 2. NUTRITION AND GESTATIONAL DIABETES .............................................................. 113 Overview.................................................................................................................................... 113 Finding Nutrition Studies on Gestational Diabetes .................................................................. 113 Federal Resources on Nutrition ................................................................................................. 118 Additional Web Resources ......................................................................................................... 119 CHAPTER 3. ALTERNATIVE MEDICINE AND GESTATIONAL DIABETES ........................................ 121 Overview.................................................................................................................................... 121 National Center for Complementary and Alternative Medicine................................................ 121 Additional Web Resources ......................................................................................................... 125 General References ..................................................................................................................... 126 CHAPTER 4. DISSERTATIONS ON GESTATIONAL DIABETES .......................................................... 127 Overview.................................................................................................................................... 127 Dissertations on Gestational Diabetes ....................................................................................... 127 Keeping Current ........................................................................................................................ 128 CHAPTER 5. CLINICAL TRIALS AND GESTATIONAL DIABETES..................................................... 129 Overview.................................................................................................................................... 129 Recent Trials on Gestational Diabetes ....................................................................................... 129 Keeping Current on Clinical Trials ........................................................................................... 130 CHAPTER 6. PATENTS ON GESTATIONAL DIABETES ..................................................................... 133 Overview.................................................................................................................................... 133 Patents on Gestational Diabetes ................................................................................................ 133 Patent Applications on Gestational Diabetes............................................................................. 137 Keeping Current ........................................................................................................................ 140 CHAPTER 7. BOOKS ON GESTATIONAL DIABETES ........................................................................ 141 Overview.................................................................................................................................... 141 Book Summaries: Federal Agencies............................................................................................ 141 Book Summaries: Online Booksellers......................................................................................... 143 The National Library of Medicine Book Index ........................................................................... 144 Chapters on Gestational Diabetes .............................................................................................. 144 CHAPTER 8. MULTIMEDIA ON GESTATIONAL DIABETES .............................................................. 147 Overview.................................................................................................................................... 147 Video Recordings ....................................................................................................................... 147 Audio Recordings....................................................................................................................... 149 CHAPTER 9. PERIODICALS AND NEWS ON GESTATIONAL DIABETES ........................................... 151 Overview.................................................................................................................................... 151 News Services and Press Releases.............................................................................................. 151 Academic Periodicals covering Gestational Diabetes................................................................. 156 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 157 Overview.................................................................................................................................... 157 U.S. Pharmacopeia..................................................................................................................... 157 Commercial Databases ............................................................................................................... 158 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 161 Overview.................................................................................................................................... 161 NIH Guidelines.......................................................................................................................... 161
viii Contents
NIH Databases........................................................................................................................... 163 Other Commercial Databases..................................................................................................... 167 APPENDIX B. PATIENT RESOURCES ............................................................................................... 169 Overview.................................................................................................................................... 169 Patient Guideline Sources.......................................................................................................... 169 Finding Associations.................................................................................................................. 178 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 181 Overview.................................................................................................................................... 181 Preparation................................................................................................................................. 181 Finding a Local Medical Library................................................................................................ 181 Medical Libraries in the U.S. and Canada ................................................................................. 181 ONLINE GLOSSARIES................................................................................................................ 187 Online Dictionary Directories ................................................................................................... 189 GESTATIONAL DIABETES DICTIONARY............................................................................ 191 INDEX .............................................................................................................................................. 241
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with gestational diabetes is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about gestational diabetes, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to gestational diabetes, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on gestational diabetes. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to gestational diabetes, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on gestational diabetes. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON GESTATIONAL DIABETES Overview In this chapter, we will show you how to locate peer-reviewed references and studies on gestational diabetes.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and gestational diabetes, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “gestational diabetes” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Impact of Social Support and Stress on Compliance in Women With Gestational Diabetes Source: Diabetes Care. 13(4): 441-443. April 1990. Summary: Adherence to medical recommendations is especially important in gestational diabetes because of the health implications for both the pregnant woman and the fetus. This study examined adherence with two daily self-management tasks, diet and insulin administration, in 98 women with gestational diabetes. The influence of stress and regimen related social support on adherence was also investigated. Results indicate that the level of reported adherence was high for both insulin administration and diet. Fewer minor stressors and greater social support were associated with greater adherence. 2 tables. 8 references. (AA-M).
4
Gestational Diabetes
•
Physical and Glycemic Responses of Women with Gestational Diabetes to a Moderately Intense Exercise Program Source: Diabetes Educator. 16(4): 309-312. July-August 1990. Contact: Available from American Association of Diabetes Educators. 100 West Monroe, 4th floor, Chicago, IL 60603. (800) 338-3633 or (312) 424-2426. Fax (312) 424-2427. Summary: Aerobic exercise machines are becoming more popular. Their use by women with gestational diabetes is reported, as well as a substantiation of their benefits in improving blood glucose management and in increasing maternal fitness without undue stress to the fetus. Of equal benefit is the use of an exercise specialist to prescribe an individual exercise program to increase the safety and effectiveness of the workout, to monitor maternal and fetal well-being, to record relevant data, and to provide feedback and information to the patient about the exercise session. The use of exercise specialists in the clinical setting should prove a useful adjunct to medical and dietary regimens for the woman with gestational diabetes. 3 tables. 12 references. (AA).
•
Race-Ethnicity and Other Risk Factors for Gestational Diabetes Source: American Journal of Epidemiology. 135(9): 965-973. May 1, 1992. Summary: Although gestational diabetes (GDM) is estimated to complicate between 1 and 5 percent of pregnancies, there are only limited data on the role of race/ethnicity as well as other risk factors in the development of this disorder. This article reports on a study in which the epidemiologic characteristics of gestational diabetes were assessed in an ethnically diverse cohort of 10,187 women who had undergone standardized screening for glucose intolerance and who delivered a singleton infant at the Mount Sinai Medical Center in New York City between January 1987 and December 1989. The overall prevalence of gestational diabetes was 3.2 percent. The data suggests that, after controlling for traditional risk factors (maternal age, prepregnancy weight, and a family history of diabetes), Orientals, first generation Hispanics, women from the Indian subcontinent and the Middle East, those with a history of infertility, and low socioeconomic status women are at an increased risk for gestational diabetes. 5 tables. 24 references.
•
Sweet Taste and Intake of Sweet Foods in Normal Pregnancy and Pregnancy Complicated by Gestational Diabetes Mellitus Source: American Journal of Clinical Nutrition. 70(2): 277-284. August 1999. Contact: Available from American Journal of Clinical Nutrition. Production Office, 9650 Rockville Pike, Bethesda, MD 20814. (301) 530-7038. Fax (301) 571-8303. Website: www.ajcn.org. Summary: Dietary compliance in gestational diabetes mellitus (GDM) is poor. Changes in sweet taste perception might alter food preferences in GDM, making dietary compliance difficult to achieve. This study documented changes in sweet taste perception and dietary intakes in pregnancy women with and without GDM and determined whether these differences persisted postpartum (after the pregnancy). Subjects were 30 pregnant women without GDM, 25 pregnancy women with recently diagnosed GDM, and 12 nonpregnancy control subjects. Pregnancy women were tested at 28 to 32 weeks gestations and retested 12 weeks postpartum. Subjects evaluated the taste of strawberry flavored milks with different sucrose (0 to 10 percent) and fat (0 to 10 percent) contents and glucose solutions. Women with GDM showed no differences in liking for the milk samples across test sessions and their liking ratings were not
Studies
5
significantly different from those of nonpregnant control subjects. Women without GDM liked the 10 percent sucrose sweetened milk samples less during pregnancy that at 12 weeks postpartum, at which time their ratings were not significantly different from those of nonpregnant control subjects. In women with GDM, plasma glucose after a 50 gram glucose load was correlated with both increased liking for the taste of glucose and higher consumption of fruit and fruit juices. The authors summarize that normal pregnancy was associated with a lower preference for 10 percent sucrose sweetened milk samples late in gestation than postpartum, whereas GDM was associated with no such differences. Plasma glucose in women with GDM was related to a higher preference for the sweet taste of glucose and higher dietary sweet food intakes from fruit and fruit juices. These findings have important implications for the dietary management of GDM. 3 figures. 2 tables. 37 references. •
Gestational Diabetes: Clinical Management Guidelines for ObstetricianGynecologists Source: Obstetrics and Gynecology. 98(3): 525-538. September 2001. Contact: Available from Elsevier Science, Inc. 655 Avenue of the Americas, New York, NY 10010. (212) 989-5800. Summary: Gestational diabetes mellitus (GDM) is one of the most common clinical issues facing obstetricians and their patients. A lack of data from well-designed studies has contributed to the controversy surrounding the diagnosis and management of this condition. This document provides a brief overview of the understanding of GDM and then provides management guidelines that have been validated by appropriately conducted clinical research. When outcomes based research is not available, expert opinion is provided to aid the practitioner. The background section covers definition and prevalence, maternal and fetal complications of GDM, and controversies regarding current screening practices and treatment benefits. Clinical considerations and recommendations are provided for: screening for GDM, gestational age at which laboratory screening should be performed, the use of venous versus capillary blood, appropriate threshold values for laboratory screening tests, the diagnosis of GDM, monitoring blood glucose values in women with GDM, the role of diet therapy in the treatment of GDM, the role of insulin in the treatment of GDM, the role of exercise and oral antidiabetic agents in the treatment of GDM, fetal assessment in pregnancies complicated by GDM, childbirth considerations in pregnancies complicated by GDM, and postpartum follow up of women who had GDM during their pregnancy. The article concludes with a summary of recommendations, categorized by those based on research studies and those based on consensus and expert opinion. 2 tables. 105 references.
•
Gestational Diabetes: What and Why Source: Living Well with Diabetes. 5(1): 11-12. Winter 1990. Summary: Gestational diabetes occurs in three to five percent of all pregnancies. Early symptoms of the disease primarily consist of a 'strange' feeling after eating foods high in sugar. Screening for gestational diabetes is performed through routine blood tests. When results of several blood tests show higher than normal levels, precise diagnosis is made by administering a glucose tolerance test. After diagnosis, treatment mainly consists of balancing the diet to maintain a blood glucose level of 60 to 120 mg/dl throughout the day. Self monitoring of the blood glucose level is performed using a meter. These measures serve to protect the infant from complications of the disease, including macrosomia, hypoglycemia, respiratory distress syndrome,
6
Gestational Diabetes
hyperbilirubinemia, and stillbirth, as well as protecting the mother from toxemia. After delivery, the mother's blood glucose level should be monitored, since up to 60 percent of women with gestational diabetes will develop Type II diabetes later in life. •
Prevalence of Gestational Diabetes Mellitus Detected by the National Diabetes Data Group or the Carpenter and Coustan Plasma Glucose Thresholds Source: Diabetes Care. 25(9): 1625-1630. September 2002. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: In 2000, the American Diabetes Association (ADA) proposed the adoption of the Carpenter and Coustan criteria for diagnosis of gestational diabetes mellitus (GDM). The Carpenter and Coustan cutoffs are lower than the previously recommended National Diabetes Data Group (NDDG) values and would result in higher prevalence of GDM. This article describes a study that estimated the magnitude of change in prevalence of GDM using the Carpenter and Coustan thresholds as compared with the NDDG thresholds by age and ethnicity. The cross-sectional study included 28,330 women aged 14 to 49 years who gave birth in 1996 and were members of the Northern California Kaiser Permanente Medical Care Program. Age, ethnicity, screening, and diagnostic test results were assessed from computerized hospitalization and laboratory systems. A total of 26,481 women (94 percent of the original sample) were screened and 4,190 women underwent a diagnostic glucose tolerance tests after an abnormal screening result. Overall, the GDM prevalence among screened women was 3.2 percent by NDDG and 4.8 percent by Carpenter and Coustan criteria, and based on either threshold, it increased with age. The age-adjusted GDM prevalence by NDDG and Carpenter and Coustan criteria, respectively, was 5.0 and 7.4 percent in Asians, 3.9 and 5.6 percent in Hispanics, 3.0 and 4.0 percent in African-Americans, and 2.4 and 3.8 percent in whites. The authors conclude that this information would be useful for clinical settings in predicting cost of GDM based on demographic characteristics of the population. 3 tables. 39 references.
•
Gestational Diabetes Mellitus: Is It a Clinical Entity? Source: Diabetes Reviews. 3(4): 602-613. 1995. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: In this article, the authors demonstrate that gestational diabetes mellitus (GDM) is not merely a clinical sign but a disease, a distinct clinical entity, with short-and long-range implications for both mother and offspring. Evidence supports the hypothesis that certain developing tissues and organs in the fetus of the mother with diabetes may receive an imprint that affects fetal neural cells, adipocytes, muscle cells, and pancreatic beta-cells. During the third trimester, the proliferation of these tissues and organs is the basis for the development later in life of obesity or NIDDM. Metabolic alterations during delivery are responsible for transient neonatal metabolic complications, such as hypoglycemia, hypocalcemia, and hypomagnesemia. Fetal hyperinsulinemia leads to a decreased level of arterial oxygen and an increase in plasma erythropoietin concentration. The chronic hypoxemic state in utero may explain some cases of intrauterine fetal death, as well as fetal polycythemia, hyperbilirubinemia, and renal vein thrombosis. These complications, together with the increased rate of labor complications and cesarean sections, contribute to the higher maternal morbidity and
Studies
7
mortality among patients with diabetes as well as a high risk of diabetes later in life. 2 figures. 9 tables. 99 references. (AA-M). •
Non-Insulin-Dependent Diabetes Mellitus and Gestational Diabetes Mellitus: Same Disease, Another Name? Source: Diabetes Reviews. 3(4): 566-583. 1995. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: In this article, the authors review the evidence that suggests that gestational diabetes mellitus (GDM) and noninsulin-dependent diabetes mellitus (NIDDM) are etiologically indistinct. The authors outline observations that provide a powerful argument that hyperglycemia detected for the first time in pregnancy actually represents an unveiling of preexisting metabolic abnormalities that characteristically precede the development of NIDDM. GDM thus may represent an early stage in the natural history of NIDDM. Diagnosis of GDM therefore assumes importance for two reasons. First, it will identify patients in whom aggressive glycemic control will prevent perinatal complications. Second, diagnosis of GDM also will identify patients who may benefit from early therapeutic intervention to prevent the development of NIDDM and associated complications later in life. 15 figures. 5 tables. 219 references. (AA-M).
•
Gestational Diabetes: Ensuring a Successful Outcome Source: Postgraduate Medicine. 99(3): 165-166, 171-172. March 1996. Summary: In this article, the fourth in a series of four articles on diabetes, the authors describe risk factors, methods of diagnosis, and a plan of management. The management plan includes a nutrition program based on American Diabetes Association nutrition guidelines, use of insulin if needed, self-monitoring of glucose levels, and appropriate exercise. The authors note that patients with gestational and pregestational diabetes are among the most ambitious and compliant patients in their resolve to manage their diabetes. Physicians can qualify for continuing medical education credits by taking the posttest following this article. 2 tables. 14 references. (AA-M).
•
Diagnosis and Management of Gestational Diabetes Mellitus Source: Clinical Diabetes. 13(2): 32-39. March-April 1995. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: In this review article, the author discusses the diagnosis and management of gestational diabetes mellitus (GDM). The author summarizes the etiology of hyperglycemia during pregnancy; discusses the rationale for normalizing the glucose level if hyperglycemia occurs; and describes one protocol that has proven to be successful in achieving and maintaining normo-glycemia during pregnancy. Specific topics include the role of early pregnancy-related hormones; the development of GDM; the complications of hyperglycemia to the fetus; a diet prescription for pregnant women with diabetes; the screening and diagnosis of GDM; the criteria for initiating insulin therapy in a woman with GDM; exercise as a treatment strategy for GDM; followup visits; the timing of delivery; labor and delivery; neonatal care; and postpartum maternal insulin requirements. 6 tables. 31 references.
8
Gestational Diabetes
•
Total Sialic Acid and Associated Elements of the Metabolic Syndrome in Women with and Without Previous Gestational Diabetes Source: Diabetes Care. 25(8): 1331-1335. August 2002. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: Inflammatory markers predict type 2 diabetes and relate to the metabolic syndrome (also known as the insulin resistance syndrome). Gestational diabetes mellitus (GDM) predicts type 2 diabetes and may be part of this syndrome. This article reports on a study undertaken to examine the association of inflammatory markers with GDM, in which the authors investigated total sialic acid (TSA) in women with and without previous GDM. All women with GDM and a random sample of women from one center of the Brazilian Study of Gestation Diabetes were invited to return 7 years after their index pregnancy. After an interview, an oral glucose tolerance test and anthropometry were performed. A total of 46 women with and 50 women without previous GDM completed the protocol. Mean TSA was significantly higher in women with previous GDM than without previous GDM. TSA was strongly correlated with individual components and aggregates of the metabolic syndrome. These findings in young women suggest that a chronic mild systemic inflammatory response is an early feature of the metabolic syndrome and that GDM may be a window for its investigation. 1 figure. 3 tables. 27 references.
•
Diagnosis of Gestational Diabetes: Are New Criteria Needed? Source: Diabetes Reviews. 3(4): 614-620. 1995. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: Many different criteria are used for diagnosing gestational diabetes mellitus (GDM) throughout the world. The author of this article calls for the development of new standards of diagnosis that are based upon outcomes directly relevant to the pregnancy and that will be universally accepted. Different populations should be expected to manifest differing prevalence rates, just as for NIDDM and IDDM. Criteria should take into account the changes in glucose metabolism brought about by pregnancy and should be validated by their predictive value for pregnancy outcome. The author discusses existing criteria; the continuum of carbohydrate intolerance; and population-specific criteria. 2 tables. 52 references. (AA-M).
•
Association of a Woman's Own Birth Weight with Subsequent Risk for Gestational Diabetes Source: JAMA. Journal of the American Medical Association. 287(19): 2534-2541. May 15, 2002. Summary: Several studies have reported links between reduced fetal growth and subsequent risk for type 2 diabetes among adults, but the association between indices of fetal growth and gestational diabetes mellitus (GDM), a major complication of pregnancy and a strong predictor of type 2 diabetes, remains little explored. This article reports on a study undertaken to test the hypothesis that a woman's own fetal growth is inversely related to her later risk for GDM. The results demonstrated that birth weight showed a U-shaped relationship to a woman's risk of GDM in her first pregnancy, with the highest risks associated with low and high birth weights. After adjustment for potential confounding factors, the odds ratio for low birth weight women was 4.23,
Studies
9
compared to odds ratio of 0.92 for high birth weight, leaving a strong inverse doseresponse relationship between birth weight and risk of GDM (low birth weight translates into a higher risk of experiencing GDM). The authors briefly discuss how early life factors, including those in utero, may be important in the etiology (cause) of GDM. 2 figures. 3 tables. 60 references. •
Preparing the Woman with Gestational Diabetes for Self-Care: Use of a Structured Teaching Plan by Nursing Staff Source: JOGNN. Journal of Obstetric, Gynecologic and Neonatal Nursing. 20(3): 189-193. May-June 1991. Summary: Staff nurses are expected to teach patients with gestational diabetes (GDM) effectively, but studies indicate that nurses are often uncertain about what information to teach and what teaching methods to use. This article reviews and outlines the components of the Structured Teaching Plan, developed by the authors to guide staff nurses in teaching patients with GDM. The tool provides reinforcement of content and objective evaluation, thereby assisting the patient to overcome learning barriers. The authors focus on the implementation and evaluation of the Teaching Plan, providing a day-by-day curriculum to use with patients. 14 references. (AA-M).
•
Maternal Plasma Phospholipid Polyunsaturated Fatty Acids in Pregnancy with and without Gestational Diabetes Mellitus: Relations with Maternal Factors Source: American Journal of Clinical Nutrition. 70(1): 53-61. July 1999. Contact: Available from American Journal of Clinical Nutrition. Production Office, 9650 Rockville Pike, Bethesda, MD 20814. (301) 530-7038. Fax (301) 571-8303. Website: www.ajcn.org. Summary: The fatty acids arachidonic acid (AA) and docosahexaenoic acid (DHA) are essential for fetal grown and development, but their metabolism may be altered in insulin resistance. This article reports on a study of maternal plasma (blood) phospholipid polyunsaturated fatty acid concentrations in pregnancy women receiving diet therapy for gestational diabetes mellitus (GDM, n = 15); the study identified maternal factors associated with plasma phospholipid AA and DHA concentrations in the third trimester. The study included a control group of 15 healthy, pregnancy women without GDM. Maternal plasma phospholipid linoleic acid, AA, and 22:5n-6 (another fatty acid) did not differ significantly between women with GDM and control subjects. The other n-6 long chain polyunsaturated fatty acids were lower in GDM subjects than in control subjects. Plasma phospholipid and summed precursors of DHA were lower and DHA adjusted for dietary DHA intake, was 13 percent higher in GDM subjects than in control subjects. Maternal blood hemoglobin A1c (glycosylated hemoglobin, a measure of blood glucose levels over time) was inversely related to plasma phospholipid AA in control subjects and positively associated with plasma phospholipid AA in women with GDM. Pregravid (before pregnancy) body mass index was negatively associated with plasma phospholipid DHA in control subjects and in women with GDM with a body mass index less than 30. The authors conclude that, in pregnancy women, both with and without GDM, maternal glycemic control and pregravid BMI appear to be significant predictors of plasma phospholipid AA and DHA, respectively, during the third trimester. Additionally, dietary DHA significantly affects phospholipid DHA concentrations. 5 tables. 34 references.
10
Gestational Diabetes
•
Is Self-Monitoring of Blood Glucose Necessary in the Management of Gestational Diabetes Mellitus? Source: Diabetes Care. 21(Supplement 2): B118-B122. August 1998. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article addresses the issue of whether self-monitoring of blood glucose (SMBG) is necessary for managing gestational diabetes mellitus (GDM). Controversy continues over the role of blood glucose monitoring in the management of pregnant women with GDM, specifically with regard to the use of capillary versus venous samples, as well as the frequency and timing of blood glucose determinants. At the Third International Workshop Conference, it was noted that self-monitoring has allowed women to participate in their own care but that its utility in mild GDM not requiring the use of insulin has not been formally proved. The article reviews the existing evidence in the literature on the impact of SMBG on outcomes in pregnancies complicated by GDM. This evidence suggests a role for the self-monitoring of capillary blood glucose in pregnancies complicated by even mild GDM. The article also presents data on the optimal timing, accuracy, costs, and psychosocial effects of self-monitored glucose determinations and concludes that SMBG provides important information on guiding and assessing dietary and insulin therapy in pregnancies complicated by GDM. Furthermore, it enhances patient education, facilitates lifestyle modifications, and allows women to actively participate in their own care. SMBG has been shown to improve neonatal outcomes in pregnancies complicated by GDM without apparently causing undue stress for the mother and at a potentially lower cost. However, the optimal management scheme of blood glucose monitoring and the appropriate threshold of glucose values for initiating insulin therapy have yet to be firmly established. 38 references. (AA-M).
•
Do Gestational Diabetes Criteria Need Revision? Source: Emergency Medicine. 24(4): 266, 268. March 15, 1992. Summary: This article addresses the need for revision of the gestational diabetes criteria as established by the American College of Obstetricians and Gynecologists (ACOG). Topics include how the guidelines were established in 1964; methods of measuring serum glucose; treatment of gestational diabetes with dietary modification; and selective screening. The article also reports on a research study conducted on 103 pregnant women who had at least two abnormal serum glucose values on the 100-gm glucose challenge; 64 of these women also met the current ACOG criteria for gestational diabetes.
•
Hormonal Choices After Gestational Diabetes: Subsequent Pregnancy, Contraception, and Hormone Replacement Source: Diabetes Care. 21(Supplement 2): B50-B55. August 1998. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article assesses the effects of subsequent states of excess hormone exposure, that is, subsequent pregnancy, hormonal contraception, and hormonal replacement therapy, on the development of diabetes in women with prior gestational diabetes mellitus (GDM). The article reviews current literature on the effect of parity, hormonal contraception, and hormonal replacement therapy in healthy women and
Studies
11
women with previous gestational diabetes and current diabetes. Subsequent pregnancy in women with prior GDM appears to triple the risk of subsequent diabetes, while lowdose progestin and estrogen combination oral contraceptives do not appear to clinically increase risk. Hormonal replacement therapy appears to lead to the greatest reduction in coronary artery disease in women at greatest risk, that is, those who have developed diabetes. Careful followup and metabolic surveillance should be provided when prescribing hormonal contraception or replacement therapy. In women with prior GDM, exposure to repeat pregnancy poses a greater risk for subsequent diabetes than either an exposure to low-dose progestin and estrogen combination oral contraceptives or to postmenopausal hormonal therapy, both of which do not appear to increase the risk of diabetes. Women must be educated about their individual risk of developing diabetes based on their identifiable risk factors. In addition, their general health status, including any cardiovascular risk factors, should be evaluated. 27 references. (AA-M). •
Gestational Diabetes: What are the Implications? Source: Postgraduate Medicine. 91(5): 393-400, 402. April 1992. Summary: This article considers the implications of gestational diabetes, including the merits of screening tests for all pregnant women. Topics discussed include diagnostic testing and screening; the management of gestational diabetes, notably diet monitoring metabolic control, and insulin use; obstetric management issues; metabolic management during labor; postpartum management; and how gestational diabetes develops. The authors note that glucose tolerance must be reevaluated in the postpartum period and periodically thereafter to detect continuing intolerance or diabetes. 3 tables. 41 references.
•
Comparison of Glyburide and Insulin in Women with Gestational Diabetes Mellitus Source: New England Journal of Medicine. 343(16): 1134-1138. October 19, 2000. Summary: This article describes a study that compared glyburide and insulin in the treatment of women with gestational diabetes. The study population consisted of 404 women with singleton pregnancies and gestational diabetes that required treatment. The women were randomly assigned between 11 and 33 weeks of gestation to receive glyburide or insulin according to an intensified treatment protocol. The primary end point was achievement of the desired level of glycemic control Secondary end points included maternal and neonatal complications. The study found that the mean pretreatment blood glucose concentration as measured at home for one week was 114 plus or minus 19 milligrams (mg) per deciliter (dl) in the glyburide group and 116 plus or minus 22 mg per dl in the insulin group. The mean concentrations during treatment were 105 plus or minus 16 mg/dl in the glyburide group and 105 plus or minus 18 mg per dl in the insulin group. Eight women in the glyburide group required insulin therapy. There were no significant differences between the glyburide and insulin groups in the percentage of infants who were large for gestational age, who had macrosomia, who had lung complications, who had hypoglycemia, who were admitted to a neonatal intensive care unit, or who had fetal anomalies. The cord serum insulin concentrations were similar in the two groups, and glyburide was not detected in the cord serum of any infant in the glyburide group. The article concludes that, in women with gestational diabetes, glyburide is a clinically effective alternative to insulin therapy. 4 tables. 49 references. (AA-M).
12
Gestational Diabetes
•
Exercise as a Treatment Modality to Maintain Normoglycemia in Gestational Diabetes Source: Journal of Perinatal and Neonatal Nursing. 6(1): 14-24. June 1992. Summary: This article discusses a study that used exercise as a treatment modality for gestational diabetes mellitus (GDM). The authors describe the study and then apply Orem's self-care model of nursing to the clinical findings. The authors provide a literature review, a discussion of the research methodology, and the results. They draw two conclusions: diet and exercise, if properly supervised and prescribed, may serve as alternatives to insulin in controlling GDM; and women who are normally sedentary can safely begin an exercise program (supervised) during pregnancy. The article concludes with a discussion of the nursing considerations for helping patients with GDM achieve optimal levels of self-care. 2 figures. 41 references.
•
Gestational Diabetes Mellitus: Diagnosis, Treatment, and Beyond Source: Diabetes Educator. 27(1): 69-72, 74. January-February 2001. Contact: Available from American Association of Diabetes Educators. 100 West Monroe Street, 4th Floor, Chicago, IL 60603-1901. (312) 424-2426. Summary: This article discusses the diagnosis and treatment of gestational diabetes mellitus (GDM). Early recognition and treatment are critical to a successful outcome for both mother and infant. GDM is defined by the American Diabetes Association (ADA) as any degree of glucose intolerance with onset or first recognition during pregnancy. A risk assessment for GDM during the first prenatal visit is important. The ADA recommends screening and the 100-gram oral glucose tolerance test for diagnosing GDM. Daily self monitoring of blood glucose can be used to determine the effectiveness of diet, exercise, and insulin in maintaining target blood glucose goals. Medical nutrition therapy is used to ensure that the woman is consuming adequate calories and nutrients for maternal and fetal health. An individualized meal plan can be developed by the patient and a registered dietitian. Exercise is vital for maintaining euglycemia because regular exercise enhances insulin sensitivity and glucose utilization. Human insulin is the only pharmacologic treatment recommended to lower blood glucose during pregnancy. Postpartum care is important because approximately 40 percent to 60 percent of women with GDM will develop type 2 diabetes. 4 tables. 4 references.
•
Risk and Prevention of Type 2 Diabetes in Women with Gestational Diabetes Source: Diabetes Care. 21(Supplement 2): B43-B49. August 1998. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article discusses the risk and prevention of type 2 diabetes in women with gestational diabetes mellitus (GDM). Women with a history of GDM are at increased risk of future diabetes, predominantly type 2, as are their children. The extent of this risk depends both on the diagnostic criteria used to identify GDM and on maternal risk factors, some of which are potentially modifiable whereas others are not. The unmodifiable risk factors are ethnicity, prepregnancy weight, age, parity, family history of diabetes, and degree of hyperglycemia in pregnancy and immediately postpartum. The modifiable risk factors are persistent obesity, future weight gain, and subsequent pregnancies. Additional modifiable risk factors in these women are likely to be levels of physical activity, dietary fat, and avoidance of other lifestyle factors that adversely influence insulin resistance, such as smoking and certain drugs. Strategies to
Studies
13
prevent diabetes need to address the modifiable risk factors and use the unmodifiable risk factors to identify women most at risk. In addition, women need to understand the potential benefits to be gained from complying with the lifestyle changes likely to be required to prevent type 2 diabetes. This can occur only through education, which must be both comprehensible and culturally relevant. 1 figure. 87 references. (AA-M). •
Stress and Intervention in Gestational Diabetes Source: Diabetes Professional. p. 28, 32, 34. Spring 1990. Summary: This article emphasizes skills that can be used in teaching and counselin g women with gestational diabetes. It includes results and insights gained from a study in which 25 patients with gestational diabetes completed the Psychosocial Adjustment to Illness Scale (PAIS). The PAIS yields information regarding patients' anxiety levels, coping mechanisms, family support, and perception of their medical treatment since the onset of illness. The author stresses the importance of immediate intervention to ease the fears of the patient and her family and to provide the best possible outcome for the pregnancy. 1 table.
•
Epidemiology of Glucose Intolerance and Gestational Diabetes in Women of Childbearing Age Source: Diabetes Care. 21(Supplement 2): B9-B13. August 1998. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article examines epidemiological data on gestational diabetes mellitus (GDM) from several sources. Available data suggest that the frequency of diabetes in pregnancy is highly variable, generally reflecting the underlying pattern of type 2 diabetes in the particular population. Different ethnic groups in the same environmental setting experience widely variable risk. Impaired glucose tolerance is usually more prevalent than diabetes in women of childbearing age. Maternal age, overweight, parity, and family history of diabetes all predispose to GDM. Incidence is low in the absence of risk factors, suggesting that selective screening programs may be cost-effective. Adverse outcome may be more frequent in women with impaired glucose tolerance than in women with normal tolerance. Programs to reduce the incidence of subsequent type 2 diabetes in women who have GDM may be cost effective to health services and improve the quality of life for those concerned. The worldwide epidemic of glucose intolerance predicted by the latest World Health Organization studies will undoubtedly increase the burden of GDM, especially in developing countries. 3 figures. 6 tables. 24 references. (AA-M).
•
Etiology and Pathogenesis of Gestational Diabetes Source: Diabetes Care. 21(Supplement 2): B19-B26. August 1998. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article focuses on the knowledge that has been generated on the pathogenesis of gestational diabetes mellitus (GDM) since the Third WorkshopConference on GDM. Although a significant amount of information has been gathered, it is still not known why GDM develops in 2 to 3 percent of all pregnant women. Similar frequencies of HLA-DR2, the-DR3, and-DR4 antigens in healthy pregnant women and women with GDM and the low prevalence of markers for autoimmune destruction of
14
Gestational Diabetes
beta cells in GDM pregnancy rule out the possibility that GDM is a disease of autoimmune origin. Insulin secretion during an oral glucose tolerance test (OGTT) or a meal is substantially increased in women with GDM compared with the same women postpartum. However, insulin secretion increases less in women with GDM than in pregnant women who retain normal glucose tolerance. Peak insulin concentrations during an OGTT occur later in women with GDM, and following intravenous glucose, a reduced first-phase insulin response is also seen in these women. Second-phase insulin responses are similar in pregnant women with normal glucose tolerance and GDM. Excessive secretion of proinsulin, which does not always return to normal postpartum, is often observed in women with GDM. This might reflect beta cells that are stressed because they are trying to counter the decreased insulin sensitivity that develops during pregnancy. Thus, insulin sensitivity decreases by 50 to 70 percent in both normal and GDM pregnancy, but whereas insulin sensitivity returns to normal postpartum in pregnant women with normal glucose tolerance, this is not always the case in patients with GDM. Insulin receptor binding to target tissues is largely unaffected by normal and GDM pregnancy, as is basal and insulin-stimulated insulin receptor-bound tyrosine kinase activity. Although there is indication that certain post-insulin receptor binding events are altered in tissues from women with GDM, data are still scarce. In addition, the impact of various pregnancy-related hormones on beta cell function or peripheral tissue sensitivity to insulin remains to be investigated. 3 tables. 105 references. (AA-M). •
Gestational and Pre-Gestational Diabetes: Comparison of Maternal and Fetal Characteristics and Outcome Source: International Journal of Gynecology and Obstetrics. 58(2): 203-209. August 1997. Contact: Available from Elsevier Science. P.O. Box 945, New York, NY 10159-0945. (888) 437-4636 or (212) 633-3730. Fax (212) 633-3680. E-mail:
[email protected]. Summary: This article is based on a study designed to determine the incidence of maternal and fetal complications of gestational diabetes mellitus (GDM) and compare such pregnancies with pre-gestational diabetes mellitus (pre-GDM) and non-diabetic pregnancies. Researchers analyzed the prenatal and intrapartum complications of 972 women with GDM, 71 women with pre-GDM, 8,904 women in the control group, and the offspring of all participants. Maternal complications included higher incidences of cesarean section and perineal lacerations in GDM and pre-GDM patients than in the non-diabetic pregnancies. In addition, there were higher rates of macrosomia and hypoglycemic episodes in the offspring of GDM and pre-GDM offspring. The authors conclude that because GDM and pre-GDM have a similar incidence of maternal, fetal, and neonatal complications, they should be monitored and managed identically. 3 tables. 24 references. (AA-M).
•
Gestational Diabetes: A Triage Model of Care for Rural Perinatal Providers Source: American Journal of Obstetrics and Gynecology. 174(6): 1719-1724. June 1996. Contact: Available from Mosby-Year Book, Inc. 11830 Westline Industrial Drive, St. Louis, MO 63146-3318. (800) 453-4351 or (314) 453-4351. Fax (415) 259-5019. E-mail:
[email protected]. Summary: This article is based on an effort to develop a protocol for surveillance, diagnosis, and management of diet-controlled gestational diabetes for rural care providers. While the California Diabetes and Pregnancy ('Sweet Success') Program (CDAPP) provides outpatient-based comprehensive educational, psychosocial, and medical services to pregnant women, the majority of women in California do not have
Studies
15
access to a CDAPP affiliate clinic. Researchers developed protocols for medical, nutritional, educational, and psychosocial education and treatment. After a diabetes educator, registered dietitian, and social worker provided on-site protocol training to rural providers, researchers collected data on maternal-fetal outcome, birth weight, and provider time specific to diabetes. The control group had multidisciplinary care according to California Diabetes and Pregnancy Program protocols. With the exception of time spent for diabetes care, there was no significant difference in outcome between the 39 protocol patients and 48 controls. The pilot providers averaged 4.3 hours and control providers 5.6 hours. The results of the study suggest that rural providers who have appropriate training and protocol guidelines can effectively supply comprehensive care to women with diet-controlled gestational diabetes. Patients with transportation restrictions would have improved access to care, and the need for referral of approximately 78 percent of all women with gestational diabetes would be reduced. A discussion section concludes the article. 4 figures. 14 references. (AA-M). •
Nutritional Management of Gestational Diabetes and Nutritional Management of Women with a History of Gestational Diabetes: Two Different Therapies or the Same? Source: Clinical Diabetes. 17(4): 170-176. 1999. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article offers practical suggestions for the nutritional management of gestational diabetes mellitus (GDM) and nutritional management of women with a history of GDM. GDM, which is the most common medical complication of pregnancy, is defined as carbohydrate intolerance of varying degrees of severity with onset or first recognition during pregnancy. Women who have GDM have a significant risk of developing GDM with a subsequent pregnancy and of developing type 2 diabetes later in life. Nutritional management is the cornerstone of treatment for GDM. Medical nutrition therapy for GDM is discussed in terms of optimal maternal weight gain; ideal caloric intake; and amount, timing, and distribution of carbohydrate intake. Other topics include self monitoring of blood glucose, testing for ketones, keeping records of all food and caloric beverages consumed, exercising, breastfeeding, and following up 6 to 12 weeks postpartum. In addition, the article addresses the issues of caring for women with a history of GDM and identifying nutritional factors influencing recurrence of GDM and progression to type 2 diabetes. The article recommends that nutrition therapy start with a modest carbohydrate level distributed among three meals and three snacks, exercise be used as an adjunct to treatment if possible to help maintain maternal euglycemia, and insulin be added to the treatment regimen if necessary. In addition, the article advises that practitioners who have chosen to use a carbohydrate level of less than 45 percent of kcal be sure to educate and evaluate postpartum whether the woman has switched to a low fat diet and has maintained the low fat diet. 1 figure. 4 tables. 37 references.
•
Euglycemic Control of Gestational Diabetes Mellitus by Specific Dietary Manipulation: A Case Study Presentation Source: Diabetes Educator. 17(6): 460-465. November/December 1991. Summary: This article presents a case review of a 32-year-old white woman with gestational diabetes whose condition was complicated by her blood glucose intolerance to lactose in milk. Topics include dietary treatment for gestational diabetes; the role of the nurse educator; the role of the registered dietitian; and ongoing management and
16
Gestational Diabetes
delivery issues. The authors note that, by following a carefully monitored regimen using specific dietary manipulation to maintain normoglycemia, the woman was able to deliver a normal, healthy baby by spontaneous vaginal delivery. A form on which to record daily blood glucose and ketone tests is included. 1 figure. 4 tables. 11 references. (AA-M). •
Historical Perspective on Gestational Diabetes Source: Diabetes Care. 21(Supplement 2): B3-B4. August 1998. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article presents a historical perspective on gestational diabetes. Extreme fetal macrosomia occurred in the first recorded case of diabetes in pregnancy in November 1823. A German woman was admitted to a Berlin hospital at 7 months into her fifth pregnancy with unquenchable thirst, excessive urination, weakness, dry skin, cold face, and back pain. From about 32 to 36 weeks, she had a recurrent sore throat and increased abdominal distention. In late December, the woman had an obstructed labor, and the child, who weighed 12 pounds, died intrapartum. Postpartum, the woman's strength improved daily, and sugar disappeared from her urine. The belief that the diabetic condition was in some way a symptom of the pregnancy, which dates to this first report, has led to the more recent concept of gestational diabetes. Lesser degrees of maternal hyperglycemia were also recognized to be a risk to the baby, and early studies of carbohydrate intolerance in pregnancy in Boston, MA, and Los Angeles, CA, have set the stage for the worldwide interest in this interaction between mother and fetus. 18 references. (AA-M).
•
Harmony and Health: A Workshop on Gestational Diabetes for Native Health Workers Source: Beta Release. 14(4): 101-104. December 1990. Summary: This article reports on a one and a half day workshop held in La Ronge, Saskatchewan, on gestational diabetes in the native population. The learners were Community Health Workers (CHWs) and Community Health Representatives (CHRs) who act as a liaison between the people in their community and various health professionals. The educators focused on three topics: meal planning, blood testing, and regular check-ups. The integration of teaching principles and the use of various teaching aids enhanced the learning sessions. The authors give both background information about diabetes in the native population as well as a description of the northern communities and the available health resources. They also discuss the program goals for the workshop, the principles used to meet these goals, and the specific teaching strategies used. 4 figures. 9 references. (AA-M).
•
Comparison of an Insulin Analog, Insulin Aspart, and Regular Human Insulin With No Insulin in Gestational Diabetes Mellitus Source: Diabetes Care. 26(1): 183-186. January 2003. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article reports on a study that assessed the short-term efficacy of insulin aspart in comparison with regular human insulin in women with gestational diabetes mellitus (GDM) during standardized meal tests. The study included 15 women with
Studies
17
GDM who had inadequate diabetes control with diet alone. On 3 consecutive days, breakfast meal tests were performed: the first with no exogenous insulin and the other two after the injection of either regular insulin or insulin aspart. The peak insulin concentration was higher and the peak glucose and C-peptide concentrations were lower with both insulin preparations than with no exogenous insulin. The authors conclude that this study demonstrates that effective postprandial glycemic control in women with GDM who required insulin was brought about by insulin aspart through higher insulin peak and lower demand on endogenous insulin secretion. 2 figures. 3 tables. 17 references. •
Effects of a Partially Home-Based Exercise Program for Women With Gestational Diabetes Source: Obstetrics and Gynecology. 89(1): 10-15. January 1997. Summary: This article reports on a study to examine the effectiveness of a partially home-based, moderate intensity aerobic exercise program for women with gestational diabetes (GDM). Thirty-three women with GDM were randomly assigned to the exercise or the no-exercise group. Subjects underwent hemoglobin A1c assay and submaximal cycle ergometer fitness tests at baseline and at study conclusion. Subjects kept diaries of home fasting and 2-hour postprandial blood glucose determinations. Exercise subjects were asked to exercise for 30 minutes three to four times weekly at 70 percent of estimated maximal heart rate for the weeks of study participation. Two exercise sessions weekly were supervised by the investigator, and two were unsupervised at home. Control group subjects were asked to maintain their current activity level. Results showed that daily fasting and postprandial blood glucose levels, hemoglobin A1c, incidence of exogenous insulin therapy, and incidence of newborn hypoglycemia were not different between the groups. There was a training effect in the exercise group, but not in the control group. A significant decline in the daily grams of carbohydrate consumed was observed in the control group, but not in the exercise group. No complications were found in the subjects who exercised. The authors conclude that this partially home-based exercise program did not reduce blood glucose levels, but did result in a modest increase in cardiorespiratory fitness. The intervention appeared safe. 3 tables. 38 references. (AA-M).
•
Did Publication of a Clinical Practice Guideline Recommendation to Screen for Type 2 Diabetes in Women with Gestational Diabetes Change Practice? Source: Diabetes Care. 26(2): 265-268. February 2003. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article reports on a study undertaken to determine whether women with previous gestational diabetes mellitus (GDM) were screened postpartum for type 2 diabetes according to the Canadian Diabetes Association (CDA) guidelines. The 1998 CDA guidelines recommend that all women diagnosed with GDM be screened postpartum for type 2 diabetes using a 2 hour, 75-gram oral glucose tolerance test (OGTT). There were 131 women in 1997 and 123 women in 2000 with confirmed GDM. Of these, only 69 women in 1997 and 52 women in 2000 had blood work recorded in the database. None of these women had an OGTT performed in either period. The authors found a significant increase in the measurement of serum glucose (50 women preguideline or 72.1 percent versus 48 women or 92.3 percent post-guideline) and glycosylated hemoglobin (HbA1c, a measure of blood glucose over time). The authors
18
Gestational Diabetes
conclude that, in the region studied, physicians are not following the CDA recommendations to screen women with GDM postpartum with an OGTT. However, they did find a significant increase in the measurement of serum glucose and HbA1c. Publication of expert opinion-based guidelines did not change the postpartum use of an OGTT in these women but may have increased the use of less reliable screening tests for type 2 diabetes. 1 figure. 2 tables. 22 references. •
Gestational Diabetes and the Incidence of Type 2 Diabetes Source: Diabetes Care. 25(10): 1862-1868. October 2002. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article reports the results of a study that examined factors associated with variation in the risk for type 2 diabetes in women with prior gestational diabetes mellitus (GDM). The authors reviewed articles published between January 1965 and August 2001, in which subjects underwent testing for GDM and then testing for type 2 diabetes after delivery. A total of 28 studies were examined. After the index pregnancy, the cumulative incidence of diabetes ranged from 2.6 percent to over 70 percent in studies that examined women 6 weeks postpartum to 28 years postpartum. Differences in rates of progression between ethnic groups was reduced by adjustment for various lengths of follow up and testing rates, so that women appeared to progress to type 2 diabetes at similar rates after a diagnosis of GDM. Cumulative incidence of type 2 diabetes increased markedly in the first 5 years after delivery and appeared to plateau after 10 years. An elevated fasting glucose level during pregnancy was the risk factor most commonly associated with future risk of type 2 diabetes. The authors conclude that targeting women with elevated fasting glucose levels during pregnancy may prove to have the greatest effect for the effort required. 2 figures. 1 table. 55 references.
•
Carbohydrate and Lipid Metabolism in Pregnancy: Normal Compared with Gestational Diabetes Mellitus Source: American Journal of Clinical Nutrition. 71(5 Supplement): 1256S-1261S. May 2000. Contact: Available from American Journal of Clinical Nutrition. Production Office, 9650 Rockville Pike, Bethesda, MD 20814. (301) 530-7038. Fax (301) 571-8303. Website: www.ajcn.org. Summary: This article reviews maternal metabolic strategies for accommodating fetal nutrient requirements in normal pregnancy and in gestational diabetes mellitus (GDM). Pregnancy is characterized by a progressive increase in nutrient stimulated insulin responses despite an only minor deterioration in glucose (sugar) tolerance, consistent with progressive insulin resistance. The hyperinsulinemic (too much insulin in the blood) euglycemic (ideal levels of blood glucose) glucose clamp technique and intravenous glucose tolerance test have indicated that insulin action in late normal pregnancy is 50 to 70 percent lower than in nonpregnant women. Metabolic adaptations do not fully compensate in GDM and glucose intolerance ensures. GDM may reflect a predisposition to type 2 diabetes or may be an extreme manifestation of metabolic alterations that normally occur in pregnancy. Recent advances in understanding carbohydrate metabolism during pregnancy suggest that preventive measures should be aimed at improving insulin sensitivity in women predisposed to GDM. Further research is needed to elucidate the mechanisms and consequences of alterations in lipid (fats) metabolism during pregnancy. 49 references.
Studies
•
19
Gestational Diabetes: When the Pregnant Woman Becomes Diabetic Source: Joslin Magazine. 6(3): 3-7. Winter 1991. Contact: Available from Joslin Diabetes Center. One Joslin Place, Boston, MA 02215. (617) 732-2560. Summary: This article reviews the condition of gestational diabetes. Topics include a definition of gestational diabetes; risk factors for developing gestational diabetes; how the health care provider tests for gestational diabetes, including a glucose tolerance test; how gestational diabetes is treated; the role of self-monitoring of blood glucose (SMBG) and the use of insulin in women with gestational diabetes; other tests performed on the woman with gestational diabetes; delivery problems; the risk of subsequently developing noninsulin-dependent diabetes; the risks of poorly controlled gestational diabetes for the mother; and the effects of gestational diabetes on the unborn child.
•
Gestational Diabetes Mellitus Screening Tests: A Review of Current Recommendations Source: Journal of Perinatal and Neonatal Nursing. 6(1): 37-42. June 1992. Summary: This article reviews the current recommendations for gestational diabetes mellitus (GDM) screening tests. Topics include patient selection for screening; preconceptional testing; the role of screening in early pregnancy; the 3-hour glucose tolerance test; the role of glycosylated hemoglobin; the significance of glycosuria; and follow-up of women with GDM. The author stresses that early recognition and management of gestational diabetes decreases the incidence of macrosomia and infant morbidity and mortality. 17 references.
•
From Diagnosis to Home Management: Nutritional Considerations for Women With Gestational Diabetes Source: Diabetes Educator. 17(6): 455-459. November/December 1991. Summary: This article reviews the nutritional considerations for women with gestational diabetes (GD). Topics include the psychosocial aspects of a diagnosis with GD; learning the self-care and management concepts; follow-up patient education for meal planning and nutrition, including teaching about portion control, hidden sugars in foods and medicine, and how to deal with special occasions such as holiday meals, travel, and illness; and special educational opportunities, including home videos, telephone support networks, special childbirth classes for women with gestational diabetes, and luncheon meetings at which nutritionally correct meals are served. 1 figure. 16 references. (AA-M).
•
Maternal Glycemic Criteria for Insulin Therapy in Gestational Diabetes Mellitus Source: Diabetes Care. 21(Supplement 2): B91-B98. August 1998. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article reviews the results of 58 original studies addressing criteria for insulin management in gestational diabetes mellitus (GDM). In the past decade, it has become clear that GDM is a clinical entity associated with perinatal mortality and morbidity. The level of glycemic control and its evaluation through self-monitoring of blood glucose are the foundation for ascertaining optimal pregnancy outcome. The article addresses the criteria for insulin initiation, including insulin requirements for the
20
Gestational Diabetes
GDM patient, identification of the patient who will benefit from insulin therapy, the timing of insulin initiation, and the patient's behavioral adjustment and compliance during insulin therapy. The article recommends that patients whose fasting plasma glucose on the oral glucose tolerance test (OGTT) is less than 96 milligrams (mg) per deciliter (dL) be assigned to diet therapy. Obese women or those with fasting plasma glucose in excess of 95 mg per dL on the OGTT should be referred to insulin therapy to minimize exposure of the fetus to a hyperglycemic environment during the diet trial. This, in conjunction with patient education on the importance of glycemic control, improves patient compliance, which in turn optimizes the management approach. 3 figures. 2 tables. 61 references. (AA-M). •
Reducing the Risks in Gestational Diabetes Source: Emergency Medicine. 22(3): 113-114, 116. February 15, 1990. Summary: This article stresses that the incidence of perinatal death or malformation at birth caused by the maternal hyperglycemic of gestational diabetes can be reduced by timely detection and careful control of the problem, both before and during labor. Topics covered include screening guidelines, risk factors for gestational diabetes, the use of the 100-gm, three-hour glucose tolerance test for diagnosis, the initial treatment regimen for gestational diabetes, the use of insulin in gestational diabetes, and considerations for delivery, including the risks of ketoacidosis. (AA-M).
•
Gestational Diabetes: State of the Union Source: Diabetes Care. 15(5): 716-717. May 1992. Summary: This brief article presents a commentary on the Third International Workshop-Conference on Gestational Diabetes Mellitus, held in Chicago in November of 1990. The author summarizes the work of each of the four panels formed at the conference: diagnosis and prevalence, perinatal implications, long-range implications, and management strategies. Specific recommendations for universal screening procedures are noted. Other topics include the role of lipids and amino acids in fetal growth, the association of gestational diabetes with increased risk of later overt diabetes in the mother, the use of self-monitoring of blood glucose as standard treatment in women with gestational diabetes, nutritional therapy, and insulin therapy. 1 reference.
•
Oral Hypoglycemic Drugs for Gestational Diabetes (editorial) Source: New England Journal of Medicine. 343(16): 1178-1179. October 19, 2000. Summary: This editorial comments on the use of oral hypoglycemic drugs for the treatment of gestational diabetes. Early use of first generation sulfonylurea drugs was not effective, as many women delivered infants with profound and prolonged hyperinsulinemic hypoglycemia. The observation that sulfonylurea drugs could cross the placenta and stimulate fetal insulin secretion was another cause for concern about their use in pregnancy. The risk of late fetal death for women with gestational diabetes is another concern that has been debated. Lastly, there has been concern about the possibility of congenital malformations in women taking sulfonylurea drugs during pregnancy. However, a recent randomized, controlled trial comparing the sulfonylurea drug glyburide with traditional insulin therapy found that only 4 percent of women in the glyburide group failed to achieve adequate blood glucose control. In addition, there was no evidence of any of complications resulting from fetal or neonatal hyperinsulinemia due to transplacental passage of the drug. The editorial considers the implications of these findings for clinical practice. 10 references.
Studies
•
21
Gestational Diabetes: Strategies for Management Source: Diabetes Spectrum. 5(1): 17-53. January-February 1992. Summary: This From Research to Practice section of Diabetes Spectrum focuses on th e strategies for managing gestational diabetes mellitus (GDM). The first research article presents the summary and recommendations of the Third International WorkshopConference on Gestational Diabetes Mellitus and the second article discusses the criteria for the oral glucose tolerance test in pregnancy. The summary and commentary section discusses insulin sensitivity in pregnancy, metabolic alterations in adulthood in individuals who underwent intrauterine development in mothers with mild diabetes, the long-term prospective evaluation of the offspring of mothers with diabetes, obstetric complications of GDM, the energy requirements of pregnancy, the metabolic effects of hypocaloric diets in managing GDM, and exercise in gestational diabetes. Each article in the section includes references.
•
Gestational Diabetes Mellitus: Practical Applications in Varied Practice Settings Source: On the Cutting Edge: Diabetes Care and Education. 13(6): 1-32. Fall-Winter 1992. Contact: Available from Anne M. Gallagher, RD. DCE Newsletter Editor, 1248 Elm Court, Glenview, IL 60025. Summary: This issue of On the Cutting Edge focuses on gestational diabetes mellitus (GDM). Written primarily for and by registered dietitians, the articles address such topics as weight gain in pregnancy; calorie requirements in GDM; carbohydrates and GDM; ketone management in GDM; insulin therapy in GDM; nutrition process and outcome review criteria; the meter loan program; nutrition reimbursement in GDM; one experience in GDM and malpractice; and GDM case studies. A final section lists and annotates eight resources on gestational diabetes. A post-test is included to receive continuing education credits.
•
Gestational Diabetes: Detection, Management and Implications Source: Clinical Diabetes. 16(1): 4-11. January-February 1998. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This review article addresses the detection, management, and implications of gestational diabetes. The authors note that gestational diabetes is the most common medical complication and metabolic disorder of pregnancy. It is defined as any degree of glucose intolerance with onset or first recognition during pregnancy. Topics include pathophysiology; maternal morbidity; perinatal morbidity and mortality; diagnosis; management; delivery timing; and postpartum follow up. Treatment for gestational diabetes includes diet therapy, glucose monitoring, and exercise. The article notes that oral hypoglycemic agents are not currently used in treating gestational diabetes. Because women with gestational diabetes have a significant risk for developing diabetes later in life, it is imperative that these women be identified. If diagnostic criteria and management based on maternal and fetal outcomes are to be established, continued research is necessary. 1 figure. 5 tables. 65 references. (AA-M).
•
Gestational Diabetes Mellitus Diagnosed with a 2-h 75-g Oral Glucose Tolerance Test and Adverse Pregnancy Outcomes Source: Diabetes Care. 24(7): 1151-1155. July 2001.
22
Gestational Diabetes
Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This review article describes a cohort study that evaluated American Diabetes Association (ADA) and World Health Organization (WHO) diagnostic criteria for gestational diabetes mellitus (GDM) against pregnancy outcomes. Although the ADA recommends a 3 hour 100 gram oral glucose tolerance test (OGTT) for the diagnosis of GDM, it has also recently included in its recommendations the use of a 2 hour 75 gram OGTT. GDM is defined by the new ADA test recommendations for the two hour 75 gram OGTT as at least two values greater than a fasting glucose of 5.3 mmol per liter, a 1 hour glucose of 10 mmol per liter, and a 2 hour glucose of 8.6 mmol per liter. WHO criteria require a fasting plasma glucose of equal to or greater than 7.0 mmol per liter or a 2 hour glucose of equal to or greater than 7.8 mmol per liter. The study population consisted of 4,977 Brazilian adult women attending general prenatal clinics who underwent a standardized 2 hour 75 gram OGTT between their estimated 24th to 28th gestational weeks. Among the women, 2.4 percent presented with GDM by ADA criteria and 7.2 percent by WHO criteria. After adjustment for the effects of age, obesity, and other risk factors, GDM by ADA criteria predicted an increased risk of macrosomia, preeclampsia, and perinatal death. Similarly, GDM by WHO criteria predicted increased risk for macrosomia, preeclampsia, and perinatal death. Of women positive by WHO criteria, 260 were negative by ADA criteria. Conversely, 22 women positive by ADA criteria were negative by WHO criteria. The article concludes that GDM based on a 2 hour 75 gram OGTT defined by either WHO or ADA criteria predicts adverse pregnancy outcomes. Thus, until consensual criteria are reached, these two criteria are valid options for the detection of a glucose tolerance state predictive of adverse pregnancy outcomes. 1 appendix. 1 figure. 2 tables. 18 references. (AA-M). •
Diagnosis and Management of Gestational Diabetes Source: Diabetes Reviews. 2(1): 43-52. Winter 1994. Summary: This review article discusses the diagnosis and management of gestational diabetes (GDM). The authors begin by briefly reviewing the controversies about the definition and diagnosis of GDM. They continue by describing a contemporary management protocol for GDM that emphasizes nutritional therapy and by discussing details associated with reductions in perinatal morbidity controlling for maternal obesity. The management scheme outlined here depends on a multidisciplinary approach in which dietitians, nurse educators, counselors, and physicians strive for integrated care. The authors stress that establishment and maintenance of euglycemia is the single most important objective to reduce perinatal morbidity and mortality. 2 figures. 7 tables. 87 references. (AA-M).
•
Summary and Recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus Source: Diabetes Care. 21(Supplement 2): B161-B167. August 1998. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This review article presents the summaries and conclusions resulting from the deliberations of four panels organized at the Fourth International WorkshopConference on Gestational Diabetes Mellitus (GDM). Panel one focused on the definition, diagnosis, and prevalence of GDM, which is defined as carbohydrate intolerance of varying degrees of severity with onset or first recognition during
Studies
23
pregnancy. The panel presented a screening strategy for detecting GDM and described one-and two-step oral glucose tolerance tests. The panel also recommended that appropriately designed clinical trials be conducted to determine whether the results of the 75-g test can be applied in a manner similar to the 100-g test. The second panel addressed the perinatal implications of GDM, including its impact on fetal growth and the consequences of excessive fetal growth for both the infant and the mother. The panel recommended that various areas be investigated to further the understanding of fetal growth and neurological and psychological development. Panel three focused on therapeutic interventions during pregnancy and discussed metabolic management of GDM in terms of therapeutic goals, nutritional therapy, metabolic surveillance, intensified metabolic therapy, and labor and delivery. In addition, the panel examined obstetric management in terms of goals and fetal and maternal surveillance. The panel recommended that controlled trials be conducted to evaluate various management strategies. The final panel considered the long-range implications of GDM and management after pregnancy, focusing on clinical implications for both the mother and her child and recommending that more studies need to be conducted on various aspects of diabetes. 4 tables. 8 references. •
American Diabetes Association's Fourth International Workshop-Conference on Gestational Diabetes Mellitus: Summary and Discussion Source: Diabetes Care. 21(Supplement 2): B131-B137. August 1998. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This review article summarizes the final session of the Fourth International Gestational Diabetes Workshop-Conference, which addressed the issue of therapeutic intervention strategies for gestational diabetes mellitus (GDM). The article focuses on the opinions of six presenters and their interpretations of a review of the literature in their specific areas, the synthesis of the 30 abstracts on therapeutic interventions presented at the symposium, and the author's interpretations of the literature on these interventions to date. The article outlines suggested intervention protocols on medical nutritional therapy, weight gain during pregnancies complicated by GDM, optimal glucose monitoring, target glucose levels, insulin therapy, and exercise programs for women with GDM. The goals of an intervention protocol for the pregnant woman who has GDM are to achieve and maintain normoglycemia and thus minimize the risk of maternal or fetal morbidity. The conclusion reached by workshop participants was that further studies of management protocols are needed. 3 tables. 66 references. (AA-M).
•
Proceedings of the Third International Workshop-Conference On Gestational Diabetes Mellitus Source: Diabetes. 40(Supplement 2): 1-204. December 1991. Summary: This special issue of Diabetes presents the proceedings of the Third International Workshop-Conference on Gestational Diabetes Mellitus (GDM), sponsored by the American Diabetes Association and held in Chicago, Illinois, on November 8-10, 1990. Forty-three presentations are included, covering such topics as the role of epidemiology in GDM, including race factors, incidence, and severity; diagnosis; insulin secretion and insulin resistance; the placenta; fetal growth factors; impact of maternal fuels and nutritional state on fetal growth; neonatal hypoglycemia; obstetric complications with GDM; diabetic embryopathy; islet function in offspring; diabetes mellitus after GDM; preconception counseling and contraception after GDM; nutrition
24
Gestational Diabetes
during pregnancy; exercise; insulin management in GDM; and management issues. Each paper includes extensive references. The issue concludes with author and subject indexes. •
Emotional Adjustment to Diagnosis and Intensified Treatment of Gestational Diabetes Source: Obstetrics and Gynecology. 84(3); 329-334. September 1994. Contact: Available from Elsevier Science, Inc. 655 Avenue of the Americas, New York, NY 10010. (212) 989-5800. Summary: This study determines the effect of intensified treatment on the emotional status of women with newly diagnosed gestational diabetes. The study also observes the relationship between metabolic control and emotional well-being. Women with newly diagnosed GDM (n=206) and nondiabetic controls (n=95) were compared for maternal characteristics and test results on the Profile of Mood States-Bipolar test. There was no significant difference between women with GDM in either the diet-or insulin-managed group and nondiabetic controls on each of the subscales of the test. Intensified therapy (SMBG and frequent insulin injections) for GDM does not negatively affect women's emotional status. Moreover, achievement of glycemic control contributes to patient reassurance. Psychological adjustment to the temporary disease state is then equal to that of a nondiabetic individual. 4 tables. 20 references. (AA-M).
•
Caloric Restriction in Gestational Diabetes Mellitus: When and How Much? Source: Journal of the American College of Nutrition. 11(3): 259-262. June 1992. Summary: Variations in nutritional intake during pregnancy have measurable effects on the circulating levels of maternal nutrients, maternal weight gain, and birth weight of the offspring. This review article addresses caloric restriction in gestational diabetes mellitus (GDM). The authors conclude that adjusting caloric intake to meet new guidelines for weight gain during pregnancy may be advantageous in reducing maternal blood sugar and insulin levels, without producing abnormalities in other metabolic variables. Modest caloric reduction that limits excessive weight gain in the mother may also be associated with a small reduction of fetal weight. However, more stringent dietary manipulations in obese pregnant women should be discouraged as a routine measure until more knowledge is available. 24 references.
•
Use of the Matchmaker Visual Reader for Women with Gestational Diabetes Source: Diabetes Educator. 16(4): 272-273. July-August 1990. Summary: Women who develop gestational diabetes are at greater risk for developing preeclampsia, undergoing operative delivery, and delivering high birth weight infants. Risks to the infants include birth injury, hypoglycemia, and hyperbilirubinemia. Research has shown that women with gestational diabetes who are diagnosed early and who maintain recommended blood glucose levels have the best maternal and infant outcomes. A case is presented in which a diabetes educator assisted a newly diagnosed woman with gestational diabetes in managing her blood glucose level using the Matchmaker Visual Reader. The Matchmaker is a relatively inexpensive visual reader designed to match Chemstrips bG with a color-chart wheel indicating blood glucose level. Directions in the use of this device are provided along with positive results from the case study described. 4 references.
Studies
25
Federally Funded Research on Gestational Diabetes The U.S. Government supports a variety of research studies relating to gestational diabetes. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to gestational diabetes. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore gestational diabetes. The following is typical of the type of information found when searching the CRISP database for gestational diabetes: •
Project Title: ADAPTATION OF ISLETS OF LANGERHANS TO PREGNANCY Principal Investigator & Institution: Sorenson, Robert L.; Professor; Cell Biology and Neuroanatomy; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 01-DEC-1984; Project End 30-JUN-2007 Summary: (provided by applicant): Pregnancy is a unique condition in the life history of islet beta-cells. At this time there is an increased need for insulin secretion at normal glucose concentrations. This demand is met by major alterations in islet structure and function. The most important are: (a) an increase in glucose-stimulated insulin secretion (4-10 fold at normal blood glucose levels); (b) a lowering of the threshold for glucosestimulated insulin secretion:and (c) increased beta-cell proliferation. Using lactogenic hormones from the same species (i.e., placental lactogen or prolactin which share a common receptor), we have shown that these hormones induce all of the changes in islets that occur during pregnancy. The common theme in this project is the PRL signaling pathway and how it changes insulin secretion, islet cell division and how lipids interact with this process during pregnancy. Using islets from pregnancy and islets treated with lactogenic hormones in vitro we will determine: (1) Why prolactin (PRL) receptor activation is so effective in enhancing islet function? (2) How PRL receptor activation increases insulin secretion? (3) How PRL receptor activation increases islet cell growth? (4) How lipids interact with islets in the presence of lactogens? (5) How complete is our understanding of the PRL receptor/JAK/STAT pathway in accounting for the changes in islet function during pregnancy? The overall goal is to understand the cellular mechanisms responsible for increasing islet function during pregnancy. This information will provide insight into the long-term regulation of islet function and beta-cell mass in the maintenance of normal blood glucose. Failure of islets to adapt to the increased need for insulin during pregnancy leads to gestational diabetes, a condition that is detrimental to normal fetal development as well as the health of the mother. Understanding the regulation of beta-cell glucose sensitivity is
2 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
26
Gestational Diabetes
critical for understanding the progression of events that lead to gestational and type Il diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTIOXIDANT TRANSGENE PROTECTS OFFPRING FROM MATERNAL DIABETES Principal Investigator & Institution: Liu, Ye Qi; University of Louisville University of Louisville Louisville, Ky 40292 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2007 Summary: Maternal diabetes is major cause of birth defects and a contributing factor to the development of diabetes in the offspring. A hyperglycemic environment during pregnancy significantly increases the rat of malformation and resorption in the fetus. In addition, children and adults from diabetic mothers have a markedly higher rate of Type 2 diabetes. The most widely proposed hypothesis for damage is free radical (oxidative) stress to the developing fetus. Based on this hypothesis, clinical trials of antioxidants are being proposed for antioxidant treatment of diabetic mothers. However, there are problems with the current evidence for this hypothesis, which we will address in our proposed studies. Most of the support for the antioxidant hypothesis derives from treatment of diabetic rats with antioxidant vitamins, E and C. Because these drugs are delivered systemically it is impossible to determine if the protective effect is exerted at the level of the fetus or the mother, since both are subject to hyperglycemia and subsequent oxidative stress. To overcome this limitation we will produce antioxidant transgenes that will be expressed exclusively in the developing embryo. An additional problem with prior studies is that they have been performed using streptozotocin induced diabetes. Streptozotocin is a powerful oxidant and its damaging effects are not confined to the pancreatic beta cell. To overcome this limitation we will use the OVE26 transgenic model of diabetes. In these mice diabetes is induced by a transgene that is absolutely confined to the pancreatic beta cell, eliminating any potential direct damaging effects on the fetus. The impact of maternal diabetes on the ultimate development of Type II diabetes in the offspring has recently been recognized. Until now most attention has been paid to the role of insulin resistance. However, impaired insulin secretion is at least as crucial to the development of Type II diabetes and diabetes will not develop unless secretion fails. The insulin secretin beta cell is one of the most sensitive cells in the body to free radical damage. We will apply our expertise in pancreatic islet function to determine if insulin secretion is impaired in the offspring of OVE26 diabetic mothers and to examine whether a fetal antioxidant transgene can protect from the development of Type II diabetes in the offspring. To test our hypothesis that fetal oxidative stress leads to congenital malformations and to long term damage to insulin secretion we will carry out the following Specific Aims: 1. Evaluate developmental aberrations in the offspring of diabetic OVE26 mice. 2. Characterize glucose homeostasis and pancreatic islet function in the offspring of diabetic OVE26 mice. 3. Produce transgenic mice that over-expressing antioxidants metallothionein (MT) and Mn superoxide dismutase (MnSOD) during embryonic and fetal development. 4. Determine if antioxidant transgenes can reduce maternal diabetes induced damage to fetal development and islet function. Completion of these Specific Aims will provide a definitive genetic test of the role of oxidative damage to the offspring. They will also provide a much-improved model of maternal diabetes, which is amenable to modern genetic manipulation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: BARRIERS TO RECRUITING DIABETES IN DIABETES PREVENTION
WOMEN
W/
27
GESTATIONAL
Principal Investigator & Institution: Marrero, David G.; Professor of Medicine; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2001 Summary: There is no text on file for this abstract. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--MODEL DEMONSTRATION UNIT Principal Investigator & Institution: Clark, Charles M.; Professor of Medicine; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2002 Summary: Description (taken from application): The guidelines for the Diabetes Research and Training Centers mandate a model demonstration unit (MDU) for the training of students and practitioners in diabetes care and for the support of diabetes research. The IU-DRTC has responded to this mandate by developing a multi-site MDU that addresses training and research in three diabetes patient populations: adults (with special emphasis on pregnant women with pre-existing and gestational diabetes), transitional age adolescents, and children. The primary goals of our multi-site MDU are to train health care professionals in state-of-the-art diabetes management and facilitate research that addresses barriers between what is thought to represent ideal diabetes care reflecting current scientific advances in the understanding of diabetes and what is routinely practiced. Even though there are distinct differences in patient populations served by the MDU, a unifying philosophy is involved in the demonstration of model diabetes care across all of these sites. Model care should: 1) be delivered by multidisciplinary teams with an emphasis on interactive decision making, 2) incorporate algorithmic protocols that are based on state-of-the-art care standards, 3) be supported by new technologies when possible, and 4) be rigorously evaluated and revised as necessary. During the past cycle we have significantly expanded diabetes treatment programs in the MDU. As a result, trainees have exposure to all aspects of model diabetes care including state-of-the-art measures to improve glycemic control, formal weight management programs, and cardiovascular risk reduction programs. The programs afford trainees exposure to patients of all age groups (i.e., pediatrics, adolescents, adults and the elderly) and of varied ethnic and socioeconomic status. Furthermore, through exposure to the proposed Women?s Health Initiative MDU program, gender-specific aspects of providing care to females with diabetes will be modeled. Finally, an important expansion of our MDU are programs designed to provide training and education in model diabetes care to medical students, trainees, and primary care physicians who practice at sites distant from these state-of-the-art model programs. 2.The specific objectives of the IU-DRTC MDU are: 1.To establish state-of-theart diabetes patient management programs for the demonstration of model care. 2.To train health professional students and practitioners in state-of-the-art management and education of persons with diabetes. 3.To serve as a resource to facilitate the conduct of biomedical, health care, educational, epidemiologic and psychosocial research in diabetes mellitus. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
28
Gestational Diabetes
•
Project Title: DEFINING DIABETES IN YOUTH Principal Investigator & Institution: Hamman, Richard F.; Professor and Chairman; Preventive Med and Biometrics; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2005 Summary: (provided by applicant): There is very limited information about the epidemiology of Type 2 diabetes mellitus in youth, though it is believed that the prevalence is increasing rapidly. Risk factors similar to those in adults with Type 2 are thought to be important, (e.g., obesity, insulin resistance, diet, physical activity, positive family history), however, there are no reliable epidemiological studies of these risk factors in youth with type 2 diabetes using appropriate controls. In addition, risk factors such as low birth weight lack of breast-feeding, maternal diabetes during pregnancy and family dysfunction and depressive symptoms have received little epidemiological study in populations other than American Indians. This application addresses the lack of such studies. The Defining Diabetes in Youth (DDY) project will focus on type 2 diabetes in youth aged 10-19, drawing upon the CDC funded SEARCH diabetes registry project in Colorado and South Carolina. The SEARCH project will ascertain all cases of diabetes in youth, collect immunologic, clinical, and metabolic information, and classify cases as Type 1 or 2 diabetes. DDY will only have to recruit appropriate controls aged 10-19 from three ethnic backgrounds including African Americans (AA), Hispanics (H), and non-Hispanic whites (NHW) to test specific etiologic hypotheses in the cases classified by SEARCH as Type 2 diabetes. It will also explore cardiovascular risk factor differences in youth with Type 2 diabetes and controls, and will evaluate insulin resistance and secretion differences among controls by level of obesity and other factors. The primary design is a case-control study, through which risk factors for diabetes, selected complications and CVD risk factors will be evaluated. The current application is an approved SEARCH ancillary study. Collaborating investigators bring expertise in multiple areas relevant to diabetes in youth, and experience in large epidemiological studies of diabetes (both type 1 and 2) in minority populations. Given the low prevalence of Type 2 in Youth, DDY is an efficient design, since case ascertainment and typing will be conducted by SEARCH, and only control recruitment, addition of new measures, and analysis are requested. The biostatistical analysis, data management and central laboratory will be the same as used in SEARCH. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DIABETES PREVENTION PROGRAM Principal Investigator & Institution: Ratner, Robert E.; Vice-President; Medstar Research Institute Hyattsville, Md 20783 Timing: Fiscal Year 2001; Project Start 20-AUG-1994; Project End 30-JUN-2003 Summary: (Directly incorporated from the application) The Washington Hospital Center/Medlantic Research Institute and the Howard University Medical School will collaborate in an effort to identify and enroll African Americans at risk for the development of IGT and NIDDM into a primary prevention trial. We will concentrate on recruitment of African Americans because of the disproportionate effect diabetes has on this community and the fact that Washington DC, with 70 percent African Americans, is estimated to have 52,000 citizens with diabetes, with half undiagnosed. The unique aspects of NIDDM in the African American population together with their disproportionate prevalence demand inclusion of African Americans as a major component of any primary prevention trial for NIDDM. Impaired glucose tolerance is
Studies
29
the optimal time when interventions aimed at reversing the insulin resistance may prevent the progression of carbohydrate intolerance to NIDDM. We propose an efficient recruitment strategy based on the documented availability of groups enriched in the proportion of individuals with abnormal glucose tolerance. These include clinic patients seen at the Washington Hospital Center (WHC) and Howard University Hospital (HUH) who are obese and have relatives with NIDDM, patients with premature cardiovascular disease, and patients with a history of gestational diabetes. We propose a two by two factorial design to investigate aggressive lifestyle modification (diet and exercise), and pharmacologic intervention with metformin. Culturally appropriate interventions and follow-up techniques based on community support and input are presented designed to enhance retention and compliance. Primary endpoint determinations will be progression form IGT to NIDDM. Improvement of carbohydrate tolerance in newly diagnosed NIDDM will also be examined. Secondary end points include metabolic parameters related to insulin resistance, insulin secretion, lipoprotein changes and cardiovascular endpoints such as hypertension. Our center is experienced in the conduct of clinical trials and is committed to working with the Steering Committed in the design and conduct of the Trial. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIABETES PREVENTION PROGRAM Principal Investigator & Institution: Wing, Rena R.; Professor of Psychiatry; Psychiatry; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2001; Project Start 15-AUG-1994; Project End 30-JUN-2003 Summary: Diabetes mellitus is a major cause of morbidity and mortality in the United States, and individuals with impaired glucose tolerance (IGT) or a history of gestational diabetes (GDM) are at increased risk of developing this disease. Research to test whether it is possible to prevent the occurrence of NIDDM is a national priority. The University of Pittsburgh proposes a primary prevention trial that optimally tests the hypothesis that NIDDM is preventable through weight loss and physical activity and simultaneously addresses whether an intervention that is more easily adopted by the health care system is of benefit. Targeted advertisement and chart review will be used to identify 100 subjects with IGT (confirmed on repeat OGTT and with at least one 2-hour BS>170); 100 GDM subjects will be identified from a registry of over 1000 women with GDM; we aim for 40% of participants to be African American. These 200 high risk subjects will be randomized to a control group, a standard life-style intervention (SLI), or an enhanced life-style intervention (ELSI). The goals for the two intervention groups will be a 10% weight loss and 3 hours/week of physical activity. To achieve these goals, the SLI group will participate in a standard diet/exercise program that could be easily implemented by the health system; community-led exercise groups will also be available. The ELSI group will be given enhanced treatment to optimally test the prevention hypothesis; these subjects will be seen individually on a monthly basis; intervention will be prescribed as needed to achieve and maintain the weight and exercise goal. The primary outcome will be development of NIDDM (WHO criteria; confirmed by second test). Other endpoints will be changes in glucose, insulin resistance, insulin secretion, and the cardiovascular risk profile. During screening, some subjects will be identified as having non-fasting diabetes (NFD; FBS 200). These subjects will participate in a secondary prevention trial using a 2 x 2 factorial design with the two life-style conditions (SLI vs ESLI) crossed with 2 drug conditions (metformin vs placebo). The primary outcome measures for this secondary prevention study will be development of fasting hyperglycemia and incidence or progression of diabetic
30
Gestational Diabetes
complications. The University of Pittsburgh is well qualified to participate in this trial as we have extensive experience in life-style interventions, exercise, clinical trials, diabetic complications, and in the medical management of diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIABETES PREVENTION PROGRAM (DDP-2) Principal Investigator & Institution: Kitabchi, Abbas E.; Professor; Medicine; University of Tennessee Health Sci Ctr Health Science Center Memphis, Tn 38163 Timing: Fiscal Year 2001; Project Start 20-AUG-1994; Project End 30-JUN-2003 Summary: Non-insulin dependent diabetes mellitus (NIDDM) has reached an epidemic proportion in the United States. Although NIDDM, cardiovascular diseases, and cancer account for two-thirds of all deaths in the United States, there is strong evidence to indicate that these diseases may be related to the lifestyle of the patients. There is no compelling evidence in the literature that the following are combined, or independent risk factors for development of NIDDM: (a) obesity, (b) family history of NIDDM, (c) upper body adiposity, (d) ethnicity, (e) hyperinsulinemia, (f) impaired glucose tolerance, (g) gestational diabetes, (h) sex hormone binding globulin (SHBG), (i) sedentary life. We hypothesize that in such individuals with high risk, alteration of lifestyle, such as dietary modification and physical exercise, will ameliorate or delay development of NIDDM. We, therefore, propose the following specific aims for this multicenter primary prevention trial: 1. To recruit a cohort of subjects at high risk for NIDDM consisting of 100 persons with previous history of gestational diabetes, most of whom will be African American, and 100 other persons who are hyperinsulinemic with upper body adiposity, insulin resistant, impaired glucose tolerant and strong family history of diabetes. Some of the patients will be undiagnosed NIDDM with fasting blood glucose of < 140 mg/dl. 2. To randomize these subjects into intensive therapy group versus usual care group (attention control). 3. The intensive therapy group will be designed to accomplish the following aims: (a) to modify the diets in these high risk subjects to reduce total fat to less than 30% of total calories and saturated fat to less than 10%, (b) to increase energy expenditure from physical activity to 2000 Kcal per week, (c) to combine dietary therapy with effective moderate exercise therapy to achieve a reduction of body weight of greater than 10% per individual which will be maintained over time, (d) to design these dietary and exercise interventions so they are flexible enough that they can be modified for the different target ethnic, gender, educational level, and other subgroups, and (e) to design a long term adherence program that will maximize adherence to prescribed therapies while minimizing drop outs and therapeutic cross overs. 4. To provide baseline and semi-annual evaluations of glycemic control and insulin resistance in all groups of patients, and repetition of all initial laboratory and physical examination data on an annual basis. We estimate 75% of our study population will be African American, and 25% will be Caucasian. Both male and female populations will be represented, with the majority being female, as 50% of our patients will consist of those persons with gestational diabetes. We understand the final protocol will be based on the decision arrived at by the Steering Committee, and may involve the use of insulin-resistancemodifying drugs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DIABETES PREVENTION PROGRAM (DPP) Principal Investigator & Institution: Shamoon, Harry; Professor and Dcrc Program Director; Medicine; Yeshiva University 500 W 185Th St New York, Ny 10033
Studies
31
Timing: Fiscal Year 2001; Project Start 15-AUG-1994; Project End 30-JUN-2003 Summary: There is increasing evidence that the development of noninsulin dependent diabetes mellitus (NIDDM) is presaged many years earlier by the presence of biochemical and other phenotypic features in susceptible individuals. Earlier intervention in such individuals may prevent or slow the occurrence of overt hyperglycemia which, in turn, may limit the morbidity and mortality associated with diabetes. By selecting populations at higher than average risk for the ultimate development of NIDDM, we propose to be able to practically test the following hypothesis: The reduction in risk of developing NIDDM in persons at high risk for the development of diabetes will be dependent on treatment which affects insulin resistance, islet B-cell dysfunction, and/or hepatic glucose production. Interventions which include diet, exercise sulfonylurea drugs, and metformin in a factorial design can address this hypothesis. The Diabetes Center at the Albert Einstein College of Medicine is a multidisciplinary aggregation of scientists and clinicians actively involved in various aspects of diabetes. With the resources and expertise available among individuals in the Center, we will participate in a multicenter NIDDM Prevention Trial. The Albert Einstein Center would be able to contribute to the success of such a Trial for the following reasons: l) a Diabetes Research and Training Center underpinning and the Institutional commitment to addressing issues in underserved populations of New York City; 2) our participation in the Diabetes Control and Complications Trial as a clinical center; 3) the availability of a large, identified population of individuals from racial and ethnic minority groups in the Bronx and Westchester Counties who receive their medical care in Einstein-affiliated programs; 4) an identified and well characterized population of women who had gestational diabetes diagnosed between 1988 and the present, and an annual accrual of an additional cohort of women with gestational diabetes; 5) expertise in the design and implementation of clinical trials; 6) strong research foci of the principal and co-investigators in areas such as pathophysiology and diagnosis as well as nutritional and pharmacologic treatment of NIDDM; 7) members of the treatment team with specific competence in diabetes in Hispanic and in AfricanAmerican individuals; 8) a new outpatient facility in which to conduct a clinical trial; 9) expertise in related areas such as hypertension control, cardiovascular risk reduction, and behavioral techniques intended to achieve therapeutic goals; and lO) a track record of participating in constructive collaborative efforts to achieve the goals of NIH-initiated multicenter projects. We will participate in the Trial by providing personnel, resources, and study volunteers to achieve the aims of the planning, implementation, and data analysis phases of the proposed 7-year study. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EARLY LIFE AND GENETIC EFFECTS ON OBESITY AND DIABETES Principal Investigator & Institution: Hunt, Kelly J.; Medicine; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, Tx 78229 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 30-JUN-2007 Summary: (provided by applicant): Immediate career goals that the Division of Clinical Epidemiology at the University of Texas Health Science Center at San Antonio provides me the opportunity to pursue as a diabetes and cardiovascular epidemiologist, include training in statistical genetics and implementation of my own study. These skills are essential for my career development, my long-term career objective being to establish a solid independent research program as a genetic epidemiologist. The objective of the research project is to investigate and characterize intrauterine and early childhood exposures and their relationship to the development of obesity and type 2 diabetes in
32
Gestational Diabetes
two ongoing studies, the San Antonio Family Diabetes Study (SAFDS) and the San Antonio Family Heart Study (SAFHS). The SAFDS and the SAFHS are studies of lowincome Mexican American families that combined include 2,361 adult participants from over 80 extended families. In each study, a standardized medical examination has been completed, including measurements of anthropometry and blood pressure, a fasting venipuncture and an oral glucose tolerance test. Moreover, in the coming months, a complete genomic scan of 400 highly polymorphic markers distributed throughout the genome at approximately 10 centimorgan intervals will be available on the vast majority of participants. Specific aims of the proposed project include collecting self-reported information on breast-feeding from over 1600 participants and mother, reported information on an array of early life exposures on 999 participants. Mother-reported exposures of interest include duration of breast-feeding, maternal smoking and alcohol consumption during pregnancy, gestational hypertension and/or diabetes during pregnancy, inter-pregnancy interval, and the time interval between pregnancy and future development of diabetes (among diabetic individuals). Research questions of interest include the association between early life exposures and adult obesity and diabetes, whether the heritability of diabetes and obesity is influenced by early life exposures that are themselves likely to be familial, and finally the identification of genes and gene by environment interactions related to obesity and diabetes. The proposed study, by combining previously collected information in two established studies with collection of information on early life exposures, bridges the gap between genetics and epidemiology, offering a unique training opportunity and an opportunity to further our understanding of obesity and diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EPIDEMIOLOGY OF GALLBLADDER SLUDGE & STONES IN PREGNANCY Principal Investigator & Institution: Lee, Sum P.; Professor and Chief; Medicine; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2003; Project Start 01-APR-1996; Project End 28-FEB-2007 Summary: (provided by applicant): The female gender and multiparity are the two most important positive correlates of cholesterol gallstone disease. Pregnancy represents the period of time when the 'lithogenic' pressure on a woman is the highest. Biliary sludge is a precursor stage of gallstones. We studied the etiological factors associated with the development of sludge and stones during pregnancy, and our early results suggest that it is inversely related to physical activity. We also found that being overweight, a known risk factor for gallstone disease, is associated with high blood leptin levels. In addition, the risk associated with high leptin levels is partially mitigated by physical activity. In order to disentangle the effects of physical activity, leptin and gestational diabetes on gallbladder disease risk, and to understand the mechanisms behind the observed associations, we propose to conduct a randomized controlled trial. This interventional study is a logical extension of our previous observational investigation. Our Specific Aims are: 1. To evaluate whether an endurance exercise program is associated with lower risk of gallbladder disease in overweight pregnant women.2. To evaluate whether an endurance exercise intervention program changes leptin levels in pregnancy among overweight women.3. To examine the associations between gallbladder disease incidence and potential causal variables in this prospective trial. These variables include leptin levels, HDL, insulin levels, BMI (as it varies within women classified as overweight), as well as changes in these variables. Gallstone disease affects 15-20% of adult Americans. Cholecystectomy is one of the most commonly performed operations.
Studies
33
The morbidity, and the burden of cost, incurred by gallstones are staggering. Yet there is a dearth of understanding in the epidemiology and the cause of this disease. The results of this investigation should generate new, important and useful insights into the pathogenesis, and provide a rational strategy for the prevention, of this common and costly disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FACTORS AFFECTING FETAL GROWTH Principal Investigator & Institution: Uvena, Jennifer; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2001 Summary: The purpose of this study is to determine if there is a relationship between fetal growth factors (leptin, tumor necrosis factor alpha, insulin, and c-peptide) and neonatal weight and body composition, in babies of women with gestational diabetes mellitus and those with normal glucose tolerance. This study will also investigate whether or not the placenta is a possible source of these growth factors. Additionally, neonatal blood at 48 hours of life will be examined to see if the baby continues to make these growth factors after birth. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FAMILY STUDIES OF NIDDM--AFRICAN AMERICANS AND HISPANICS Principal Investigator & Institution: Guze, Carol D.; Professor; California State UnivDominguez Hills Carson, Ca 90747 Timing: Fiscal Year 2001; Project Start 30-SEP-1992; Project End 31-MAR-2005 Summary: The objective of this pilot study is to generate empiric counseling risks for use in counseling patients and families as well as to identify risk factors that contribute to the development and course of type 2 diabetes (DM-2) in African Americans and Hispanics in Central Los Angeles. Type 2 diabetes mellitus is a common disorder usually of middle-aged individuals and, if untreated, complications can arise. DM-2 is one of the top ten health problems in the United States and the prevalence in African Americans is estimated to be 10% and in Hispanics, 15%. These communities are also at greater risk for developing long-term complications of diabetes such as retinopathy (including blindness). An alarming new trend is an increase in DM-2 among young people especially Hispanics and African Americans. DM-2 has also been shown to have a disproportionate impact among ethnic seniors. We plan to use family studies gathered by personal interviews and questionnaires to obtain the necessary informati on from our DM-2 patients. 100 adult African American patients and 100 adult Hispanic patients in diabetes clinics at King Drew Medical Center and its outlying clinics will be interviewed. Interviews of non English speaking Hispanics will be conducted in Spanish. The specific aims of our project are 1. To develop empiric counseling risks using the information gathered from the family history studies and 2. to explore within our families those risk factors which in other studies have not been looked at in detail. These include the regions of origin in Mexican-Americans; acculturation factors; maternal pregnancy factors; birth weight; birth order; obesity in the family members. We anticipate that the information gathered from our pilot study will suggest testable hypothesis for future more focused studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
34
Gestational Diabetes
•
Project Title: FETAL METABOLIC CONSENQUENCES OF SPONTANEOUS GESTATIONAL DIABETES MELLITUS Principal Investigator & Institution: Friedman, Jacob E.; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2001 Summary: The long-term goal of these studies is to understand how defects in maternal insulin transduction contribute to gestational diabetes mellitus (GDM) and the mechanisms leading to fetal macrosomia and obesity. Metabolic imprinting suggests the transmission of diabetic susceptibility genes from moth to offspring is less important than the maternal environment in producing second-generation insulin resistance, obesity, and diabetes. This proposal will use a series of established heterozygous transgenic mouse models will combined gene knockouts in the insulin receptor (IR/+), insulin receptor substrate-1 (IRS-1/+), and leptin receptor (db/+) genes to establish how genetic defects in insulin signaling and the hormones of pregnancy interact to provoke abnormalities in insulin signal transduction, beta-cell hypertrophy, and spontaneous hyperglycemia during pregnancy. Our studies will also determine how modifying maternal insulin resistance during pregnancy decreases hyperglycemia and the development of fetal macrosomia by studying db/+ mice that over-express the human GLUT4 gene. The association between maternal hyperglycemia and fetal genotype on fetal over/under growth and expression of insulin signaling proteins in liver and skeletal muscle will be determined during the perinatal period. The last goal will be to determine whether insulin resistance and obesity in early and later life is modified by inheritance of an abnormal genotype or the consequences of epigenetics (i.e. information that is heritable and alters the phenotype of offspring but is not encoded specifically in the genetic code of DNA. One of the immediate benefits of these models is that they provide information on the role of biochemical defects expressed against a constant genetic background, thus enabling us to observe epigenetic transmission of an altered metabolic phenotype originally induced by a genetic event (inheritance of the IR/IRS-1 or leptin receptor mutation). Because many metabolic disorders, such as diabetes, have both genetic and epigenetic components, this approach offers an opportunity to identify metabolic alterations that may be unique to genetic or epigenetic effects. The outcome of these studies will have important implications for the prevention and treatment of GDM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FETOPLACENTAL GROWTH RETARDATION Principal Investigator & Institution: Clapp, James F.; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2001 Summary: The three specific aims of this project continue to focus on the role of two maternal environmental factors (diet and physical activity) in prenatal growth regulation and their indirect effects, if any on postnatal growth and development. The project uses a prospective, randomized design to evaluate the effects of maternal diet and activity on maternal blood glucose levels, feto-placental growth, and post-natal growth and development. Parallel mechanistic studies will also be carried out using a prospective, randomized cross-over design. The basic hypothesis to be tested is that diet and activity during pregnancy modulate many aspects of the growth process through their effects on multiple maternal metabolic and cardiovascular parameters. The specific maternal parameters which will be evaluated include: glucose, insulin, glycolated
Studies
35
hemoglobin, TNF-alpha, and leptin levels, metabolizable energy intake, weight gain and fat deposition, resting metabolic rate, glucose oxidative and non-oxidative disposal, and insulin sensitivity. Placental growth and functional capacity will also be evaluated as well as neonatal morphometrics and postnatal growth, metabolism and neurodevelopment. The techniques used include: tight control of the subject's diet and activity, diet and exercise tolerance tests, ultrasound, indirect calorimetry, stable isotope infusion, the hyperinsulinemic-euglycemic clamp, and standard gross and microscopic morphometry. The significance of the project is that it will define the effects of diet and physical activity during pregnancy on outcome and identify some of the underlying mechanisms responsible for these effects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENES & GESTATIONAL DM: CASE CONTROL ASSOCIATION STUDY Principal Investigator & Institution: King, Kathleen U.; None; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2003; Project Start 28-SEP-2003; Project End 27-SEP-2006 Summary: (provided by applicant): Gestational Diabetes (GDM) is diabetes that is first diagnosed during pregnancy; it occurs in 7% of all pregnancies. Many women with GDM are diagnosed with Type 2 Diabetes (T2DM) later in life. Certain genes are associated with T2DM but studies have not been done to determine whether these genes are associated with GDM. This case-control-association-study, matching women for age, ethnicity and body mass index will examine genes associated withT2DM in women with GDM as compared to those without. These genes include the PPAR gamma, B3-AR, GRL and CAPN10. From blood samples, DNA will be extracted. Polymerase Chain Reaction will be used to amplify the 4 genes and fragment size analysis will determine which of the gene variants are present in each sample. Chi square analysis will compare the frequency of the individual gene variants in women with GDM vs. those without. This study will contribute to an understanding of the genetics of GDM and T2DM. Identification of genes associated with diabetes may facilitate interventions to prevent the onset or ameliorate the complications associated with diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GESTATIONAL DIABETES IN WOMEN:TASTE & ENDOCRINE FACTORS Principal Investigator & Institution: Tepper, Beverly J.; Associate Professor; Food Science; Rutgers the St Univ of Nj New Brunswick Asb Iii New Brunswick, Nj 08901 Timing: Fiscal Year 2002; Project Start 08-APR-2002; Project End 31-MAR-2005 Summary: provided by applicant): Gestational Diabetes Mellitus (GDM) is a common complication of pregnancy with serious consequences for maternal and child health. Diet is an integral part of the management of GDM, but current diet strategies for pregnant women with 0DM are poorly defined and often fail. We have shown that GDM increases the preference for sweet taste and dietary intake of sweet foods, which could have important implications for the management of this disease. At the time of diagnosis (-30 30 wk gestational age) pregnant women with GDM showed a higher preference for sweetened dairy drinks compared to pregnant women without GDM. In addition, increased plasma glucose in women with GDM was related to higher preference for the sweet taste of glucose and higher dietary intake of simple sugars as fruit and fruit juices. Because these studies were limited to a single observation point
36
Gestational Diabetes
during gestation and excluded women with severe diabetes or those treated with insulin, further studies are needed. The specific aims of this project are: 1) to determine the relationship between hyperglycemia and increased taste preference and dietary intake of sweet foods in GDM, 2) to compare the temporal pattern of taste and dietary changes in women with GDM to those of women without 0DM across pregnancy stages, and 3) to relate these taste changes to alterations in gestational hormone and metabolic profiles. A single prospective study will be conducted. We will measure sweet taste preferences, food cravings, dietary intake of sweet foods and plasma indices of selected hormones and metabolites (including insulin, cortisol and leptin) during early, middle and late gestation and at 6-wk and 26 wk post-delivery. Four groups of pregnant women will be studied; overweight women with GDM; normal weight women with GDM; overweight women without GDM and normal weight women without GDM. Non-pregnant controls will also be studied. The long-term goal of this project is to obtain a better understanding of taste changes in GDM to develop better preventative and therapeutic dietary intervention strategies for this disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GESTATIONAL DIABETES MELLITUS & HYPERTENSION Principal Investigator & Institution: Solomon, Caren; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001 Summary: The purpose of this study is to assess whether there are differences in blood pressures, glucose tolerance, insulin resistance, and lipid levels in women who have had a pregnancy complicated by diabetes or hypertension, as compared with women who have had uncomplicated pregnancy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: OUTCOMES
GESTATIONAL
DIABETES:
DIAGNOSTIC
CRITERIA
AND
Principal Investigator & Institution: Ferrara, Assiamira; Research Scientist Ii; Kaiser Foundation Research Institute 1800 Harrison St, 16Th Fl Oakland, Ca 94612 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2004 Summary: (Adapted from Investigator's Abstract) Gestational diabetes mellitus (GDM) is associated with increased risk of several adverse infant and maternal outcomes and its clinical recognition can reduce these risks. There is concern that the current criteria for GDM may be to restrictive and that residual excess risk of perinatal complications exists below present cutoff values. The proposed study will evaluate whether among women without GDM (as defined by current criteria), increasing levels of maternal glycemia are associated with increased risk of selected perinatal complications: infant severe macrosomia, severe hyperbilirubinemia, hypoglycemia, respiratory distress syndrome, and maternal preeclampsia/eclampsia. To accomplish this, the investigators propose to conduct five nested case-control studies, one for each of the complications of interest, within a large multiethnic cohort of approximately 74,000 women who were screened at 24 to 28 weeks of gestation at Kaiser Permanente, Northern California between 1995 and 1998. In this setting nearly 94 percent of the pregnant women are screened for GDM by a 50 gm., 1 hr. oral glucose tolerance test (50 g, 1-h OGTT) and approximately 15 percent have are abnormal screening and go on to receive the diagnostic (100-g, 3-h OGTT) test. Potential cases of each type of complication will be identified by searching computerized hospitalization and laboratory databases. For each of the infant
Studies
37
complications, 500 cases will be randomly selected without knowledge of the maternal glucose values. A single control group for the infant complication case groups will be 1,000 infants randomly selected from all births and frequency matched on gestational age to the distribution of the combined case group. Five hundred women with either preeclampsia or eclampsia and 500 age-matched controls will be randomly selected. The medical records of the 3,000 mother-infant pairs in the four case-control studies on infant complications, and 1,000 women for the case-control study of preeclampsia/eclampsia, will be abstracted to confirm eligibility, and, if so, to ascertain data on possible maternal and infant covariates. Logistic regression will be used to estimate the odds ratios associated with several levels of pregnancy glycemia and perinatal complications. The investigators state that the proposed study will provide important knowledge about the magnitude of the risk of severe perinatal complications associated with degrees of maternal hyperglycemia below the glucose cutpoints currently used to diagnose GDM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLUCOSE AND AMINO ACID METABOLISM IN PREGNANCY Principal Investigator & Institution: Kalhan, Satish C.; Professor; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2001 Summary: The objectives of the proposed studies are to quantify longitudinally maternal metabolic responses to progressions of pregnancy and growth of the fetus. Specifically, the impact of pregnancy and alterations in fetal growth, e.g. in diabetes, upon whole body amino acid and glucose metabolism will be quantified using stable isotope tracer method. Data from our previous studies in human pregnancy have shown that while changes in energy delivering substrates, e.g. glucose and fatty acids, during pregnancy occur parallel with the energy requirements of the mother and growing conceptus, adaptive responses in protein/nitrogen metabolism appear in anticipation of the fetal needs. In addition, preliminary data suggest that (a) liver/splanchnic tissue may be an important organ system involved in the pregnancy related adaptation, and (b) amino acid transamination may be an important component of nitrogen conservation and accretion. The proposed studies are aimed at testing these two hypotheses. Multiple isotope tracers will be used simultaneously to quantify splanchnic extraction and metabolism of essential amino acids. Whole body kinetics of glutamine, a major nitrogen source for urea and for the fetus and its nitrogen source will be quantified. Since fetal macrosomia has continued to be a persistent problem in gestational diabetes despite rigorous intervention strategies, this clinical model of abnormal fetal growth will be evaluated for the changes in gluconeogenesis and amino acid metabolism. A recently developed novel method employing labeling of body water which has already been applied to normal pregnancy will be used to quantify gluconeogenesis in gestational diabetes. These studies will quantify kinetics of key nutrients and substrates in the whole body (mother and fetus) which can impact fetal growth. It is anticipated that these data will permit the development of intervention strategies for amelioration of aberrant fetal growth. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HAPO: DATA COORDINATING CENTER Principal Investigator & Institution: Dyer, Alan R.; Professor and Associate Chair; Preventive Medicine; Northwestern University Office of Sponsored Programs Chicago, Il 60611
38
Gestational Diabetes
Timing: Fiscal Year 2001; Project Start 04-MAY-1999; Project End 31-MAR-2004 Summary: There is a consensus that overt diabetes mellitus (DM), whether or not accompanied by symptoms or signs of metabolic decompensation, is associated with a significant risk of adverse pregnancy outcome. On the other hand, the risk of adverse outcome associated with degrees of glucose intolerance less severe than overt DM is controversial. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study is a basic epidemiologic investigation aiming to clarify unanswered questions on the association of various levels of glucose intolerance during the third trimester of pregnancy and risk of adverse outcomes. Its General Aim -- by means of an international cooperative study involving 16 centers and approximately 25,000 pregnant women -- is to achieve a major advance in knowledge on levels of glucose during pregnancy that place the mother, fetus, and neonate at increased risk. The primary hypothesis is that hyperglycemia during pregnancy, less severe than overt DM, is associated with increased risk of adverse maternal, fetal, and neonatal outcome that is independently related to the degree of metabolic disturbance. Specific Aims of HAPO are: 1. to examine glucose tolerance in a large, heterogeneous, multinational, multicultural, ethnically diverse cohort of women in the third trimester of gestation with medical caregivers "blinded" to status of glucose tolerance (except in those instances where fasting and/or two hour OGTT plasma glucose concentration exceeds a predefined cutoff value); and 2. to derive internationally acceptable criteria for the diagnosis and classification of gestational diabetes mellitus (GDM) based on the specific relationships between maternal glycemia and the risk of specific adverse outcomes that are established through this study. The study is to be accomplished with high quality standardized data collection on the women during the third trimester of gestation (including the OGTT) and at time of delivery for assessment of adverse outcomes, including operative delivery (caesarean section), increased fetal size (macrosomia/obesity), neonatal morbidity (hypoglycemia), and fetal hyperinsulinism. HAPO is to include a Clinical Coordinating Center and Data Coordinating Center, both located at the Northwestern University Medical School in Chicago, as well as a Central Laboratory located in Belfast, United Kingdom. This application requests support for the Data Coordinating Center for HAPO. Cost effectiveness for HAPO is enhanced through cost sharing by colleagues in non-U.S. centers. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HYPERGLYCEMIA AND ADVERSE PREGNANCY OUTCOMEN Principal Investigator & Institution: Metzger, Boyd Northwestern University 633 Clark St Evanston, Il 60208
E.;
Professor;
Medicine;
Timing: Fiscal Year 2001; Project Start 04-MAY-1999; Project End 31-MAR-2004 Summary: There is a consensus that overt diabetes mellitus (DM), whether or not accompanied by symptoms or signs of metabolic decompensation, is associated with a significant risk of adverse pregnancy outcome. On the other hand, the risk of adverse outcome associated with degrees of glucose intolerance less severe than overt DM is controversial. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study is a basic epidemiologic investigation aiming to clarify unanswered questions on the association of various levels of glucose intolerance during the third trimester of pregnancy and risk of adverse outcomes. Its General Aim, by means of an international cooperative study involving 16 field centers and approximately 25,000 pregnant women, is to achieve a major advance in knowledge on levels of glucose during pregnancy that place the mother, fetus, and neonate at increased risk. The primary hypothesis is that hyperglycemia, less severe than overt DM, is associated with increased risk of adverse
Studies
39
maternal, fetal, and neonatal outcome that is independently related to the degree of metabolic disturbance. Specific Aims of HAPO are: 1. To examine glucose tolerance in a large, heterogeneous, multinational, multicultural, ethnically diverse cohort of women in the third trimester of gestation with medical caregivers "blinded" to status of glucose tolerance (except in those instances where fasting and/or two hour OGTT plasma glucose concentration exceeds a predefined cutoff value); and 2. To provide data that can be used to derive internationally acceptable criteria for the diagnosis and classification of gestational diabetes mellitus (GDM) based on the identification of pregnancies at risk for specific adverse outcomes. The study is to be accomplished with high quality standardized data collection on the women during the third trimester of gestation (including the OGTT) and at time of delivery for assessment of adverse outcomes, including fetal hyperinsulinism, fetal obesity (macrosomia), operative delivery (caesarian section), and neonatal morbidity (hypoglycemia). HAPO is to include field centers and regional centers where the participants will be studied, a Clinical Coordinating Center and Data Coordinating Center, both located at the Northwestern University Medical School in Chicago, as well as a Central Laboratory located in Belfast, Northern Ireland. This application requests support for the Clinical Coordinating Center, the field and regional centers and Central Laboratory. Cost effectiveness for the HAPO study is enhanced through cost sharing by colleagues in non-U.S. centers. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IN UTERO METABOLIC PROGRAMMING OF THE OFFSPRING Principal Investigator & Institution: Devaskar, Sherin U.; Professor; Pediatrics; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2001; Project Start 05-AUG-2001; Project End 31-JUL-2006 Summary: Perinatal Origins of Adult Disease describes the association between the adult disease Syndrome X characterized by insulin resistance, obesity, dyslipidemia, hypertension and coronary artery disease, and intrauterine growth restriction (IUGR). To decipher the mechanism behind this association we examined the skeletal muscle insulin responsive glucose transporter (GLUT 4), that mediates the critical rate-limiting step in the insulin signaling cascade. We used two in-utero extremes of metabolic perturbations (nutrient excess versus restriction) associated with IUGR, along with postnatal nutrient modifications (ad lib restricted access to milk intake) and observed a decline in the adult skeletal muscle GLUT 4 function. This change was mediated by divergent mechanisms, e.g., by suppression of insulin-induced GLUT 4 translocation to the sarcolemma in the case of in-utero nutrient excess and a transcriptional decrease in GLUT 4 expression in the case of in-utero nutrient restriction. Based on the available information and our preliminary results, we hypothesize that aberrations in the in-utero metabolic environment of the IUGR progeny along with postnatal nutritional modifications (ad lib versus restricted access to milk intake) and observed a decline in the adult skeletal muscle GLUT 4 function. This change was mediated by divergent mechanisms, e.g., by suppression of insulin- induced GLUT translocation to the Sarcolemma in the case of in-utero nutrient excess and transcriptional decrease in GLUT 4 expression in the case of in-utero nutrient restriction. Based on the available information and our preliminary results, we hypothesize that aberrations in the in-utero metabolic environment of the IUGR progeny alone with postnatal nutritional modifications regulate mechanisms responsible for aberrant skeletal muscle GLUT4 expression, translocation, and function which cause a maladaptation in the adult that
40
Gestational Diabetes
leads to insulin resistance. We will test this hypothesis by the following specific aims in rat models of streptozotocin-induced maternal diabetes with IUGR and prenatal starvation with IUGR. In both cases the offsprings will have ad lib or restricted access to milk intake 1] to determine the mechanisms regulating skeletal muscle GLUT 4 expression, availability, and function in the adult IUGR progeny exposed in-utero to nutrient excess and postnatal nutritional modifications, we will assess: a] total GLUT 4 mRNA and protein concentrations; b] the insulin-induced translocation of GLUT 4 from the intracellular, low-density microsomes to the sarcolemmal compartment; c] the alteration(s) in GLUT 4 DNA-bindability by certain nuclear trans-activating factors; and, d] the insulin translocation of GLUT 4 from LDM to PM, and the basal and insulininduced cytochalasin B inhibitable 14C- glucose transport at d2, d21, d60 and d180 developmental stages in the progeny of the prenatally starved or control mothers who are allowed either ad lib or restricted postnatal milk intake. The results of these investigations will test our hypothesis and characterize the divergent mechanisms involved that alter the adult IUGR skeletal muscle GLUT4 concentrations/availability and function due to an in-utero metabolic program modified by postnatal nutritional influences. Defining these aberrant mechanisms will provide insights into the etiology of NIDDM. These studies will ultimately server as an impetus for the future development of interventional strategies to implement in childhood to target and prevent adult disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INSULIN RESISTANCE AND GLUCOSE METABOLISM IN PREGNANCY Principal Investigator & Institution: Catalano, Patrick M.; Professor; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2001; Project Start 01-DEC-2000; Project End 30-NOV-2001 Summary: The long term objectives are to understand the relationship of pregavid maternal lipid metabolism and maternal metabolic adaptations during pregnancy at the system and cellular level. The specific aims of this proposal are to : evaluate the longitudinal changes in maternal insulin sensitivity as it relates to maternal lipid metabolism and fat accretion in lean and obese women with normal glucose tolerance and gestational diabetes; evaluate the alterations in maternal lipid metabolism in late pregnancy in relationship to neonatal body composition; and, identify the cellular mechanisms underlying decreased insulin sensitivity in adipose tissue during late gestation in normal glucose tolerance and gestational diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INSULIN SENSITIVITY AND LIPID TURNOVER Principal Investigator & Institution: Reece, E A.; Temple University 406 Usb, 083-45 Philadelphia, Pa 19122 Timing: Fiscal Year 2001 Summary: The purpose of this project is to study fuel metabolism longitudinally during normal gestation and during pregnancies complicated by diabetes mellitus. The objectives are to examine insulin sensitivity and glucose turnover through normal pregnancy and the postpartal period and to characterize the normal and pathologic metabolic alterations that occur in a pregnancy complicated by both pre-gestational and gestational diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
41
Project Title: INSULIN SIGNALING IN GDM & PLACENTAL HORMONES Principal Investigator & Institution: Barbour, Linda A.; Medicine; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2007 Summary: As a candidate, I have a longstanding interdepartmental collaboration between the departments of Medicine and Obstetrics and Gynecology with a long-term goal to become an independent researcher in gestational diabetes (GDM) and placental hormone physiology. The K-23 Award would allow me to combined clinical research skills I have gained by attaining my MSPH degree and basic research skills I am obtaining through my endocrinology fellowship in order to become a productive clinical investigator. My proposed patient oriented research focuses on the mechanisms of abnormal insulin signaling in GDM and the role of placental hormones in causing the insulin resistance of pregnancy. This award would allow me to gain expertise in executing patient oriented research on the Adult GCRC. The goal of this proposed longitudinal research project is to define the underlying abnormalities in insulin signaling in women with gestational diabetes, determine whether these abnormalities persist in women with normalize their glucose tolerance postpartum versus those who do not, and determine the placental hormones responsible for causing the insulin resistance of pregnancy. Gestational diabetes (GDM) complicates 3-10% of all pregnancies and is increasing in incidence, yet little is known about the molecular mechanisms of the insulin resistance. It results in significant morbidity to both the mother and the fetus, including a 50% risk of developing Type 2 DM in the mother, and a high prevalence of childhood obesity and adult DM in the offspring. This research would examine mechanisms of insulin resistance in others with GDM compared to pregnant controls by studying abnormalities in insulin signaling in skeletal muscle in a longitudinal prospective manner. This would be achieved by obtaining muscle biopsies before and after an oral glucose load in these two groups of women at 24-32 weeks of pregnancy. In order to examine whether or not these abnormalities persist postpartum, repeat muscle biopsies will be taken at 8-12 weeks postpartum before and after the same glucose load. Women with history of GDM who normalize their glucose tolerance will be compared to those who continue to have impaired glucose tolerance postpartum. Lastly, the cause of the insulin resistance in pregnancy will be examined by exposing muscle fibers taken at elective abdominal surgeries in non- pregnant women to placental hormones, including human placental growth hormone and human placental lactogen. This will determine whether the in-vivo insulin signaling abnormalities can be recreated in vitro with placental hormones individuals or in combination. Identifying the abnormalities in insulin signaling in this high risk population as well as the role of placental hormones in mediating the insulin resistance of pregnancy is critical so that progress can ultimately be made towards the prevention of Type 2 diabetes in the mother as well obesity and glucose tolerance in her offspring. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ISLET FUNCTION IN TYPE 2 DIABETES Principal Investigator & Institution: Kahn, Steven E.; Medicine; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2001; Project Start 01-AUG-1999; Project End 30-JUN-2004 Summary: The clinical studies in this application are focused on the pathophysiology of type 2 diabetes mellitus and specifically the alterations in islet B-cell function that characterize this disease process. Three specific objectives (with their experimental
42
Gestational Diabetes
approaches) have been identified. 1. To determine whether subjects at high risk of developing type 2 diabetes (women with a history of gestational diabetes, individuals with a first degree relative with the disease and individuals with impaired glucose tolerance) have defects in B-cell function that can be exacerbated by increased secretory demand resulting in the development of hyperglycemia. Increased B-cell secretory demand will be produced by inducing experimental insulin resistance with nicotinic acid. 2. To determine whether the disproportionate pro-insulinemia observed in subjects with type 2 diabetes is due to a fundamental alteration in pro- insulin processing or whether it results from an increase in secretory demand with the premature release of Bcell secretory granules. Individuals with type 2 diabetes and healthy controls will be studied before and following 24 hours of islet B-cell result produced by an infusion of somatostatin. 3. To determine whether the disproportionate pro-insulinemia observed in subjects with type 2 diabetes is associated with disproportionate release of pro-islet amyloid polypeptide (proIAPP). An assay for proIAPP will be developed and measurements will be made in plasma from health subjects and subjects with type 2 diabetes to determine whether disproportionate release of proIAPP occurs in type 2 diabetes. The applicant has successfully trained a number of young investigators in the areas of patient-oriented and basic research and a plan to continue doing so is presented. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: KIDNEY PATHOLOGICAL STATES
DEVELOPMENT
DURING
NORMAL
AND
Principal Investigator & Institution: Robillard, Jean E.; Professor; University of Virginia Charlottesville Box 400195 Charlottesville, Va 22904 Timing: Fiscal Year 2002; Project Start 01-SEP-1997; Project End 31-AUG-2007 Summary: The processes that lead to the development and interaction of the specific absorptive and secretory functions of different nephron segments have not been evaluated in details. Recent studies have suggested that transition from metanephrogenic mesenchyme to functional epithelium is accompanied by reorganization and repatterning of plasma membrane ion channel expression and conductance. Studies by our group, as well as others have shown that Na+/K+-ATPase is localized to the apical membrane during early tubulogenesis and repolarized to the basolateral membrane later during development. Preliminary studies have demonstrated that alterations in the integrity of the fetal environment such as fetal hyperglycemia may have a profound effect on the normal development of Na+/K+ATPase polarization. The present proposal is designed to investigate in normal and pathological states (i.e., fetal hyperglycemia secondary to maternal diabetes) the mechanisms regulating the development of vectorial transport function in the kidney using Na+/K+-ATPase as a marker of tubular epithelial polarity. To achieve this aim we are proposing to test three specific hypotheses: (1) fetal hyperglycemia (as observed during maternal diabetes mellitus) leads to abnormalities of basolateral polarization of Na+/K+-ATPase and rearrangements of cytoskeleton proteins, namely ankyrin and spectrin; (2) phosphorylation of Na+/K+-ATPase and associated cytoskeleton proteins contributes to the development of Na+/K+-ATPase polarization and that fetal hyperglycemia alters these mechanisms; (3) abnormalities in epithelial Na+/K+-ATPase polarity originating during kidney embryogenesis become imprinted and lead to permanent alterations in tubular cellular organization postnatally. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
43
Project Title: MATERNAL DIABETES AND OOCYTE QUALITY Principal Investigator & Institution: Moley, Kelle H.; Associate Professor; Obstetrics and Gynecology; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): Despite a century of improvements in metabolic control, pregnancies in women with insulin-dependent diabetes are complicated by increased rates of spontaneous miscarriages and congenital malformations. In addition, animal models of diabetes show more serious in vivo effects on pregnancy outcome with diabetes starting prior to ovulation as compared to embryo culture in "diabetic" conditions. These observations suggest that the insult of maternal diabetes is occurring at the oocyte or early zygote stage and that this may represent irreversible maternal programming. In preliminary studies, we report that nuclear maturation is delayed in oocytes obtained from streptozotocin-induced diabetic mice and maturation is closely regulated by glucose metabolism. These mice also have a delay in the in vivo progression to a 2-cell zygote. We hypothesize that maternal hyperglycemia adversely affects the oocyte and/or early zygote at both a metabolic and morphologic level. We suggest this early programming may be responsible for subsequent problems in embryo development and for the adverse pregnancy outcomes in these patients. The following specific aims are designed to test these hypotheses: Specific Aim 1. Do denuded or intact murine oocytes exposed to hyperglycemia in vivo demonstrate any abnormalities compared to control oocytes with regard to in vivo maturation, glucose utilization and metabolism during maturation, or morphology and apoptotic signaling before and during maturation? Specific Aim 2. Are these abnormalities due to an irreversible preovulatory event or does ovarian transplantation into a nondiabetic mouse reverse these effects? Is embryo development improved with ovarian transplantation? Specific Aim 3. Are the delays at both the oocyte and early zygote stage responsible, in part, for the abnormalities in pre-implantation embryo development and poor pregnancy outcome? Is embryo development and pregnancy outcome improved with 1-cell transfer? If our hypothesis proves correct, abnormal carbohydrate metabolism, characteristic of not only insulin-dependent but also insulin-independent diabetics, as well as patients with Polycystic Ovary Syndrome, may be a risk factor for poor oocyte quality. These oocyte changes may explain the increased incidence of pregnancy failure in all three of these groups as well as obese, insulin resistant patients. Treatment that is more aggressive may be indicated for these patients throughout their reproductive years may be indicated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS BY WHICH GDM LEADS TO DIABETES IN OFFSPRING Principal Investigator & Institution: Simmons, Rebecca A.; Associate Professor of Pediatrics; Pediatrics; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-JUL-2006 Summary: (provided by applicant) In the human, diabetic pregnancy induces marked abnormalities in glucose homeostasis and insulin secretion in the fetus that results in aberrant fetal growth. Studies have suggested that there are long-term consequences for the offspring of diabetic mothers. We have developed a model of gestational diabetes (GDM) in the rat to determine whether an altered metabolic intrauterine milieu is directly linked to the development of diabetes later in life. Uteroplacental insufficiency
44
Gestational Diabetes
is induced in the pregnant rat on day 19 of gestation. Offspring are growth retarded at birth, however they catch-up by 5- 7 weeks of age. At 8 weeks of age they are bred to normal males. During pregnancy these animals develop hyperglycemia, hyperinsulinemia, and hyperlipidemia accompanied by impaired glucose tolerance and insulin resistance. Offspring, (F2's) are heavier at birth and remain heavy throughout life. F2's are insulin resistant very early in life and glucose homeostasis is progressively impaired. F2 rats go on to develop diabetes as adults. Although F2 animals display marked insulin resistance, the failure of the Beta-cell to compensate for defects in insulin action is the essential factor coincident with onset of diabetes. This failure of the Betacell to compensate may be due to a lack of compensatory increase in insulin secretion, an increased rate of cell death, a reduction in the rate of Beta-cell proliferation, or a combination of these events. The mechanism(s) underlying this lack of Beta-cell compensation and eventual decrease in Beta-cell mass in F2 animals are the focus of this proposal. We hypothesize that mitochondrial DNA damage from hyperglycemia via the production of reactive oxygen species (ROS) results in further escalation of genetic damage in the mitochondria, specifically in mutations. A self- reinforcing cycle of progressive deterioration in mitochondrial function leads to a corresponding decline in Beta-cell function. Finally, a threshold in mitochondrial dysfunction and ROS production is reached and Beta-cell death occurs. The onset of diabetes ensues when a critical level of abnormal Beta-cell insulin secretion combined with Beta-cell loss is reached. We will test the hypothesis that GDM does in fact cause mitochondrial dysfunction, oxidative stress, and deletions in mtDNA in the Beta-cell of the offspring, and whether these effects act synergistically to lead to the development of the Beta-cell failure and type II diabetes. To link the damage to the mitochondria caused by hyperglycemia to the Beta-cell phenotype observed in type II diabetes we will induce Beta-cell failure in vitro by transferring damaged mitochondria from F2 animals into Beta-cells from unaffected. non-F2 animals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: METABOLIC EFFECTS OF PREGNANCY IN CYSTIC FIBROSIS (SS) Principal Investigator & Institution: Hardin, Dana S.; Associate Professor; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2001; Project Start 01-DEC-2000; Project End 31-MAR-2002 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR BASIS OF ISL-1 INDUCED BIRTH DEFECTS Principal Investigator & Institution: Dinh, Hong-Khanh B.; Munroe-Meyer Institute; University of Nebraska Medical Center Omaha, Ne 681987835 Timing: Fiscal Year 2002; Project Start 01-AUG-2002 Summary: (provided by applicant): The purpose of this research is to investigate the molecular basis of birth defects, characteristic of diabetic embryopathy, resulting from maternal diabetes using an Islet-1 (Isl-1) transgenic mouse model. Expression of the transcription factor lsl-l is necessary for normal pancreatic development. We found that dysreguIation of Isl-1 causes sacral/caudal agenesis similar to human dIabetic embryopathy. These results suggest that embryonic lsl-1 expression may be dysregulated in diabetic pregnancies. The Isl-1 transgenic mouse model, therefore provides a suitable model for studying the genetic response and will be utilized to elucidate the molecular pathways and possible biological/transcriptional targets
Studies
45
downstream of Is!-!. Using a binary transgenic mouse model to generate IsI- I transgenics. we have control over incremental differences in gene dosage, dependent on whether the embryo is hemizygous or homozygous for the transactivator or transresponder gene. This allows us to identify transcriptional targets of Isl-1 by focusing on two parameters, gene dosage and developmental tune point (E8.5-E 12.5). Three specific aims will be pursued: I) Evaluation of candidate lsl-1 targets using quantitative RT-PCR and in situ hybridizations. 2) Identification of new Isl-1 targets by gene expression profiling. The 15K mouse developmental gene cDNA collection and an interpretation framework specifically designed for this project will be used. in particular. microarray analysis of transgenics with high gene dosage. resulting in a more severe phenotype, will help identify compulsory target genes to the defect. 3) Gene expression studies on candidate and new Isl-l targets will be used to compare the developmental defects in lsl-1 transgenics to chemically (Alloxan) induced diabetic embrvopathies. Comparison of the genetic and the pharmacological mode! will determine whether developmental defects in diabetic embryopathv and in our Isl-1 transgenic model arise through common molecular perturbations. This study will elucidate the molecular pathways leading to sacral/caudal agenesis. The information may be further used to devise treatment strategies for diabetic mothers during pregnancy to offset the molecular changes that Lead to diabetic embrvopathies and to reduce newborn morbidity due to the developmental defect. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR GENETICS OF GESTATIONAL DIABETES MELLITUS-A GENETIC PREDISPOSITION Principal Investigator & Institution: Lowe, William; Northwestern University Office of Sponsored Programs Chicago, Il 60611 Timing: Fiscal Year 2001 Summary: Women who develop gestational diabetes mellitus (GDM) progress to diabetes outside of pregnancy at a rate >5%/yr and account, therefore, for a sizable proportion of people with non-insulin dependent diabetes mellitus (NIDDM) whose mean age at diagnosis is relatively young. Moreover, impaired b-cell function is an important early predictor of the risk of developing DM among women with GDM. For these reasons, we have hypothesized that women with gestational diabetes mellitus (GDM) share a unique set of genetic characteristics apart from other presentations of NIDDM. The proposed studies are designed to create a bank of genomic DNA from and phenotypic information on several groups of participants, including (i)women with NIDDM subsequent to a history of GDM, (ii)women with a history of GDM who have normal glucose tolerance, (iii)women who do not have a history of GDM, (iv)individuals with typical, late-onset NIDDM (defined as onset after age 50), and (v)a reference group of individuals with normal glucose tolerance but who are at risk factor for late-onset NIDDM based upon a family history of a first degree relative with NIDDM, age over 50, or ethnicity (African-American, Hispanic, or Native American). This DNA and phenotypic information will be used to address our hypothesis in the present and future studies by examining the frequency of polymorphisms/mutations in previously identified genes that predispose to the development of maturity onset diabetes of the young (MODY), NIDDM, and obesity (a risk factor for NIDDM) in the different groups of participants and the association of those polymorphisms/mutations with alterations in the different phenotypic characteristics. These studies will be conducted using the about 1000 people who are currently undergoing oral glucose tolerance tests to determine their eligibility for participation in the Diabetes Prevention
46
Gestational Diabetes
Program at Northwestern University Medical School and about 450 people who will be enrolled in another CRC-approved study ("Are Polymorphic Variants of the Leptin Receptor Gene Associated with Obesity and Gestational Diabetes Mellitus" - Protocol 597). The specific analysis that will be conducted in the proposed study will be to determine the prevalence rate of mutations in the transcription factor hepatocyte nuclear factor-1a in women with NIDDM subsequent to a history of GDM compared to the other four groups. Mutations in this gene result in maturity-onset diabetes of the young (MODY) and are, thus, associated with onset of diabetes at a young age. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER NETWORK OF MATERNAL-FETAL MEDICINE UNITS Principal Investigator & Institution: Conway, Deborah L.; Obstetrics and Gynecology; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, Tx 78229 Timing: Fiscal Year 2001; Project Start 01-MAY-1996; Project End 31-MAR-2003 Summary: We propose to participate as one of the academic centers in the Cooperative Multicenter Maternal-Fetal Medicine Units Network. The investigators are members of the Departments of Obstetrics, Internal Medicine, and Pediatrics (Neonatology) of the University of Texas Health Science Center at San Antonio. We have the capability of drawing from the large Mexican-American populations of Bexar County, Texas and surrounding counties in our region. We have extensive and recent experience in research design, recruitment of minority populations, and conduct of clinical and basic science studies. Our investigators are experienced in large clinical studies that have been multicentric, randomized, and observational studies. Prior investigations included two studies in which more than 5000 Mexican-American subjects were successfully enrolled. We also have extensive experience in the conduct of NIH-sponsored studies. Although our Department has multiple research interests in clinical obstetrics, it is in the areas of diabetes in pregnancy and prematurity that we have a special expertise. Diabetes is the most common medical complication in pregnancy and is especially common in Mexican-American women. A unique feature of our diabetic program is the conglomerate of experts available in San Antonio to study all aspects of the disease, i.e., epidemiological, clinical, and basic science components. Low birth weight and prematurity have been extensively studied in this Department where our added strength lies in the attention to psychosocial factors in the etiology of disease including design and evaluation of behavioral interventions, and experience with culturally appropriate questionnaires and protocols. With the largest Mexican-American pool of prospective subjects for study in Texas, our center may serve as a facilitator in a collaborative effort across centers that would allow comparison of several clinical conditions in different ethnic groups. At the UTHSCSA, the investigators are enthusiastic at the prospect of participating in the MFMU Network. They have a long record of successful collaboration and anticipate cooperative interaction with the NIH project officer, the Network, and Publication Committee in the implementation, conduct and publication of studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MULTICENTER NETWORK OF MATERNAL-FETAL MEDICINE UNITS Principal Investigator & Institution: Varner, Michael W.; Obstetrics-Gynecology; University of Utah 200 S University St Salt Lake City, Ut 84112
Studies
47
Timing: Fiscal Year 2001; Project Start 01-MAY-1996; Project End 31-MAR-2001 Summary: The purpose of this proposal is to show that the Division of Maternal- Fetal Medicine (MFM) at the University of Utah Health Sciences Center is an excellent candidate to become a member of the Maternal-Fetal Medicine Units (MFMU) Network sponsored by the National Institute of Child Health and Human Development. The MFM Division has the past record of academic productivity, previous success in participating in multicenter trials, access to a suitable and cooperative patient population, and several unique strengths which allows the MFM Division to bring to the MFMU Network the ability to successfully perform clinical trials with a strong basic science background. The specific aims of this proposal are: (1) to describe the organizational structure of the division with regard to the MFMU network, the demographics of our patient population, and the strengths of individual division members; (2) to show our ability to design and propose a multicenter trial; and (3) to describe special strengths of the division which will be made available to the MFMU network. We have been successful in several multicenter trials over the past five years, and our participation in these studies will be detailed. We will describe the organization of our research efforts, the patient population available for study, research nurse staffing, the clinical strengths of our program, our computerized perinatal data base, and the neonatology services available for multicenter studies. Our proposed study, entitled "The safety and efficacy of single vs. weekly administration of corticosteroids for the acceleration of fetal lung maturity", will demonstrate our ability to use our current perinatal data base to design and execute a randomized clinical multicenter trial. The on-going research efforts in our Division have led to the development of renowned basic science programs in Perinatal Genetics (including molecular genetics) and Reproductive lmmunology and the services of these laboratories will be made available for participation in MFMU Network protocols. Most importantly, the MFM Division has access to a large number of high-risk and low-risk pregnancies because we provide clinical coverage for four affiliated hospitals with a combined delivery total of greater than 12,000 deliveries per year. Adequate patient numbers for MFMU Network protocols would be expected given the total number of patients which can be approached for enrollment and the cooperative nature of the population. These features, along with our unique geographic region, distinguish the MFM Division at the University of Utah as a productive and successful academic group which will enhance the MFMU Network. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER NETWORK OF MATERNAL-FETAL MEDICINE UNITS Principal Investigator & Institution: Egerman, Robert S.; Associate Professor; Obstetrics and Gynecology; University of Tennessee Health Sci Ctr Health Science Center Memphis, Tn 38163 Timing: Fiscal Year 2000; Project Start 05-MAY-1996; Project End 31-DEC-2003 Summary: The Department of Obstetrics and Gynecology at the University of Tennessee, Memphis has been part of the Maternal-Fetal Medicine Network since April 1986. With this application, we hope to participate in a large multicenter network designed to develop and conduct clinical trials in the field of Maternal-Fetal Medicine, which could not be undertaken in a single center. In comparison to our previous application, we have recently expanded our resources and facilities to include patients at all major hospitals in the city. The obstetric population will now total approximately 13,000 women of various ethnic and economic groups. We are particularly interested in
48
Gestational Diabetes
pursuing trials which require large sample size in order to adequately address specific questions and those regarding rare events of obstetric interest. The Principal Investigator, Dr. Baha Sibai, and the Alternate Principal Investigator, Dr. Brian Mercer, as well as the faculty in the Division of Maternal-Fetal Medicine continue to be active in Network administrative activities, and the design and conduct of protocols. The Principal Investigator currently participates on the Concurrent Research Committee, the Ad Hoc Committee on Preterm Studies, and the "High-Risk" Aspirin Protocol, the Interim Progesterone, and the Preliminary Terbutaline subcommittees. The Alternate Principal Investigator chairs the "Premature Rupture of Membranes" protocol and the Chart Review Subcommittee. He serves on the Capitation Subcommittee, Preterm PROM Pathology Subcommittee, Preterm Prediction Protocol Subcommittee, Obstetrical Determinants of Neonatal Survival Protocol Subcommittee, Neural Tube Defect Protocol Subcommittee and the Preliminary MgSO4 Subcommittee. He has recently submitted for consideration a clinical trial regarding tocolytic, corticosteroid and antimicrobial therapy after PROM. We are applying to continue as a clinical research center within the Network and agree to join protocols in existence and participate in the design of protocols in cooperation with other centers selected by the NICHD. The University of Tennessee, Memphis, and the Department of Obstetrics and Gynecology are committed to collaborative Maternal-Fetal research as documented by listed publications and the enclosed letters of commitment. The Division of Maternal-Fetal Medicine agrees to cooperate with the policy of capitation of research costs for each individual protocol, in addition to a base budget. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER NETWORK OF MATERNAL-FETAL MEDICINE UNITS Principal Investigator & Institution: Leveno, Kenneth J.; Professor; Obstetrics and Gynecology; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2001; Project Start 05-MAY-1996; Project End 31-MAR-2001 Summary: This proposal describes the qualifications and experience of the MaternalFetal Medicine faculty and research team at the University of Texas Southwestern Medical Center and Parkland Hospital and the facilities and patient population available to them for carrying out clinical protocols to be designed by the NICHD Maternal-Fetal Medicine Units Network. UT Southwestern's Division of Maternal-Fetal Medicine include 11 physicians, 9 of whom are board-certified in Maternal-Fetal Medicine. A total of 6 research nurses experienced in perinatal research lead by a research nurse coordinator with 12 years experience in protocol development and implementation are available for participation in MFM Units Network protocols. A computerized perinatal database that has been operational since late 1982 is a centerpiece in perinatal research team efforts at UT Southwestern Medical Center Parkland Hospital. The perinatal research team has successfully completed several randomized trials and submitted with this application is an example of such effort in 2,138 women with pregnancy-induced hypertension who were randomized to receive magnesium sulfate or phenytoin for eclampsia prophylaxis during labor. In 1994 there were 13,935 deliveries at Parkland Hospital and approximately 55% were high-risk. Pregnancy complications of particular interest to the MFM Units Network, e.g. preterm birth and gestational diabetes are well represented in the obstetric population at Parkland Hospital. Importantly the maternal-fetal medicine physicians at Parkland Hospital are philosophically committed to rigorous controlled trials intended to objectively evaluate principals of obstetrical care before adoption of these interventions
Studies
49
into clinical practice. Other resources brought to the MFM Units Network include support of UT Southwestern's NIH General Clinical Research Center, the Cecil H. and Ida Green Center for Reproductive Biology Sciences and collaboration with the NICHD Neonatal Unit Network through support of the local neonatal network principle investigator. The perinatal research team now described is committed to collaborative participation consistent with the goals of the MFM Units Network. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER NETWORK OF NEONATAL INTENSIVE CARE UNITS Principal Investigator & Institution: Korones, Sheldon B.; Pediatrics; University of Tennessee Health Sci Ctr Health Science Center Memphis, Tn 38163 Timing: Fiscal Year 2001; Project Start 01-APR-1991; Project End 31-MAR-2003 Summary: We present qualifications in this application to justify continued participation in the Neonatal Network. They are as follow: Size: Few, if any single, nurseries can contribute a larger patient population for study. Expertise: We have an uncommonly rich and protracted experience in multicenter trials. Our scientific research and its publications are substantial; the diversity and depth of expert support personnel is noteworthy. Training program: As a division of the Department of pediatrics, Newborn Medicine is taught in accordance with residency requirements. We are approved for fellowship training in Neonatal- perinatal Medicine. Administrative control: This large unit has been favored with considerable intramural control and institutional priority by virtue of its role in community health and its research activities. Facilities: Copious space, ample equipment and intramural control of a clinical laboratory with broad functions provide the wherewithal for effective clinical investigation. Perinatal data system: We have compiled data manually since 1972, by computer since 1979. We have extensive data stored for the past 15 years, describing demographics, diagnoses, outcomes, procedures and therapies. Inborn admissions: Approximately 95% of admissions are inborn and the number of back-transferred outborn infants is negligible, thereby increasing the number of babies available for study. Obstetrical coordination: The Neonatal Division is an official component of the Department of Obstetrics and Gynecology. Historically, our relationship with the obstetricians has been exemplary and productive. Fiscal efficiency: We are adept at budget management; in previous multicenter studies our costs have been lower than most other participants. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEUROPHYSIOLOGIC ASSESSMENT OF AT RISK NEWBORNS Principal Investigator & Institution: Nelson, Charles A.; Distinguished Mcknight University Profes; Institute of Child Development; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2001; Project Start 01-JAN-1995; Project End 30-APR-2003 Summary: (adapted from applicant's abstract) In this competing continuation grant we propose to continue testing samples of infants born to diabetic mothers (IDM) and health control infants. The hypothesis under investigations is that iron deficiency with or without fetal hypoxia can selectively damage the structures in the medial temporal lobe that are involved in explicit memory; thus, we predict that IDM infants may be at risk for developing impairments in memory. In our current grant we have focused on evaluating auditory and visual recognition memory in newborn through 12 month old infants. In this competing continuation grant, we intend to a) enroll subjects for one
50
Gestational Diabetes
additional year, and b) test these subjects, as well as our existing cohort of subjects, through the age of 4 years. In the first year of life we will use electrophysiological (event-related potentials, or ERPs) and behavioral (e.g., looking time) tools to evaluate infants recognition memory of social) e.g., mother's voice, face) stimuli, as well as evaluate simple auditory discrimination abilities (speech vs. non-speech). At 12 months of age the Bayley exam will be performed, as well as the first of three tests involving deferred imitation abilities (a task presumed to be mediated by the hippocampus). Deferred imitation will also be performed at 18 and 24 months of age. At 36 and 48 months we will evaluate hippocampal and amygdala functioning by studying children's performance in (respectively) a Delayed Non-Matching to Sample paradigm, and in a task of visual recognition of emotion. At all ages beyond 1 year testing will involve the recording of high-density (128 channels) ERPs. Finally, at 48 months of age the WPPSI IQ test will be administered. We are hypothesizing that our IDM infants will show selective deficits in our temporal lobe (memory) tasks, and will perform in the normal range on our IQ outcome measures. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NIDDM PRIMARY PREVENTION TRIAL (DPT 2) Principal Investigator & Institution: Pi-Sunyer, F. Xavier.; Director; St. Luke's-Roosevelt Inst for Hlth Scis Health Sciences New York, Ny 10019 Timing: Fiscal Year 2001; Project Start 15-AUG-1994; Project End 30-JUN-2003 Summary: The specific aims of this proposal are two-fold: the first aim is to conduct a multi-center, randomized clinical trial to evaluate the efficacy of intervening to delay or prevent the onset of non-insulin dependent diabetes mellitus (NIDDM) in individuals at increased risk of NIDDM. These individuals will consist of persons with impaired glucose tolerance (IGT) and persons with a previous diagnosis of gestational diabetes mellitus (GDM) who now have IGT. The second aim is to conduct a multi-center, randomized clinical trial to evaluate the efficacy of intervening to prevent the deterioration of previously undiagnosed NIDDM (early, asymptomatic NIDDM found during screening). All subjects will be identified by screening. At least 50% of the sample will be minority. The individuals in the first group will be those with IGT. Individuals in the second group will be those with newly diagnosed NIDDM. Criteria will be set to take only mild NIDDM for the trial, the more severely compromised patients will be referred for treatment. Individuals in both groups will be randomized into an Experimental and a Control Group. Intervention for the Experimental Group will consist of two Levels. Level I will be initiated first and will be a diet, exercise, and behavior modification program. Level II, pharmacological intervention with metformin, will be added in Level I is unsuccessful. Intervention in the Control Group will only be contact every 6 months for glucose testing. Subjects will be followed for 5 yrs with periodic testing for glucose intolerance. The major end point will be the 2 hr post glucose venous plasma. value. Twenty sites will serve as Centers and each site will enroll 98 patients. Each site will emphasize one or two racial/ethnic groups. Our Center will plan to study Caucasian and Black volunteers, although we could also study Hispanics if the protocol writers wished us to do so. There will be an initial planning phase of 1 yr, a clinical trial phase of 5 yrs, and a close-out phase of 1 yr. There will be a Data Coordinating Center that will collect all data and will be in charge of the central clinical laboratory. Our Center has the appropriate population base for both the IGT and the GMD parts of this clinical trial and well-trained, experienced personnel for carrying out the protocol. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
51
Project Title: NIDDM PRIMARY PREVENTION TRIAL (DPT 2) Principal Investigator & Institution: Goldstein, Barry J.; Director; Medicine; Thomas Jefferson University Office of Research Administration Philadelphia, Pa 191075587 Timing: Fiscal Year 2001; Project Start 15-AUG-1994; Project End 30-JUN-2003 Summary: The objective of this multicenter clinical trial is to develop interventions to prevent the development of NIDDM in people with a history of gestational diabetes (GDM) and impaired glucose tolerance (IGT) (Cohort I primary prevention) and the worsening of glucose tolerance in people with newly diagnosed NIDDM with an FPG less than 140 mg/dl (Cohort II, secondary prevention). The central hypothesis of this application is that improvement of insulin resistance will delay the onset of NIDDM in individuals at risk. Therefore, we propose a five year randomized non-pharmacological and pharmacological factorial treatment design aimed to improve insulin resistance: Stratification will assure an overall trial representation of Black (0.4), Hispanic (0.2), Native American (0.2), GDM (0.2) and other races including Caucasian (1.0) Power calculations indicate that 20 centers contributing with 200 patients each will be necessary to fulfill the goal of the study. We will recruit the study subjects from among the Thomas Jefferson University employees. From a preliminary survey of the 7,294 fulltime employees with a response rate of 58% revealed that 52% of the employees are at risk for NIDDM and that 76% have indicated interest in a NIDDM prevention trial, if available. It is hoped that the screening treatment follow-up and outcome measures methods will be translated to the society at large. To this end, it is important that both community and work-site models be developed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NIDDM PRIMARY PREVENTION TRIAL (DPT 2) Principal Investigator & Institution: Bray, George A.; Director; None; Lsu Pennington Biomedical Research Ctr 6400 Perkins Rd Baton Rouge, La 70808 Timing: Fiscal Year 2001; Project Start 15-AUG-1994; Project End 30-JUN-2003 Summary: Non-insulin Dependent Diabetes Mellitus develops in individuals who have peripheral tissue resistance to the action of insulin. These individuals often make normal or increased amounts of insulin but are unable to maintain physiologic blood glucose concentrations because of this defect. Women who develop gestational diabetes mellitus manifest this peripheral insulin resistance and 30% go on to develop noninsulin dependent diabetes within five years of the diagnosis of gestational diabetes mellitus. Women with increased risk for developing NIDDM will be identified as high risk at the Genesis Obstetrical Center in Tampa. These women will be evaluated after pregnancy and divided into two categories based upon fasting plasma glucose values. The first will be those women with fasting plasma glucose values less than 110 mg/ dl. The second will be women with fasting plasma glucose equal to or greater than 110 mg/ dl but less than 140 mg/dl. These individuals will have serum islet cell antibodies, insulin autoantibodies, tested to determine that they do not have autoimmune diabetes mellitus. They will then have an oral glucose tolerance test to determine whether they have normal or impaired glucose tolerance or diabetes mellitus as defined by the National Diabetes Data Group. These individuals will then be randomized into four intervention groups. Each individual will have - peripheral insulin sensitivity determined with a glucose clamp experiment. The first group will be placed on a calorically restricted diet (1600-1800 Kcal/day) and started on an aerobic exercise program designed to reduce body mass index. The next group will receive one of a number of oral agents (sulfonylureas, thiozolidinolione, or magnesium chloride) with
52
Gestational Diabetes
potential for reducing peripheral insulin resistance will be evaluated. The third group will have intensified insulin therapy provided 5 days annually since this has been shown in insulin dependent diabetes to reduce peripheral insulin resistance. The fourth group will receive an oral placebo and serve as controls. Each of these individuals will be seen on a quarterly basis to measure their height, weight, blood pressure, fasting plasma glucose levels, glycosylated hemoglobin, sex hormone binding protein, serum insulin and urinary C-peptide levels. Each of these individuals will have a glucose clamp experiment performed to determine the degree of insulin resistance and oral glucose tolerance test as an indicator of glucose homeostasis on an annual basis. This protocol will require two years to enroll the study subjects and 5-6 years of follow-up to determine the role of peripheral insulin resistance and the above interventions for the delay or prevention of NIDDM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NIDDM PRIMARY PREVENTION TRIAL (DPT-2) Principal Investigator & Institution: Goldberg, Ronald B.; Chief, Division of Diabetes and Metaboli; Medicine; University of Miami-Medical Box 248293 Coral Gables, Fl 33124 Timing: Fiscal Year 2001; Project Start 20-AUG-1994; Project End 30-JUN-2003 Summary: The objectives of this research proposal is to participate as a clinical center in a multicenter trial to determine whether the development of non- insulin dependent diabetes (NIDDM) can be prevented. We propose to identify 200 subjects at high risk for developing NIDDM over a 12-month period. Group I subjects with impaired glucose tolerance (IGT) will be identified from the African-American minority group by oral glucose tolerance testing (OGTT) and Group Il subjects with IGT will be identified from a large data base of women who have had post-gestational diabetes. In the course of screening these populations, it is anticipated that a proportion of subjects with undiagnosed diabetes will be identified by OGTT. Those without fasting hyperglycemia (<140 mg/dl) represent a very high risk group for progression to fasting hyperglycemia and will be included in the trial (Group III). Recruited subjects will be randomized either into a usual referred care (RC) group and a special intervention (SI) group aimed at achieving dietary modification (4% weight loss) and increased physical activity (600 Kcal/week) for a 4-5 year period. Half of the SI group will in addition receive the antihyperglycemic drug, Metformin (850 mg b.i.d.), and the other half placebo. Performance of yearly OGTT's will be used to compare rates of deterioration to fasting hyperglycemia in each of the three treatment groups, in addition to changes in insulin and cardiovascular risk factors. Subjects with IGT will be analyzed separately from those originally found to have diabetes, since the natural history and response to treatment may differ between the two. It is anticipated that intervention in patients at high risk for diabetes, with diet, physical activity or pharmacologic agents may slow or prevent their deterioration to NIDDM and offer a new approach to the treatment of this disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NIDDM PRIMARY PREVENTION TRIAL (DPT-2) Principal Investigator & Institution: Saudek, Christopher D.; Professor of Medicine; Endocrinology and Metabolism; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 01-SEP-1994; Project End 30-JUN-2003
Studies
53
Summary: The application proposes to be a collaborating clinical center in the Noninsulin-dependent diabetes (NIDDM) Primary Trial. Working on a Steering Committee, we will help design the trial and Operations Manual in Year 01, implement it in Years 02-06, and close it in Year 07. The enormity of the NIDDM problem, rationale for primary prevention, and specific background are reviewed. Eligibility will be determined by the presence of impaired glucose tolerance, a history of gestational diabetes mellitus, or previously undiagnosed mild (FPG less than 140 mg/dl) NIDDM. Recruitment of more than 200 subjects randomized will be accomplished by proven methods of community screening and mailings, in large employment and population centers, targeting more than 50% African-American subjects. The trial will be implemented in an existing facility (Hopkins ProHealth) designed and staffed specifically for the implementation of large, multicenter, NIH-supported clinical trials. A faculty with wide diversity of expertise in clinical diabetes, epidemiology, behavioral change, exercise, diet and community intervention strategies and assessment will take part in study development and implementation; an expert staff is already in place at ProHealth, including a Study Coordinator, Recruiters, Interventionists and Data Collectors, will implement the study on a daily basis. Based on preliminary biostatistical considerations, a 3-arm trial is proposed, comparing intensive life style changes (diet and increased activity) with a pharmacologic arm (sulfinylureas) and a placebo are. The proposed primary outcome measure is incidence of NIDDM with FPG greater than 140 mg/dl; secondary outcome measures include a stepped deterioration of glucose tolerance, cardiovascular risk factors associated with NIDDM, quality of life measures, cost, and morbidity/mortality. Intervention strategies and visit schedules are outlined. Assuming a placebo-group event rate of 5% to 10% per year, two intervention groups will detect a 22% to 30% effect of interventions. In sum, this is a strong faculty and staff with extensive experience, an up-and-running clinical trials facility ready to take part in the collaborative effort of designing and implementing this primary prevention trial. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NIDDM PRIMARY PREVENTION TRIAL (DPT-2) Principal Investigator & Institution: White, Neil; Pediatrics; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2001; Project Start 20-AUG-1994; Project End 30-JUN-2003 Summary: The applicants propose that the overall goal of the proposed NIDDM Primary Prevention Trial should be to prevent the development or progression of early NIDDM in high risk volunteers with IGT or a prior history of gestational diabetes mellitus (GDM) by correcting behaviors thought responsible for the increase in NIDDM. The proposed intervention is centered on an intensive, multi-disciplinary, program to promote long-term weight loss and increased physical activity among 200 volunteers who work in or live near the Washington University Medical Center in St. Louis. The proposed intervention is designed to minimize physical discomfort and life style disruption, to emphasize gradual, moderate changes in the foods usually eaten, to maximize continued adherence over five years and to be acceptable to both white and African American volunteers. In order to sustain this weight loss long term, it is proposed to have the intensively managed patients seen regularly by trained members of a multidisciplinary team that will consist of an exercise technician, a nutritionist, a nurse, and a social worker trained in behavioral medicine. Volunteers randomized to the control group will be seen quarterly and provided with state of the art educational and motivational materials that will include recommendations for weight loss, increased physical activity aid a prudent diet low in saturated fats and cholesterol. Three first
54
Gestational Diabetes
stage studies are proposed for high risk white and African American volunteers. The NIDDM Primary Prevention Study, will compare rates of conversion from persistent IGT to persistent, mild NIDDM (defined operationally as patients with fasting plasma glucoses less than 140 mg/dl and both one and two hour values above 200 mg/dl) and improvement to normal glucose tolerance. The NIDDM Early Intervention Study, will examine the effects of the intensive intervention on patients found during screening to have mild NIDDM. The third, GDM Primary Prevention Study, will compare rates of progression from normal glucose tolerance to IGT or NIDDM in women with previous GDM. A single, second stage, intervention is proposed for volunteers who proceed to develop sustained fasting glucoses> 140 mg/dl. These patients will remain in their original treatment assignment (i.e. intensive or conventional treatment) for the duration of the Trial but will be randomly assigned to one of two drug treatment protocols to be chosen by early 1995 during the design of the trial. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NIDDM PRIMARY PREVENTION TRIAL (DPT-2) Principal Investigator & Institution: Horton, Edward S.; Director, Endocrinology & Metabolism; Joslin Diabetes Center Boston, Ma 02215 Timing: Fiscal Year 2001; Project Start 20-AUG-1994; Project End 30-JUN-2003 Summary: Several factors are known to increase the risk of developing NIDDM, including a family history of diabetes, previous history of gestational diabetes (GDM), obesity, decreased physical activity, presence of impaired glucose tolerance (IGT) or insulin resistance. Moreover, the incidence of NIDDM is higher in several racial and ethnic minority groups in the US including African Americans, Hispanics, Native Americans, Native Alaskans, and Asian Americans. A five year multicenter trial is proposed to evaluate intervention strategies to prevent or delay the progression of IGT to NIDDM, or the progression of previously undiagnosed NIDDM with normal fasting glucose to fasting hyperglycemia. Within the context of the overall study design, the Joslin Diabetes Center, (JDC) South Cove Community Health Center (SCCHC) and Brigham and Women's Hospital (BWH) will collaborate to form a participating clinical center and will identify a cohort of 200 high risk patients (equal to approximately 100 patients with IGT or previously undiagnosed NIDDM and 100 obese women with a previous history of GDM) to be prospectively and randomly assigned to one of four intervention groups, comprising a 2 x 2 factorial design. Half of the patients will receive standard diet and exercise recommendations (standard group), while half will receive an intensive lifestyle modification program, including individualized dietary and exercise programs, instruction in behavioral change, stress reduction, smoking cessation and close follow up (intensive group). Within each group, half will be randomized to treatment with low dose sulfonylurea, and half will receive placebo. Volunteers will be screened and recruited from specifically identified high risk populations. These include first degree relatives of patients with NIDDM at the JDC, first degree relatives of patients with NIDDM at the SCCHC, first degree relatives of patients with NIDDM in the Harvard Community Health Plan and patients with a past history of obesity and GDM at BWH. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: OBESITY, GLUCOSE METABOLISM AND DIET IN OLDER WOMEN Principal Investigator & Institution: Ryan, Alice S.; Associate Professor; Medicine; University of Maryland Balt Prof School Baltimore, Md 21201
Studies
55
Timing: Fiscal Year 2001; Project Start 01-SEP-1997; Project End 31-AUG-2003 Summary: The candidate is an Exercise Physiologist whose initial research and funded pilot projects focused on the effects of diet and exercise on obesity and glucose metabolism in sedentary normals and patients with diabetes. The proposed MRSDA will allow her to gain training in the areas of muscle and fat metabolism while investigating the interactions of aging and glucose metabolism in women with a high risk of developing diabetes. Research: Gestational diabetes mellitus (GDM) affects 90,000 women per yr in the U.S. Within 10-20 y of pregnancy, 40-65% of these women develop non-insulin dependent diabetes mellitus (NIDDM); a disease linked to obesity, physical inactivity and characterized by abnormalities in glucose and fatty acid metabolism. We hypothesize that women with a history of GDM who present with impaired glucose tolerance (IGT) or NIDDM after the menopause will be sedentary, have visceral obesity and abnormalities in their glucose, fat and muscle metabolism. A structured weight loss and aerobic exercise program (WL+AEX) will be more effective than weight loss (WL) alone in reducing visceral obesity and increasing aerobic capacity to 1) decrease free fatty acid (FFA) levels and increase fat oxidation; 2) increase muscle GLUT-4 protein and glycogen storage; and 3) enhance insulin sensitivity thereby improving glucose tolerance. This study will investigate glucose homeostasis in IGT or NIDDM (N=80) postmenopausal women (50-60 y) with a history of GDM. Measurements will be performed at baseline and after 6 months of WL or WL+AEX. Follow-up of patients will occur 1 yr after the intervention(s) to evaluate the patient's glucose tolerance, body composition and VO2max. Total and regional percent body fat, fat mass, lean tissue mass and hone mineral content will be determined by dual-energy x-ray absorptiometry. Computed tomography will quantify' intraabdominal and subcutaneous adipose tissue areas and mid-thigh muscle and adipose tissue area. VO2 max will be measured during a progressive treadmill test. Hyperinsulinemiceuglycemic clamps with tritiated glucose will assess glucose utilization, insulin sensitivity, and quantitate the role of the liver with respect to glucose production. During the clamp, plasma FFA levels and fat oxidation will be determined. Muscle biopsies of the vastus lateralis will be obtained for measurement of fiber characteristics, GLUT-4 transporters, and oxidative enzyme levels. The effects of WL or WL+AEX program on glucose homeostasis in IGT or NlDDM postmenopausal women with prior GDM are unknown. The projected study will contribute valuable information to help develop guidelines for the management of the metabolic control in the obese glucose intolerant and diabetic patient. Environment: Receipt of this MSRDA with the guidance of Drs. Goldberg and Nagey will allow the candidate to launch a career in gerontology studying disorders of glucose homeostasis in women at a high risk for NIDDM, and investigate the mechanisms by which WL or WL+AEX improve carbohydrate metabolism. The interdisciplinary environment in the School of Medicine provides excellent training and resources for advanced learning in gerontology and metabolism. The proposed work will provide the candidate with the requisite skills and training to embark on an independent research career. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ORAL GLUCOSE TOLERANCE TEST & PREPARATORY DIET Principal Investigator & Institution: Mastrobattista, Joan M.; University of Texas Hlth Sci Ctr Houston Box 20036 Houston, Tx 77225 Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
56
Gestational Diabetes
•
Project Title: PERINATAL IMPRINTING OF ENERGY METABOLISM IN THE FETUS Principal Investigator & Institution: Bernstein, Ira M.; Associate Professor; University of Vermont & St Agric College 340 Waterman Building Burlington, Vt 05405 Timing: Fiscal Year 2002 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PERIODONTAL DISEASE IN DIABETIC WOMEN WITH PRETERM BIRTH Principal Investigator & Institution: Offenbacher, Steven; Professor of Periodontology; Periodontology; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant): This pilot proposal is in response to an RFA to Prevent or Reduce Oral Health Disparities and seeks to establish a collaborative study partnering the periodontal and molecular epidemiology expertise at the University of North Carolina School of Dentistry with the Obstetrics/Gynecology expertise at the University of Hawaii School of Medicine to examine the role of periodontal disease in pre-term deliveries among pregnant diabetic Asian & Pacific Islander (API) women. This is an understudied minority population with a high prevalence of both diabetes and pre-term delivery. Periodontal disease is an oral infection that is more severe among diabetics and also increases insulin resistance among diabetics. Periodontitis also is associated with increased risk for pre-term delivery, pre-term premature rupture of membranes and growth restriction. Diabetes among pregnant women is a risk factor for both pre-term delivery and macrosomia. Thus, we seek to examine whether periodontal infection among diabetic women may provide some contribution to the observed high rate of pre-term delivery among API diabetics. Specifically, this proposal seeks to conduct a pilot case-control study to determine the extent of periodontal disease in API diabetic (Type 1, Type 2 or gestational) and non-diabetic women who have term and pre-term deliveries (<37 weeks gestational age). Approximately 92 diabetic and 92 nondiabetic pre-term delivery API mothers and 184 diabetic and 184 non-diabetic term delivery API mothers will be studied (frequency matched on race 1 case: 2 controls). Full-mouth periodontal examinations will be performed using standardized methods and calibrated examiners. Preliminary data will be generated by analyzing fetal cord blood for markers of fetal exposure to oral pathogens of maternal origin, as indexed by bacterial-specific fetal IgM levels and fetal stress as reflected by slCAM and CRP levels. In addition a subset of fetal membranes will be analyzed for protein expression of IL-lb, TNFa and IL-6 by ELISAs and MMP-8 mRNA by Northerns. Pilot data will be generated to support an R01 application that will originate from the U of H (a minority institution) with Dr. Millar as PI, to test the hypothesis that periodontitis is more extensive among API diabetic women and associated with higher rate of fetal exposure to oral pathogens than among non-diabetics and that the prevalence of periodontal disease and frequency of fetal exposure is higher among pre-term deliveries for both diabetics and nondiabetics, as compared to term deliveries. In this collaboration UNC will also provide the U of H study personnel the periodontal and molecular epidemiology research training and experience needed in multi-disciplinary studies of periodontal disease and obstetrics to conduct the planned R01 application. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
57
Project Title: PILOT--ETHNIC GROUPS AT RISK FOR ADVERSE PREGNANCY OUTCOMEN Principal Investigator & Institution: Silva, Jana; University of Hawaii at Manoa Honolulu, Hi 96822 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 29-SEP-2007 Summary: SUBPROJECT ABSTRACT NOT PROVIDED Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PLACENTAL GLUCOSE TRANSPORT IN DIABETIC PREGNANCIES Principal Investigator & Institution: Illsley, Nicholas P.; Associate Professor; Ob/Gyn & Women's Health; Univ of Med/Dent Nj Newark Newark, Nj 07103 Timing: Fiscal Year 2001; Project Start 01-AUG-1999; Project End 31-JUL-2003 Summary: Diabetes in pregnancy is associated with a number of perinatal problems such as macrosomia and neonatal hypoglycemia. There is also evidence suggesting that diabetes or even impaired glucose tolerance during pregnancy may be risk factors for the development of diabetes in the offspring. It is clear that the perinatal consequences of gestational diabetes are not simply a function of maternal hyperglycemia, since macrosomic infants are frequently born to mothers whose diabetes is well controlled. Preliminary research suggests that there are increases in the expression and activity of GLUT1 glucose transporters in the syncytial basal membrane of placental tissue from women whose diabetes is adequately controlled. Thus there appear to be continuing perturbations in a system intimately involved in fetal growth and development. It is hypothesized that elevated fetal glucose, resulting from maternal fetal hyperglycemia, causes, through stimulation of fetal growth factors, increased fetoplacental growth including increased expression of the basal membrane GLUT1 glucose transporter, the rate-limiting barrier to placental glucose transport. The resultant increase in transplacental glucose flux prolongs fetal hyperglycemia and leads to continued derangement of the fetal growth axis, despite normalization of maternal plasma glucose. This project is designed to explore this hypothesis by investigating the expression and activity of the human placental GLUT1 glucose transporter in diabetic pregnancies. Aim number 1 : To characterize the changes in placental glucose transporter expression and activity in diabetic pregnancy and to correlate these parameters with measures of maternal glycemic status and fetal growth factors. Aim number 2 : To assess the functional consequences of changes in glucose transporter expression and activity for the placental transfer of glucose. Aim number 3 : To establish the mechanisms responsible for the changes in glucose transporter expression and activity through transcriptional and posttranscriptional modulation and through short term regulatory events. Aim number 4 : To examine the mechanisms governing the (re)distribution of transporters between microvillous and basal membranes. The information obtained from these experimental approaches will significantly advance our understanding of the fetal response to maternal diabetes and the factors generating adverse perinatal consequences. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PRECOSE IN GLUCOSE AND HORMONES OF GESTATIONAL DIABETES Principal Investigator & Institution: Matsumoto, Larry; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, Ca 92093
58
Gestational Diabetes
Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TREATMENT
PREGNANT
BLACK
DIABETIC
WOMEN--ADHERENCE
TO
Principal Investigator & Institution: Brooks, Latina M.; None; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2001; Project Start 15-NOV-2000 Summary: Diabetes during pregnancy is a major health problem. Pregnant women with diabetes are at risk for acute and chronic complications while their infants are at high risk for morbidity and mortality. African American childbearing women have higher rates of diabetes, higher maternal complication rates and higher rates of low birthweight infants. These combined factors make study of pregnant African American women with diabetes a very timely and important group to study. The purpose of the proposed research is to examine barriers to treatment adherence in African American women whose pregnancies have been complicated by gestational diabetes. Using focus groups, modification of the Barriers to Self-Care Scale, and the Diabetes Compliance Questionnaire, the proposed study will examine: 1) what aspects of the diabetes treatment regimen are most difficult to adhere to; 2) environmental and social factors that act as barriers to adherence; 3) whether barriers and measures of adherence vary according to age, parity, or level of education; and 4) environmental and social factors that may be related to adherence among African American women with gestational diabetes. This information is basic to developing acceptable and effective plans of care for this group. The major long-term goal of this program of research is to develop acceptable, and effective treatment plans that improve pregnancy outcomes for African American women whose pregnancies are complicated by diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PRIMARY PREVENTION PROGRAM -DATA COORDINATING CENTER Principal Investigator & Institution: Fowler, Sarah E.; Professor and Director; Statistics; George Washington University 2121 I St Nw Washington, Dc 20052 Timing: Fiscal Year 2001; Project Start 20-AUG-1994; Project End 30-JUN-2003 Summary: (Directly incorporated from the application) The Biostatistics Center of The George Washington University proposes to work in cooperative agreement with the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) to serve as the Data Coordinating Center (DCC) for a proposed multi-center clinical trial of the primary prevention of non-insulin dependent diabetes mellitus (NIDDM). Adiposity and inactivity have been established as critical factors in the etiology of glucose intolerance and are strongly associated with increased risk of glucose intolerance. We propose to determine the safety and efficacy of an intensive lifestyle intervention or prophylactic use of an oral hypoglycemic agent on the incidence of NIDDM among high risk patients (obese, minority, family history of NIDDM, history of gestational diabetes mellitus) in a state of impaired glucose tolerance (IGT). The objective of the one year planning phase is to develop a protocol, operations manual and data collection forms to be implemented in a five year full-scale clinical trial. The trial will require large-scale screening and randomization of 4,000 high risk patients with a diagnosis of IGT over a one year period in 20 clinical centers. Eligible patients will be randomized to
Studies
59
"conventional" dietary counseling or one of the comparison groups (intensive lifestyle intervention or an oral hypoglycemic agent). Randomized patients will be followed for a minimum of four years with quarterly follow-up visits. Conversion from a state of IGT to overt NIDDM will be determined by semi-annual 2-hour oral glucose tolerance tests (OGTTs) following a 75 g glucose load confirmed by a central laboratory. Covariates and secondary outcomes include carotid ultrasound imaging, electrocardiograms, serum lipids, albumin excretion rate, adiposity, insulin sensitivity, hemoglobin A1c, and fundus photographs. The specific aims of the DCC are to provide centralized support and biostatistical consultation in the development of the patient management protocols, operations manual, data collection forms and randomization procedures; implementation of a data processing system including data quality assessment; interim analysis of protocol performance, patient safety and treatment efficacy; and final analysis for publication of the results in collaboration with the clinical investigators. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PRIMARY PREVENTION TRIAL (DPT-2) Principal Investigator & Institution: Olefsky, Jerrold M.; Professor; Medicine; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, Ca 92093 Timing: Fiscal Year 2001; Project Start 10-SEP-1994; Project End 30-JUN-2003 Summary: Non-insulin dependent diabetes mellitus (NIDDM) is a common, chronic disease with increasing incidence in the United States, responsible for an enormous burden of morbidity and mortality. Most of the morbidity, mortality, and financial burden of NIDDM is related to the development of complications. Consequently, prevention of NIDDM, or even a substantial delay in disease onset, will have a major financial and health impact in this country. Compelling evidence exists to indicate that insulin resistance is an early defect present in the pre-diabetic state. Consequently, it is logical to direct primary prevention interventions at improving this metabolic defect. It is well established that physical exercise is a lifestyle intervention which can ameliorate insulin resistance, and therefore, might prevent NIDDM. Troglitazone is a newly available oral hypoglycemic agent, from the Thiozoladinedione class of drugs. This agent exerts its effects primarily by improving insulin resistance, and this has been demonstrated in NIDDM and IGT populations. Consequently, we propose a 2 X 2 factorial design in which patients will be randomly assigned in a double blind fashion to either Troglitazone, placebo, exercise, or Troglitazone plus exercise groups. The study will be performed in patients with IGT, as well as in those with NIDDM who do not have fasting hyperglycemia. Power calculations indicate that a total of 4,000 patients in this multi-center cooperative trial will be sufficient to detect positive outcomes, and this will incorporate approximately 200 patients/Clinical Center. This study cohort will consist of patients with IGT, former gestational diabetes mellitus, NIDDM without fasting hyperglycemia, and approximately 50% of all subjects should be from minority populations. This study will be conducted over 7 years, including a planning phase, recruitment phase, 4-5 year treatment phase, and close out phase. This study should provide a rigorous test of the hypothesis that the proposed interventions will prevent NIDDM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PRIMARY PREVENTION TRIAL (DPT-2) Principal Investigator & Institution: Schade, David S.; Professor; Medicine; University of New Mexico Albuquerque Controller's Office Albuquerque, Nm 87131
60
Gestational Diabetes
Timing: Fiscal Year 2001; Project Start 20-AUG-1994; Project End 30-JUN-2003 Summary: During the last 30 years, the combined mortality of the Native American and Hispanic populations living in New Mexico has almost doubled. This dramatic rise can be partially attributed to the increased incidence of type II diabetes. We will assess the outcome of interVention strategies to prevent the onset of type Il diabetes in high risk groups (impaired glucose tolerance and/or a history of gestational diabetes). The two principal minority groups in the state of New Mexico will be studied: the urban Native American population and the urban Hispanic (Mexican-American) population. Recruitment techniques will include direct interrogation of three large health care databases and participation of many community support organizations involved with Native Americans and Hispanics. Two hundred individuals (100 Native Americans, 100 Hispanics) will be randomized into one of four treatment groups. The first treatment group will receive standard therapy (diet plus exercise counseling every six months). The second treatment group will also receive standard therapy plus glyburide 5 mg once per day. The third treatment group will receive' intensified dietary instruction plus scheduled exercise with the goal of achieving ideal body weight and a healthy lifestyle. These individuals will exercise three times per week and meet monthly for dietary counseling and body weight measurements. The fourth treatment group will receive the same therapy as the third group (a combination of the intensified dietary instruction and scheduled exercise) plus glyburide 5 mg once per day. In order to increase adherence, volunteers and their families will interact with nurse/educators sensitive to the cultural needs of the study population. Positive reinforcement techniques will be used. Primary study endpoints include 75 gm oral glucose tolerance testing every six months plus measurement of integrated C-peptide and insulin. Secondary endpoints include hemoglobin AlC, body composition measurements, body weight, dietary alterations, and changes in health status. Administratively, a Central Coordinating Unit, composed of individuals experienced in the various treatments, will oversee the trial. Guidance to the Central Coordinating Unit will be provided by an Advisory Committee comprised of prominent members of both the Native American and Hispanic communities. A nurse/educator will be provided for each of the three satellite clinics caring for the volunteers. Comparing standard treatment against other treatment(s), the protocol design provides 90% power to detect a 33% minimum improvement in the conversion rate from impaired glucose tolerance to diabetes, p<0.Ol. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PRIMARY PREVENTION TRIAL (DPT-2) Principal Investigator & Institution: Molitch, Mark E.; Professor; Northwestern University Office of Sponsored Programs Chicago, Il 60611
Medicine;
Timing: Fiscal Year 2002; Project Start 20-AUG-1994; Project End 30-APR-2003 Summary: This proposal is submitted in response to the RFA: DK-93-07, "NIDDM primary Prevention Trial" NIDDM is a major public health problem in the United States and its prevalence is disproportionately high among a number of minority groups including Native American, Hispanics and African-Americans, Members of these minority groups, obese subjects, persons with a family history of NIDDM among first degree relatives and women with prior gestational diabetes mellitus (GDM) of all racial and ethic groups are at high risk for the development of NIDDM. We have developed a protocol for a multicenter study to test the hypothesis that the appearance of NIDDM can be delayed or prevented by life style or pharmacological intervention in women with prior GDM or in subjects at high risk for NIDDM who presently have impaired glucose tolerance (IGT). We propose to compare the rate of progression of IGT to
Studies
61
NIDDM and mild NIDDM to NIDDM with fasting hyperglycemia in groups receiving intensive life-style intervention with diet, (low fat moderated fiber reduced calorie) and exercise (supervise instruction and maintenance of physical fitness) or drug treatment (sulfonylurea oral hypoglycemic agent or an anorectic agent) with conventional advice regarding diet and exercise. We propose that subjects with prior GDM represent half of the women recruited for the study and that the total population enrolled include 20 percent Hispanics, 20 percent African-American, 10 percent native Americans and 50 percent Caucasians and members of other minorities. We have identified a large population of women with previous GDM that includes approximately equal numbers of Black, hispanic and White women and are prepared to serve as a center for a concentrated subgroup enrollment of such subjects. We are also prepared to recruit Hispanic, African- American and White subjects from the general population who are at high risk for IGT. Our study investigators have extensive experience in the care of patients with diabetes mellitus, have broad and in depth experience in collaborative diabetes related and cardiovascular disease related clinical and epidemiological studies. These projects have provided extensive experience in recruitment and retention of minority subjects including women with prior GDM. The project investigators are prepared to collaborate and cooperate in the final design of the study protocol by the steering committee as well as implement it with enthusiasm and to the best of our collective abilities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROMOTING HEALTHY LIFESTYLES AMONG WOMEN Principal Investigator & Institution: Kieffer, Edith C.; Health Behavior and Hlth Educ; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2007 Summary: (provided by applicant): The prevalence of type 2 diabetes is rising among African American and Latino women of childbearing age, with severe consequences for individuals, families and communities. Diet and exercise behaviors, excessive pregnancy weight gain and postpartum weight retention may lead to the development of longerterm obesity that contributes to this trend. The prenatal-postpartum period offers a unique opportunity for interventions that may reduce these risks. The overall aim of this community-based randomized controlled clinical trial is to demonstrate the effectiveness of a healthy lifestyle intervention tailored to the needs of pregnant and postpartum African American and Latino women in Detroit, Michigan and designed to reduce behavioral and clinical risk factors for type 2 diabetes. Two hypotheses (specific aims 1 and 2) will be tested: Compared to the control intervention, healthy lifestyle intervention participants will have 1) improved levels of protective behaviors (increased daily level of physical activity and improved daily dietary composition) that reduce the risk of type 2 diabetes; and 2) improved their status on clinical measures of risk for type 2 diabetes (anthropometric and metabolic status). Specific aim 3 addresses whether theory-based variables, including changes in attitudes, behavioral and control beliefs, perceived social support and behavioral intention change from baseline, and whether these changes influence behavioral outcomes. Specific aim 4 will identify aspects of project planning and implementation that contribute. to achievement of behavioral and clinical outcomes. The study will be conducted by an existing partnership between university and community organizations that has a successful record of communitybased participatory epidemiological and intervention research. The healthy lifestyle intervention draws from the theories of planned behavior and social support and takes
62
Gestational Diabetes
into account specific social, cultural, economic and physical environmental challenges faced by low-income women in Detroit. It addresses the rapidly changing context of pregnancy and the postpartum period, which bring additional challenges but also opportunities for adoption and maintenance of healthy behaviors. The target population will be 400 Latino and African American women who will be recruited in prenatal care settings during their first trimester of pregnancy. After a qualifying period designed to reduce later attrition, 320 will be randomized into either a healthy lifestyle intervention or a control intervention group. The healthy lifestyle intervention will include a 17session curriculum that integrates pregnancy, childbirth and postpartum preparation, social support from a Women's Health Advocate (WHA) and group social support activities. The control intervention group will receive a 4-session curriculum that integrates pregnancy, childbirth and postpartum preparation. Measures will be collected at 10-14 weeks, -26 weeks and -36 weeks of gestation and -6 weeks postpartum. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PSYCHIATRIC DISORDERS IN ADULTS WITH DIABETES MELLITUS Principal Investigator & Institution: Lustman, Patrick J.; Professor of Psychiatry; Psychiatry; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2001; Project Start 01-JUL-1985; Project End 31-MAR-2004 Summary: Diabetes increases the risks of maternal, fetal, and neonatal complications from pregnancy. Tight glycemic control during pregnancy reduces these risks but is difficult to achieve. Major depression is present in approximately 25 percent of diabetic women and is associated with significant deterioration in glycemic control. There has been no study in diabetic or nondiabetic subjects of depression treatment during pregnancy, and the effects of depression treatment on obstetric outcomes remain unknown. Recently, we showed that cognitive behavior therapy (CBT) was an effective nonpharmacologic treatment for depression in diabetes that produced durable improvements in glycemic control. In this study we plan to treat major depression in pregnant diabetic women with CBT and determine its effects on depression, glycemic control, and maternal and neonatal outcomes. We also plan to assess the relationship of diabetes during pregnancy and postpartum depression to neuropsychological development of the infants. 150 pregnant diabetic women will be recruited for study: 100 with and 50 without major depression. The nondepressed subjects function only as a comparison group in some of the statistical analyses. All subjects will be assessed serially during the 2nd and 3rd trimesters and the 1 year postpartum period while receiving the usual degree of intensive medical care for the diabetic pregnancy. Depressed patients will be assigned randomly to treatment with individual CBT (n =50) or supportive counseling (n =50). The pregnancy care team is informed of the depression status of all subjects and advised to give usual care for depression. The design blinds the pregnancy care team to treatment assignment, controls for nonspecific effects of attention and the influence of enhanced diabetes control on mood, provides a comparison group likely to remain depression free during gestation and the postpartum period, and is sensitive to human subject issues. We hypothesize that CBT will be superior to supportive counseling in terms of improving depression and glycemic control, and that the treatment-related improvements in glycemic control will reduce the adverse effects of diabetes in pregnancy, including c-section, macrosomia, neonatal hypoglycemia, and fetal hyperinsulinemia. We also expect that by improving glycemic control during pregnancy and reducing the risk of postpartum depression CBT will improve neuropsychological development in the offspring. The findings should
Studies
63
demonstrate the relevance of depression treatment to maternal and neonatal outcomes of diabetic pregnancies and translate directly to the management of patients living with diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RACE AND LONG-TERM DIABETES SELF-MANAGEMENT IN AN HMO Principal Investigator & Institution: Ross-Degnan, Dennis; Harvard Pilgrim Health Care, Inc. 93 Worcester St Wellesley, Ma 02481 Timing: Fiscal Year 2002; Project Start 15-JAN-2002; Project End 31-DEC-2004 Summary: (provided by applicant): This project will examine the complex relationships between race, diabetes self-management (including self-monitoring of blood glucose and diabetes drug therapy), glycemic control, and diabetes complications in a managed care setting over a nine-year period. African Americans with diabetes are less likely to be in glycemic control, a major risk factor for development of complications, including nephropathy, retinopathy, and peripheral vascular disease. Randomized controlled trials suggest that diabetes self-management including patient education, drug therapy, changes in diet, and regular exercise can improve glycemic control in the African American population. However, there is little epidemiological evidence regarding the role of race/ethnicity as a determinant of adherence to recommended diabetes selfmanagement practices, or regarding the relationship between self-management, glycemic control, and subsequent clinical outcomes. Further, previous studies of race and diabetes self-management have been limited by short study periods, inadequate sample size, and reliance on self-reported measures of self-monitoring of blood glucose. The clinical setting for this study is Harvard Vanguard Medical Associates (HVMA), a large multi-site, multi-specialty group affiliated with Harvard Pilgrim Health Care. HVMA consists of 14 health centers serving over 300,000 people in the Boston area. We will use an open cohort design to enroll all adult (l8 years) patients between 1991 and 1999 who have 24 months or more of uninterrupted enrollment in HVMA following ascertainment of non-gestational diabetes, defined by (1) hospital discharge diagnosis of diabetes mellitus, (2) outpatient diagnoses of diabetes mellitus, HbAlc lab test result 8.0, or use of a diabetes drug (insulin, sulfonylurea, or metformin). We estimate that the cohort will include approximately 1,800 adults identified as African American and 5,000 identified as Caucasian. Access to HVMA computerized medical records, hospital emergency room and inpatient claims, lab, and pharmacy data will allow us to create reliable, objective measures of self-monitoring (home glucose monitor test strip use), drug therapy. glycemic control (HbAlc lab results), and diabetes complications (as measured in outpatient visits, emergency room visits, and hospitalizations). Stratifying by type of drug therapy (insulin/combined therapy vs. oral therapy), we will use descriptive analyses, generalized linear mixed models, and proportional hazards models to (1) identify racial differences in self-management practices and diabetes-related health outcomes over time; (2) assess whether African American race is an independent predictor of self-monitoring practice or adherence to drug regimen; and (3) whether there are racial/ethnic differences in the association between self-management and specific clinical endpoints, including glycemic control (HbAlc<8.0) and the incidence of diabetes-related complications over the nine-year study period. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
64
Gestational Diabetes
•
Project Title: RISK OF TYPE 1 AND TYPE 2 DIABETES AMONG YOUNG FINNS Principal Investigator & Institution: Tuomilehto, Jaakko O.; National Public Health Institute Mannerheimintie 166, Sf-00280 Helsinki, Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2006 Summary: (provided by applicant): The incidence of type 1 diabetes (DM1) in children (14 years or under) is the highest in the world in Finland. DM1 can, however, develop at any age. Clinical, biological and epidemiological data obtained from children may not be fully applicable to adults with DM1. It will be very important to know about the factors that postpone the disease onset to occur later in life. Such information might be crucial for the development of preventive measures against DM1. Type 2 diabetes (DM2) is increasing rapidly worldwide and its age-of-diagnosis is becoming younger. There are hardly any population-based epidemiological data on DM2 in youth or young adults. This research aims at assessing the incidence of DM1 and DM2 in young adults and we have a unique possibility to compare findings with data from Finnish DM1 children. We will determine the incidence of DM1 and DM2 in young adults (15-39 years) in Finland during 1992 to 2001. This will also permit us to calculate the 10-year trend in incidence, and the cumulative incidence of DM1 in the Finnish population by the age of 40 years. We will assess the familial aggregation and sibling risk of DM1 in young adults and compare it with that in childhood-onset DM1. In addition, we have a possibility to ascertain diabetes in the offspring of these patients with DM1 and DM2 whose age-at-onset of diabetes is in preadolescence or in adulthood. The reasons for the apparent gender differences in the risk of DM1 and the familial aggregation of DM1 will be studied in detail. The effect of intra-uterine growth retardation, fetal programming, and growth and weight development during childhood on the risk of DM1 and DM2 in young adults will be assessed. Cases originally classified as DM2 or gestational diabetes will be followed up five to nine years, and thereby population-based estimates for slowonset DM1 will be obtained. The detailed epidemiological data obtained in this study will also lay a foundation for further research of etiological factors, genetic and environmental, predisposing to DMI and DM2 in this age group. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SEARCH FOR THE MOLECULAR CAUSES OF DIABETIC EMBRYOPATHY Principal Investigator & Institution: Loeken, Mary R.; Assistant Professor; Joslin Diabetes Center Boston, Ma 02215 Timing: Fiscal Year 2001; Project Start 01-AUG-1998; Project End 31-JUL-2003 Summary: Diabetic embryopathy is a well recognized, but poorly understood, complication of diabetes in which the early embryo of a diabetic method develops congenital malformations. The objective of the work proposed here is to study the regulation by diabetes of a critical development control gene, Pax-3, during the development of one of the most common diabetes- associated malformations, neural tube defects (NTD). Using a new mouse model that was developed in my laboratory, we have observed that the rate of NTD is about three-fold higher in the embryos of diabetic mice than in the embryos of non-diabetic mice. The high rate of NTD is correlated with reduced expression of Pax-3, an embryonic gene which encodes a DNA-binding transcription factor that is required for formation of the brain and spinal chord. Subsequent to the reduction in expression of Pax-3, and apparently as a consequence, cells forming the neural tube are seen to undergo unscheduled apoptosis. There are three specific aims of this proposal. In the first aim, we will test the hypothesis that
Studies
65
glucose toxicity associated with maternal diabetes is responsible for abnormalities in embryonic gene expression, apoptosis, and NTD. This will be accomplished by (1) attempting to prevent glucose toxicity by lowering glucose levels in pregnant diabetic mice with insulin or phlorizin administration, (2) attempting to induce glucose toxicity in pregnant non-diabetic mice by a hyperglycemic glucose clamp procedure, (3) attempting to induce glucose toxicity during culture of post-implementation mouse embryos in media containing elevated levels of glucose, and (4) testing whether expression of the high Km GLUT-2 glucose transporter renders the early embryos sensitive to glucose toxicity during diabetic pregnancy. In the second aim, we will determine whether the reduction in Pax-3 mRNA observed in embryos of diabetic and non-diabetic mice is due to transcriptional or post-transcriptional control, and identify the Pax-3 control elements involved in inhibition by diabetes. In the third aim, we will test the hypothesis that mouse strains which fail to develop NTD during diabetic pregnancy are resistant to the inhibition of Pax-3 expression that occurs in strains which are susceptible to NTD. These experiments will reveal, in a way that has not been done in the past, the molecular mechanisms by which embryonic development is during diabetic pregnancy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SENSITIZATION OF INSULIN STIMULATED PHOSPHORYLATION BY EXERCISE Principal Investigator & Institution: Mandarino, Lawrence; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, Tx 78229 Timing: Fiscal Year 2001 Summary: This study is part of a program project the overall goal of which is to determine how insulin resistance alters insulin-stimulated phosphorylation events in vivo in humans and to determine how exercise interacts with insulin to influence these early phosphorylation events. This study will determine if a prior bout of exercise enhances subsequent insulin stimulation of protein phosphorylation by comparing and contrasting five groups: nondiabetic subjects, patients with impaired glucose tolerance, normal glucose tolerant subjects who have a parent with NIDDM, subjects with a history of gestational DM, and subjects with NIDDM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TROGLITAZONE IN WOMEN WITH PRIOR GESTATIONAL DIABETES MELLITUS Principal Investigator & Institution: Buchanan, Thomas S.; Professor and Director; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2001; Project Start 01-DEC-2000; Project End 30-NOV-2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TROPHOBLAST REGULATION /ANGIOGENESIS /DIABETIC PLACENTA Principal Investigator & Institution: Golos, Thaddeus G.; Associate Professor; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2006
66
Gestational Diabetes
Summary: The placenta and uterus conduct an essential dialogue at the maternal- fetal interface for the initiation, maintenance and completion of pregnancy via the coordinated functions of trophoblasts in contact with maternal blood, and the fetal vasculature within the chorionic in the placental vascular system in diabetic pregnancies is incompletely understood. Our overall hypothesis is that the dysregulation of glucose disposition in Type I diabetic pregnancy precipitates changes in angiogenesis impacting the placental villous vasculature, responsible for the pathophysiology of fetal growth and maternal well-being associated with the Type I diabetic pregnancy. We further hypothesize that glucose and oxygen-mediated pathways influence placental (trophoblast) regulation of angiogenesis. In order to test these hypotheses, we have set the following Specific Aims. Specific Aim 1, To define the changes in expression of mRNAs and proteins important for angiogenic and vasodilatory adaptation in normal and Type I diabetic placentas. Expt.1A/B. Angiogenic factors, eNOS, oxidative stress marker expression in viii and placental vessels Expt. 1C Morphometric analysis of placental villous proliferation, structure and vascular density. Expt. 1D Molecular phenotyping of the diabetic placenta Specific Aim 2. Define in vitro the mechanisms by which glucose, NO and hypoxia alter placental angiogenesis. Expt 2B. Effects of diabetes on trophoblast function and glucose-oxygen responsiveness Expt. 2D Evaluate the role of eNOS/NO in mediating glucose effects on trophoblast function Expt. 2D Evaluate the role of oxidative stress in glucose effects on trophoblast function. Reductions in placental vascularity due to the disruption of angiogenesis in Type 1 diabetic pregnancy can lead to decreased placental blood flow and reduction in fetal weight, survivability and health of the neonate. The mother is also at increased risk for development of ketoacidosis, pyelonephritis and preeclampsia. Type I Diabetes during pregnancy may have additional significance in the offspring for the long-term health and risk for adult disease. A better understanding of the intrauterine environment and its regulation will benefit not only maternal and fetal health, but also further the understanding of disease processes in all individuals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “gestational diabetes” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for gestational diabetes in the PubMed Central database: •
3 4
Birth characteristics of women who develop gestational diabetes: population based study. by Egeland GM, Skjaerven R, Irgens LM.; 2000 Sep 2; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27469 Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
67
•
Does screening for gestational diabetes mellitus make a difference? by Sermer M.; 2003 Feb 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=143548
•
Intervening to reduce weight gain in pregnancy and gestational diabetes mellitus in Cree communities: an evaluation. by Gray-Donald K, Robinson E, Collier A, David K, Renaud L, Rodrigues S.; 2000 Nov 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=80308
•
Using fasting plasma glucose concentrations to screen for gestational diabetes mellitus: prospective population based study. by Perucchini D, Fischer U, Spinas GA, Huch R, Huch A, Lehmann R.; 1999 Sep 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28232
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with gestational diabetes, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “gestational diabetes” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for gestational diabetes (hyperlinks lead to article summaries): •
A comparison of costs associated with screening for gestational diabetes with twotiered and one-tiered testing protocols. Author(s): Lavin JP Jr, Lavin B, O'Donnell N. Source: American Journal of Obstetrics and Gynecology. 2001 February; 184(3): 363-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11228488&dopt=Abstract
•
A comparison of glyburide and insulin in women with gestational diabetes mellitus. Author(s): Dornhorst A. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2001 May; Suppl 3: 12-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11534307&dopt=Abstract
6 PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
68
Gestational Diabetes
•
A planned randomized clinical trial of treatment for mild gestational diabetes mellitus. Author(s): Landon MB, Thom E, Spong CY, Gabbe SG, Leindecker S, Johnson F, Lain K, Miodovnik M, Carpenter M. Source: J Matern Fetal Neonatal Med. 2002 April;11(4):226-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12375675&dopt=Abstract
•
A population-based study of maternal and perinatal outcome in patients with gestational diabetes. Author(s): Jacobson JD, Cousins L. Source: American Journal of Obstetrics and Gynecology. 1989 October; 161(4): 981-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2801849&dopt=Abstract
•
A postnatal fasting plasma glucose is useful in determining which women with gestational diabetes should undergo a postnatal oral glucose tolerance test. Author(s): Holt RI, Goddard JR, Clarke P, Coleman MA. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2003 July; 20(7): 594-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12823243&dopt=Abstract
•
A prospective controlled study of neonatal morbidities in infants born at 36 weeks or more gestation to Women with diet-controlled gestational diabetes (GDM-class Al). Author(s): Sarkar S, Watman J, Seigel WM, Schaeffer HA. Source: Journal of Perinatology : Official Journal of the California Perinatal Association. 2003 April-May; 23(3): 223-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12732860&dopt=Abstract
•
A random plasma glucose method for screening for gestational diabetes. Author(s): Maheshwari JR, Mataliya MV. Source: Journal of Postgraduate Medicine. 1989 January; 35(1): 36-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2585336&dopt=Abstract
•
A randomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia. Author(s): Garcia-Patterson A, Corcoy R, Balsells M, Altirriba O, Adelantado JM, Cabero L, de Leiva A. Source: Diabetes Care. 2002 July; 25(7): 1261; Author Reply 1261-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12087047&dopt=Abstract
Studies
69
•
A randomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia. Author(s): Kjos SL, Schaefer-Graf U, Sardesi S, Peters RK, Buley A, Xiang AH, Bryne JD, Sutherland C, Montoro MN, Buchanan TA. Source: Diabetes Care. 2001 November; 24(11): 1904-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11679455&dopt=Abstract
•
A simple index for detection of gestational diabetes mellitus. Author(s): Perea-Carrasco R, Perez-Coronel R, Albusac-Aguilar R, Lombardo-Grifol M, Bassas-Baena de Leon E, Romero-Diaz C. Source: Journal of the Royal Society of Medicine. 2002 September; 95(9): 435-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12205206&dopt=Abstract
•
Accuracy of glucose meter use in gestational diabetes. Author(s): Ryan EA, Nguyen G. Source: Diabetes Technology & Therapeutics. 2001 Spring; 3(1): 91-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11469713&dopt=Abstract
•
ACOG Practice Bulletin. Clinical management guidelines for obstetriciangynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Author(s): American College of Obstetricians and Gynecologists Committee on Practice Bulletins--Obstetrics. Source: Obstetrics and Gynecology. 2001 September; 98(3): 525-38. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11547793&dopt=Abstract
•
Acute effect of exercise on blood glucose and insulin levels in women with gestational diabetes. Author(s): Avery MD, Walker AJ. Source: The Journal of Maternal-Fetal Medicine. 2001 February; 10(1): 52-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11332421&dopt=Abstract
•
alpha-Thalassaemia trait and gestational diabetes mellitus in Hong Kong. Author(s): Lao TT, Ho LF. Source: Diabetologia. 2001 August; 44(8): 966-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11484072&dopt=Abstract
•
An unusual case of gestational diabetes mellitus. Author(s): Shankar P, Sundarka MK, Sundarka A. Source: Postgraduate Medical Journal. 2002 September; 78(923): 562-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12357021&dopt=Abstract
70
Gestational Diabetes
•
Antenatal fetal testing in pregnancies complicated by gestational diabetes mellitus. Author(s): Rosenn BM. Source: Semin Perinatol. 2002 June; 26(3): 210-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12099311&dopt=Abstract
•
Association between maternal and child leptin levels 9 years after pregnancy complicated by gestational diabetes. Author(s): Malee MP, Verma A, Messerlian G, Tucker R, Vohr BR. Source: Hormone and Metabolic Research. Hormon- Und Stoffwechselforschung. Hormones Et Metabolisme. 2002 April; 34(4): 212-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11987032&dopt=Abstract
•
Association between maternal pre-existing or gestational diabetes and health problems in children. Author(s): Aberg A, Westbom L. Source: Acta Paediatrica (Oslo, Norway : 1992). 2001 July; 90(7): 746-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11519976&dopt=Abstract
•
Association of a woman's own birth weight with subsequent risk for gestational diabetes. Author(s): Innes KE, Byers TE, Marshall JA, Baron A, Orleans M, Hamman RF. Source: Jama : the Journal of the American Medical Association. 2002 May 15; 287(19): 2534-41. Erratum In: Jama 2002 June 26; 287(24): 3212. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12020334&dopt=Abstract
•
Autoimmunity in “type 2” and gestational diabetes mellitus. Author(s): Fitz-Patrick D. Source: Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2001 September-October; 7(5): 407-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11585380&dopt=Abstract
•
Beta-cell function and visceral fat in lactating women with a history of gestational diabetes. Author(s): McManus RM, Cunningham I, Watson A, Harker L, Finegood DT. Source: Metabolism: Clinical and Experimental. 2001 June; 50(6): 715-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11398150&dopt=Abstract
•
Birth characteristics of women who develop gestational diabetes: population based study. Author(s): Egeland GM, Skjaerven R, Irgens LM. Source: Bmj (Clinical Research Ed.). 2000 September 2; 321(7260): 546-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10968815&dopt=Abstract
Studies
71
•
Birth weight influence on the subsequent development of gestational diabetes mellitus. Author(s): Savona-Ventura C, Chircop M. Source: Acta Diabetologica. 2003 June; 40(2): 101-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12861409&dopt=Abstract
•
Birth weight of women with gestational diabetes. Author(s): Moses RG, Moses J, Knights S. Source: Diabetes Care. 1999 July; 22(7): 1059-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10388967&dopt=Abstract
•
Birthweight in women with potential gestational diabetes mellitus--an effect of obesity rather than glucose intolerance? Author(s): Lauszus FF, Paludan J, Klebe JG. Source: Acta Obstetricia Et Gynecologica Scandinavica. 1999 July; 78(6): 520-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10376862&dopt=Abstract
•
Blood glucose monitoring in gestational diabetes mellitus. Author(s): Buchanan TA, Kjos SL, Montoro MN. Source: The New England Journal of Medicine. 1996 February 29; 334(9): 598-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8569836&dopt=Abstract
•
Blood glucose monitoring in gestational diabetes mellitus. Author(s): Miles JM, Coppack SW. Source: The New England Journal of Medicine. 1996 February 29; 334(9): 598; Author Reply 599. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8569835&dopt=Abstract
•
Blood glucose monitoring in gestational diabetes mellitus. Author(s): Bansal RK, Ecker JL, Laros RK Jr. Source: The New England Journal of Medicine. 1996 February 29; 334(9): 598; Author Reply 599. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8569834&dopt=Abstract
•
Blood glucose monitoring in gestational diabetes mellitus: 1- versus 2-h blood glucose determinations. Author(s): Leguizamon G, Krupitzki H, Glujovsky D, Olivera Ravasi M, Reece EA. Source: J Matern Fetal Neonatal Med. 2002 December;12(6):384-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12683648&dopt=Abstract
72
Gestational Diabetes
•
Blood glucose rise following prenatal vitamins in gestational diabetes. Author(s): Sparks SP, Jovanovic-Peterson L, Peterson CM. Source: Journal of the American College of Nutrition. 1993 October; 12(5): 543-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8263271&dopt=Abstract
•
Blood glucose targets for gestational diabetes. Author(s): Cheung NW, Byth K, Simmons D. Source: The Medical Journal of Australia. 2000 November 6; 173(9): 502-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11149311&dopt=Abstract
•
Blood pressure predicts insulin requirement and exogenous insulin is associated with increased blood pressure in women with gestational diabetes mellitus. Author(s): Bevier WC, Jovanovic-Peterson L, Burns A, Peterson CM. Source: American Journal of Perinatology. 1994 September; 11(5): 369-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7993522&dopt=Abstract
•
Blood viscosity and erythrocyte deformability in gestational diabetes. Author(s): Kaibara M, Marumoto Y, Kobayashi T. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 1984 June; 22(3): 221-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6148281&dopt=Abstract
•
Body fat distribution before pregnancy and gestational diabetes: findings from coronary artery risk development in young adults (CARDIA) study. Author(s): Zhang S, Folsom AR, Flack JM, Liu K. Source: Bmj (Clinical Research Ed.). 1995 October 28; 311(7013): 1139-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7580711&dopt=Abstract
•
Chromosomal anomalies among the offspring of women with gestational diabetes. Author(s): Moore LL, Bradlee ML, Singer MR, Rothman KJ, Milunsky A. Source: American Journal of Epidemiology. 2002 April 15; 155(8): 719-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11943689&dopt=Abstract
•
Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with previous gestational diabetes. Author(s): Mittermayer F, Mayer BX, Meyer A, Winzer C, Pacini G, Wagner OF, Wolzt M, Kautzky-Willer A. Source: Diabetologia. 2002 October; 45(10): 1372-8. Epub 2002 August 16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12378377&dopt=Abstract
Studies
73
•
Clinical impact of mild carbohydrate intolerance in pregnancy: a study of 2904 nondiabetic Danish women with risk factors for gestational diabetes mellitus. Author(s): Jensen DM, Damm P, Sorensen B, Molsted-Pedersen L, Westergaard JG, Klebe J, Beck-Nielsen H. Source: American Journal of Obstetrics and Gynecology. 2001 August; 185(2): 413-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11518901&dopt=Abstract
•
Clinical outcomes related to either the 1- or 2-hour postprandial glucose level in women with gestational diabetes. Author(s): Moses RG, Lucas EM. Source: American Journal of Obstetrics and Gynecology. 2002 September; 187(3): 817-8; Author Reply 818. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12237669&dopt=Abstract
•
Clinical predictors for a high risk for the development of diabetes mellitus in the early puerperium in women with recent gestational diabetes mellitus. Author(s): Schaefer-Graf UM, Buchanan TA, Xiang AH, Peters RK, Kjos SL. Source: American Journal of Obstetrics and Gynecology. 2002 April; 186(4): 751-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11967502&dopt=Abstract
•
Clinically useful estimates of insulin sensitivity during pregnancy: validation studies in women with normal glucose tolerance and gestational diabetes mellitus. Author(s): Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM. Source: Diabetes Care. 2001 September; 24(9): 1602-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11522706&dopt=Abstract
•
Comparison of alterations in insulin signalling pathway in adipocytes from Type II diabetic pregnant women and women with gestational diabetes mellitus. Author(s): Tomazic M, Janez A, Sketelj A, Kocijancic A, Eckel J, Sharma PM. Source: Diabetologia. 2002 April; 45(4): 502-8. Epub 2002 March 26. Retraction In: http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12032625&dopt=Abstract
•
Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Author(s): Pettitt DJ, Ospina P, Kolaczynski JW, Jovanovic L. Source: Diabetes Care. 2003 January; 26(1): 183-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12502678&dopt=Abstract
•
Comparison of two diagnostic tests for gestational diabetes in predicting macrosomia. Author(s): Chastang N, Hartemann-Heurtier A, Sachon C, Vauthier D, Darbois Y, Bissery A, Golmard JL, Grimaldi A. Source: Diabetes & Metabolism. 2003 April; 29(2 Pt 1): 139-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12746634&dopt=Abstract
74
Gestational Diabetes
•
Congenital anomalies in the offspring of women with type 1, type 2 and gestational diabetes. Author(s): Farrell T, Neale L, Cundy T. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2002 April; 19(4): 322-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11943005&dopt=Abstract
•
Continuous glucose monitoring during pregnancy complicated by gestational diabetes mellitus. Author(s): Jovanovic L. Source: Curr Diab Rep. 2001 August; 1(1): 82-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12762962&dopt=Abstract
•
Contraindications to use of metformin. Metformin may be useful in gestational diabetes. Author(s): Hague WM, Davoren PM, Oliver J, Rowan J. Source: Bmj (Clinical Research Ed.). 2003 April 5; 326(7392): 762; Author Reply 762. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12680386&dopt=Abstract
•
Correlation of maternal serum fetuin/alpha2-HS-glycoprotein concentration with maternal insulin resistance and anthropometric parameters of neonates in normal pregnancy and gestational diabetes. Author(s): Kalabay L, Cseh K, Pajor A, Baranyi E, Csakany GM, Melczer Z, Speer G, Kovacs M, Siller G, Karadi I, Winkler G. Source: European Journal of Endocrinology / European Federation of Endocrine Societies. 2002 August; 147(2): 243-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12153747&dopt=Abstract
•
Cost-effectiveness analysis of gestational diabetes mellitus screening in France. Author(s): Poncet B, Touzet S, Rocher L, Berland M, Orgiazzi J, Colin C. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2002 July 10; 103(2): 122-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12069733&dopt=Abstract
•
Could fasting plasma glucose be used for screening high-risk outpatients for gestational diabetes mellitus? Author(s): de Aguiar LG, de Matos HJ, de Brito Gomes M. Source: Diabetes Care. 2001 May; 24(5): 954-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11347763&dopt=Abstract
Studies
75
•
Counterpoint: glucose monitoring in gestational diabetes: lots of heat, not much light. Author(s): Buchanan TA, Kjos SL. Source: Diabetes Care. 2003 March; 26(3): 948-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12610065&dopt=Abstract
•
C-reactive protein and gestational diabetes: the central role of maternal obesity. Author(s): Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B. Source: The Journal of Clinical Endocrinology and Metabolism. 2003 August; 88(8): 3507-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12915627&dopt=Abstract
•
Critical appraisal of published research evidence: treatment of gestational diabetes. Author(s): Dornan T, Hollis S. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2001 May; Suppl 3: 1-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11534305&dopt=Abstract
•
Current controversies in the mechanisms and treatment of gestational diabetes. Author(s): Tamas G, Kerenyi Z. Source: Curr Diab Rep. 2002 August; 2(4): 337-46. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12643194&dopt=Abstract
•
Cutoff value of 1 h, 50 g glucose challenge test for screening of gestational diabetes mellitus in a Japanese population. Author(s): Miyakoshi K, Tanaka M, Ueno K, Uehara K, Ishimoto H, Yoshimura Y. Source: Diabetes Research and Clinical Practice. 2003 April; 60(1): 63-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12639767&dopt=Abstract
•
Decompensation of leucine nitrogen kinetics in gestational diabetes mellitus. Author(s): Kalhan S, Rossi K, Gruca L. Source: Diabetes Care. 2000 July; 23(7): 1033-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10895870&dopt=Abstract
•
Decrease in incidence of gestational diabetes mellitus in far north Queensland between 1992 and 1996. Author(s): Humphrey M. Source: The Australian & New Zealand Journal of Obstetrics & Gynaecology. 2000 August; 40(3): 362. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11065055&dopt=Abstract
76
Gestational Diabetes
•
Decreased insulin binding in Asian Indian women with gestational diabetes mellitus. Author(s): Ramachandran A, Susheela L, Mohan V, Kuzhali DA, Viswanathan M. Source: Acta Diabetol Lat. 1989 April-June; 26(2): 123-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2675519&dopt=Abstract
•
Decreased insulin receptor tyrosine kinase activity and plasma cell membrane glycoprotein-1 overexpression in skeletal muscle from obese women with gestational diabetes mellitus (GDM): evidence for increased serine/threonine phosphorylation in pregnancy and GDM. Author(s): Shao J, Catalano PM, Yamashita H, Ruyter I, Smith S, Youngren J, Friedman JE. Source: Diabetes. 2000 April; 49(4): 603-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10871198&dopt=Abstract
•
Delayed metabolic and thermogenic response to a mixed meal in normoglycemic European women with previous gestational diabetes. Author(s): Kousta E, Parker KH, Lawrence NJ, Penny A, Millauer BA, Anyaoku V, Mulnier H, Forster DC, MacDonald IA, Robinson S, McCarthy MI, Johnston DG. Source: The Journal of Clinical Endocrinology and Metabolism. 2002 July; 87(7): 3407-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12107258&dopt=Abstract
•
Detecting glucose intolerance after gestational diabetes: inadequacy of fasting glucose alone and risk associated with gestational diabetes and second trimester waist-hip ratio. Author(s): Jacob Reichelt AA, Ferraz TM, Rocha Oppermann ML, Costa e Forti A, Duncan BB, Fleck Pessoa E, Schmidt MI. Source: Diabetologia. 2002 March; 45(3): 455-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11914756&dopt=Abstract
•
Determinants of fetal growth at different periods of pregnancies complicated by gestational diabetes mellitus or impaired glucose tolerance. Author(s): Schaefer-Graf UM, Kjos SL, Kilavuz O, Plagemann A, Brauer M, Dudenhausen JW, Vetter K. Source: Diabetes Care. 2003 January; 26(1): 193-8. Erratum In: Diabetes Care. 2003 April; 26(4): 1329. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12502680&dopt=Abstract
•
Determinants of mild gestational hyperglycemia and gestational diabetes mellitus in a large dutch multiethnic cohort. Author(s): Weijers RN, Bekedam DJ, Smulders YM. Source: Diabetes Care. 2002 January; 25(1): 72-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11772904&dopt=Abstract
Studies
77
•
Determination of cytokine mRNA-expression in term human placenta of patients with gestational hypertension, intrauterine growth retardation and gestational diabetes mellitus using polymerase chain reaction. Author(s): Heinig J, Wilhelm S, Muller H, Briese V, Bittorf T, Brock J. Source: Zentralblatt Fur Gynakologie. 2000; 122(8): 413-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11005132&dopt=Abstract
•
Diabetes and abnormal glucose tolerance in women with previous gestational diabetes. Author(s): Albareda M, Caballero A, Badell G, Piquer S, Ortiz A, de Leiva A, Corcoy R. Source: Diabetes Care. 2003 April; 26(4): 1199-205. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12663597&dopt=Abstract
•
Diabetes Prevention in high-risk women with gestational diabetes. Author(s): Banerji MA. Source: Curr Diab Rep. 2003 June; 3(3): 185-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12762964&dopt=Abstract
•
Diabetic family history is an isolated risk factor for gestational diabetes after 30 years of age. Author(s): Chan LY, Wong SF, Ho LC. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2002 February; 81(2): 115-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11942900&dopt=Abstract
•
Diagnosing gestational diabetes mellitus. Is the gold standard valid? Author(s): Naylor CD. Source: Diabetes Care. 1989 September; 12(8): 565-72. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2673696&dopt=Abstract
•
Diagnosis of gestational diabetes by use of a glucose polymer. Author(s): Reece EA, Gabrielli S, Abdalla M, O'Connor T, Bargar M, Hobbins JC. Source: American Journal of Obstetrics and Gynecology. 1989 February; 160(2): 383-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2916622&dopt=Abstract
•
Did publication of a clinical practice guideline recommendation to screen for type 2 diabetes in women with gestational diabetes change practice? Author(s): Clark HD, van Walraven C, Code C, Karovitch A, Keely E. Source: Diabetes Care. 2003 February; 26(2): 265-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12547846&dopt=Abstract
78
Gestational Diabetes
•
Dietary regulation for 'gestational diabetes'. Author(s): Walkinshaw SA. Source: Cochrane Database Syst Rev. 2000; (2): Cd000070. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10796112&dopt=Abstract
•
Dietary therapy for gestational diabetes: how long is long enough? Author(s): McFarland MB, Langer O, Conway DL, Berkus MD. Source: Obstetrics and Gynecology. 1999 June; 93(6): 978-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10362166&dopt=Abstract
•
Does insulin secretion in patients with one abnormal glucose tolerance test value mimic gestational diabetes mellitus? Author(s): Ergin T, Lembet A, Duran H, Kuscu E, Bagis T, Saygili E, Batioglu S. Source: American Journal of Obstetrics and Gynecology. 2002 February; 186(2): 204-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11854636&dopt=Abstract
•
Does screening for gestational diabetes mellitus make a difference? Author(s): Sermer M. Source: Cmaj : Canadian Medical Association Journal = Journal De L'association Medicale Canadienne. 2003 February 18; 168(4): 429-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12591783&dopt=Abstract
•
Downregulated IRS-1 and PPARgamma in obese women with gestational diabetes: relationship to FFA during pregnancy. Author(s): Catalano PM, Nizielski SE, Shao J, Preston L, Qiao L, Friedman JE. Source: American Journal of Physiology. Endocrinology and Metabolism. 2002 March; 282(3): E522-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11832353&dopt=Abstract
•
Early diagnosis of gestational diabetes mellitus and prevention of diabetes-related complications. Author(s): Bartha JL, Martinez-Del-Fresno P, Comino-Delgado R. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2003 July 1; 109(1): 41-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12818441&dopt=Abstract
•
Early glycemic control reduces large-for-gestational-age infants in 250 Japanese gestational diabetes pregnancies. Author(s): Sameshima H, Kamitomo M, Kajiya S, Kai M, Furukawa S, Ikenoue S. Source: American Journal of Perinatology. 2000; 17(7): 371-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12141524&dopt=Abstract
Studies
79
•
Early postpartum metabolic assessment in women with prior gestational diabetes. Author(s): Pallardo F, Herranz L, Garcia-Ingelmo T, Grande C, Martin-Vaquero P, Janez M, Gonzalez A. Source: Diabetes Care. 1999 July; 22(7): 1053-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10388966&dopt=Abstract
•
Early-pregnancy glucose screening for gestational diabetes mellitus. Author(s): Nahum GG, Wilson SB, Stanislaw H. Source: J Reprod Med. 2002 August; 47(8): 656-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12216433&dopt=Abstract
•
Effect of a high monounsaturated fatty acid diet on blood pressure and glucose metabolism in women with gestational diabetes mellitus. Author(s): Lauszus FF, Rasmussen OW, Henriksen JE, Klebe JG, Jensen L, Lauszus KS, Hermansen K. Source: European Journal of Clinical Nutrition. 2001 June; 55(6): 436-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11423920&dopt=Abstract
•
Effect of fetal hyperinsulinism on oral glucose tolerance test results in patients with gestational diabetes mellitus. Author(s): Weiss PA, Scholz HS, Haas J, Tamussino KF. Source: American Journal of Obstetrics and Gynecology. 2001 February; 184(3): 470-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11228505&dopt=Abstract
•
Effect of modem transmission of blood glucose data on telephone consultation time, clinic work flow, and patient satisfaction for patients with gestational diabetes mellitus. Author(s): Kruger DF, White K, Galpern A, Mann K, Massirio A, McLellan M, Stevenson J. Source: Journal of the American Academy of Nurse Practitioners. 2003 August; 15(8): 371-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14509102&dopt=Abstract
•
Effect of selective screening for gestational diabetes. Author(s): Williams CB, Iqbal S, Zawacki CM, Yu D, Brown MB, Herman WH. Source: Diabetes Care. 1999 March; 22(3): 418-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10097921&dopt=Abstract
80
Gestational Diabetes
•
Effects of gestational diabetes on human placental glucose uptake, transfer, and utilisation. Author(s): Osmond DT, Nolan CJ, King RG, Brennecke SP, Gude NM. Source: Diabetologia. 2000 May; 43(5): 576-82. Erratum In: Diabetologia 2000 November; 43(11): 1451. Diabetologia 2001 July; 44(7): 927. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10855532&dopt=Abstract
•
Effects of gestational diabetes on junctional adhesion molecules in human term placental vasculature. Author(s): Babawale MO, Lovat S, Mayhew TM, Lammiman MJ, James DK, Leach L. Source: Diabetologia. 2000 September; 43(9): 1185-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11043866&dopt=Abstract
•
Effects of maternal gestational diabetes on offspring adiposity at 4-7 years of age. Author(s): Vohr BR, McGarvey ST, Tucker R. Source: Diabetes Care. 1999 August; 22(8): 1284-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10480772&dopt=Abstract
•
Effects of new criteria for type 2 diabetes on the rate of postpartum glucose intolerance in women with gestational diabetes. Author(s): Conway DL, Langer O. Source: American Journal of Obstetrics and Gynecology. 1999 September; 181(3): 610-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10486471&dopt=Abstract
•
Elevation of soluble E-selectin levels following gestational diabetes is restricted to women with persistent abnormalities of glucose regulation. Author(s): Lawrence NJ, Kousta E, Penny A, Millauer B, Robinson S, Johnston DG, McCarthy MI. Source: Clinical Endocrinology. 2002 March; 56(3): 335-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11940045&dopt=Abstract
•
Enhanced fetoplacental angiogenesis in pre-gestational diabetes mellitus: the extra growth is exclusively longitudinal and not accompanied by microvascular remodelling. Author(s): Mayhew TM. Source: Diabetologia. 2002 October; 45(10): 1434-9. Epub 2002 September 05. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12378385&dopt=Abstract
•
Etiology and pathogenesis of gestational diabetes. Author(s): Kuhl C. Source: Diabetes Care. 1998 August; 21 Suppl 2: B19-26. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9704223&dopt=Abstract
Studies
81
•
Evaluation of DIABNET, a decision support system for therapy planning in gestational diabetes. Author(s): Hernando ME, Gomez EJ, Corcoy R, del Pozo F. Source: Computer Methods and Programs in Biomedicine. 2000 July; 62(3): 235-48. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10837909&dopt=Abstract
•
Evaluation of light exercise in the treatment of gestational diabetes. Author(s): Garcia-Patterson A, Martin E, Ubeda J, Maria MA, de Leiva A, Corcoy R. Source: Diabetes Care. 2001 November; 24(11): 2006-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11679479&dopt=Abstract
•
Evaluation of T-cell receptor CD3+ gamma delta in gestational diabetes mellitus. Author(s): Lapolla A, Sanzari M, Betterle C, Dalfra MG, Masin M, Zanchetta R, Zancanaro F, Capovilla F, Toniato R, Plebani M, Fedele D. Source: Acta Diabetologica. 2000; 37(4): 207-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11450505&dopt=Abstract
•
Evidence-based screening for gestational diabetes? Author(s): Hadden D. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2000 May; 17(5): 402-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10872544&dopt=Abstract
•
Exercise: the alternative therapeutic intervention for gestational diabetes. Author(s): Artal R. Source: Clinical Obstetrics and Gynecology. 2003 June; 46(2): 479-87. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12808397&dopt=Abstract
•
Factors predictive of recurrent gestational diabetes diagnosed before 24 weeks' gestation. Author(s): Wein P, Dong ZG, Beischer NA, Sheedy MT. Source: American Journal of Perinatology. 1995 September; 12(5): 352-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8540942&dopt=Abstract
•
Factors predisposing to and outcome of gestational diabetes. Author(s): Maresh M, Beard RW, Bray CS, Elkeles RS, Wadsworth J. Source: Obstetrics and Gynecology. 1989 September; 74(3 Pt 1): 342-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2761910&dopt=Abstract
82
Gestational Diabetes
•
Failure to obtain follow-up testing for gestational diabetes in a rural population. Author(s): Jonas GQ. Source: Obstetrics and Gynecology. 1999 September; 94(3): 481. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10472884&dopt=Abstract
•
Fasting plasma glucose as a screening test for gestational diabetes in a multi-ethnic, high-risk population. Author(s): Agarwal MM, Hughes PF, Punnose J, Ezimokhai M. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2000 October; 17(10): 720-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11110505&dopt=Abstract
•
Fasting plasma glucose is a useful test for the detection of gestational diabetes. Brazilian Study of Gestational Diabetes (EBDG) Working Group. Author(s): Reichelt AJ, Spichler ER, Branchtein L, Nucci LB, Franco LJ, Schmidt MI. Source: Diabetes Care. 1998 August; 21(8): 1246-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9702428&dopt=Abstract
•
Fasting plasma glucose test at the first prenatal visit as a screen for gestational diabetes. Author(s): Sacks DA, Chen W, Wolde-Tsadik G, Buchanan TA. Source: Obstetrics and Gynecology. 2003 June; 101(6): 1197-203. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12798525&dopt=Abstract
•
Fetal erythrocyte phospholipid polyunsaturated fatty acids are altered in pregnancy complicated with gestational diabetes mellitus. Author(s): Wijendran V, Bendel RB, Couch SC, Philipson EH, Cheruku S, Lammi-Keefe CJ. Source: Lipids. 2000 August; 35(8): 927-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10984116&dopt=Abstract
•
Fetal hyperinsulinism at 14-20 weeks and subsequent gestational diabetes. Author(s): Carpenter MW, Canick JA, Star J, Carr SR, Burke ME, Shahinian K. Source: Obstetrics and Gynecology. 1996 January; 87(1): 89-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8532274&dopt=Abstract
•
Fetal lung maturity in pregnancies complicated by insulin-dependent and gestational diabetes: a matched cohort study. Author(s): Piazze JJ, Anceschi MM, Maranghi L, Brancato V, Marchiani E, Cosmi EV. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 1999 April; 83(2): 145-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10391524&dopt=Abstract
Studies
83
•
Fetal outcome in gestational diabetes with elevated amniotic fluid insulin levels. Dietary versus insulin treatment. Author(s): Weiss PA, Hofmann HM, Kainer F, Haas JG. Source: Diabetes Research and Clinical Practice. 1988 May 19; 5(1): 1-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3042342&dopt=Abstract
•
Fetal overnutrition in polynesian pregnancies and in gestational diabetes may lead to dysregulation of the adipoinsular axis in offspring. Author(s): Simmons D, Breier BH. Source: Diabetes Care. 2002 September; 25(9): 1539-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12196424&dopt=Abstract
•
First-trimester blood pressure and gestational diabetes in high-risk Chinese women. Author(s): Lao TT, Ho LF. Source: Journal of the Society for Gynecologic Investigation. 2003 February; 10(2): 94-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12593998&dopt=Abstract
•
First-trimester C-reactive protein and subsequent gestational diabetes. Author(s): Wolf M, Sandler L, Hsu K, Vossen-Smirnakis K, Ecker JL, Thadhani R. Source: Diabetes Care. 2003 March; 26(3): 819-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12610043&dopt=Abstract
•
First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus. Author(s): Thadhani R, Wolf M, Hsu-Blatman K, Sandler L, Nathan D, Ecker JL. Source: American Journal of Obstetrics and Gynecology. 2003 July; 189(1): 171-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12861158&dopt=Abstract
•
Foetal outcome in gestational diabetes in south Indians. Author(s): Ramachandran A, Snehalatha C, Clementina M, Sasikala R, Vijay V. Source: Diabetes Research and Clinical Practice. 1998 September; 41(3): 185-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9829347&dopt=Abstract
•
Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Overview and commentary on first session. Author(s): Oats JJ. Source: Diabetes Care. 1998 August; 21 Suppl 2: B58-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9704228&dopt=Abstract
84
Gestational Diabetes
•
Free fatty acids and gestational diabetes mellitus. Author(s): Meyer B, Calvert D, Moses R. Source: The Australian & New Zealand Journal of Obstetrics & Gynaecology. 1996 August; 36(3): 255-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8883745&dopt=Abstract
•
Frequency of islet autoantibodies in relatives of patients with Type II diabetes or gestational diabetes. Author(s): Naserke HE, Schenker M, Ziegler AG. Source: Diabetologia. 1999 November; 42(11): 1377. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10550425&dopt=Abstract
•
Fructosamine in the management of gestational diabetes. Author(s): Roberts AB, Baker JR, James AG, Henley P. Source: American Journal of Obstetrics and Gynecology. 1988 July; 159(1): 66-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3394755&dopt=Abstract
•
Fuel metabolism in pregnancy and in gestational diabetes mellitus. Author(s): Boden G. Source: Obstetrics and Gynecology Clinics of North America. 1996 March; 23(1): 1-10. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8684772&dopt=Abstract
•
Gestational diabetes and its impact on the neonate. Author(s): Jones CW. Source: Neonatal Netw. 2001 September; 20(6): 17-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12144115&dopt=Abstract
•
Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Author(s): Kim C, Newton KM, Knopp RH. Source: Diabetes Care. 2002 October; 25(10): 1862-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12351492&dopt=Abstract
•
Gestational diabetes complicated by hydramnios was not associated with increased risk of perinatal morbidity and mortality. Author(s): Shoham I, Wiznitzer A, Silberstein T, Fraser D, Holcberg G, Katz M, Mazor M. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2001 December 10; 100(1): 46-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11728656&dopt=Abstract
Studies
85
•
Gestational diabetes in Victoria in 1996: incidence, risk factors and outcomes. Author(s): Stone CA, McLachlan KA, Halliday JL, Wein P, Tippett C. Source: The Medical Journal of Australia. 2002 November 4; 177(9): 486-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12405890&dopt=Abstract
•
Gestational diabetes in Victoria in 1996: incidence, risk factors and outcomes. Author(s): Davey RX. Source: The Medical Journal of Australia. 2003 July 21; 179(2): 118; Author Reply 118-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12864728&dopt=Abstract
•
Gestational diabetes mellitus and glucose tolerance test: value of the values. Author(s): Rohilla M. Source: American Journal of Obstetrics and Gynecology. 2002 November; 187(5): 1424; Author Reply 1424-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12439542&dopt=Abstract
•
Gestational diabetes mellitus and lesser degrees of pregnancy hyperglycemia: association with increased risk of spontaneous preterm birth. Author(s): Hedderson MM, Ferrara A, Sacks DA. Source: Obstetrics and Gynecology. 2003 October; 102(4): 850-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14551018&dopt=Abstract
•
Gestational diabetes mellitus and neonatal hyperthyrotropinemia. Author(s): Lao TT, Lee CP. Source: Gynecologic and Obstetric Investigation. 2002; 53(3): 135-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12053096&dopt=Abstract
•
Gestational diabetes mellitus in women of single gravidity in Tianjin City, China. Author(s): Yang X, Hsu-Hage B, Zhang H, Yu L, Dong L, Li J, Shao P, Zhang C. Source: Diabetes Care. 2002 May; 25(5): 847-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11978679&dopt=Abstract
•
Gestational diabetes mellitus. Author(s): American Diabetes Association. Source: Diabetes Care. 2003 January; 26 Suppl 1: S103-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12502631&dopt=Abstract
•
Gestational diabetes mellitus: a kitchen table approach. Author(s): Vogel E, Anderson K, Raine K, Clandinin T. Source: Can J Diet Pract Res. 2001 Winter; 62(4): 169-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11742557&dopt=Abstract
86
Gestational Diabetes
•
Gestational diabetes mellitus: a call for systematic tracing. Author(s): Tan HH, Tan HK, Lim HS, Tan AS, Lim SC. Source: Ann Acad Med Singapore. 2002 May; 31(3): 281-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12061286&dopt=Abstract
•
Gestational diabetes mellitus: accuracy of Midwives Data Collection. Author(s): Moses RG, Webb AJ, Comber CD. Source: The Medical Journal of Australia. 2003 August 18; 179(4): 218-9; Discussion 219. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12914515&dopt=Abstract
•
Gestational diabetes mellitus: diagnosis, treatment, and beyond. Author(s): Borsello AA, Shickmanter B. Source: Diabetes Educ. 2001 May-June; 27(3): 419. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11912803&dopt=Abstract
•
Gestational diabetes mellitus: diagnosis, treatment, and beyond. Author(s): Simon ER. Source: Diabetes Educ. 2001 January-February; 27(1): 69-74. No Abstract Available. Erratum In: Diabetes Educ 2001 May-June; 27(3): 419. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11912617&dopt=Abstract
•
Gestational diabetes mellitus: is a diagnosis associated with an increase in maternal anxiety and stress in the short and intermediate term? Author(s): Daniells S, Grenyer BF, Davis WS, Coleman KJ, Burgess JA, Moses RG. Source: Diabetes Care. 2003 February; 26(2): 385-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12547867&dopt=Abstract
•
Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes. Author(s): Xiong X, Saunders LD, Wang FL, Demianczuk NN. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2001 December; 75(3): 221-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11728481&dopt=Abstract
•
Gestational diabetes versus obesity as risk factors for pregnancy-induced hypertensive disorders and fetal macrosomia. Author(s): van Hoorn J, Dekker G, Jeffries B. Source: The Australian & New Zealand Journal of Obstetrics & Gynaecology. 2002 February; 42(1): 29-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11926638&dopt=Abstract
Studies
87
•
Gestational diabetes: implications of variation in diagnostic criteria. Author(s): Agarwal MM, Punnose J. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2002 July; 78(1): 45-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12113970&dopt=Abstract
•
Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis. Author(s): Goetzl L, Wilkins I. Source: Journal of Perinatology : Official Journal of the California Perinatal Association. 2002 July-August; 22(5): 403-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12082477&dopt=Abstract
•
Hair chromium content of women with gestational diabetes compared with nondiabetic pregnant women. Author(s): Aharoni A, Tesler B, Paltieli Y, Tal J, Dori Z, Sharf M. Source: The American Journal of Clinical Nutrition. 1992 January; 55(1): 104-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1728809&dopt=Abstract
•
Heavy-for-date infants: their backgrounds and relationship with gestational diabetes. Author(s): Hiramatsu Y, Masuyama H, Mizutani Y, Kudo T, Oguni N, Oguni Y. Source: The Journal of Obstetrics and Gynaecology Research. 2000 June; 26(3): 193-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10932981&dopt=Abstract
•
Height and gestational diabetes mellitus. Author(s): Tabak AG, Kerenyi Z, Nagy E, Bosnyak Z, Madarasz E, Tamas G. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2002 April; 19(4): 344-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11943010&dopt=Abstract
•
High frequency of antithyroid autoantibodies in pregnant women at increased risk of gestational diabetes mellitus. Author(s): Olivieri A, Valensise H, Magnani F, Medda E, De Angelis S, D'Archivio M, Sorcini M, Carta S, Baccarini S, Romanini C. Source: European Journal of Endocrinology / European Federation of Endocrine Societies. 2000 December; 143(6): 741-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11124856&dopt=Abstract
88
Gestational Diabetes
•
High prevalence of gestational diabetes in women from ethnic minority groups. Author(s): Dornhorst A, Paterson CM, Nicholls JS, Wadsworth J, Chiu DC, Elkeles RS, Johnston DG, Beard RW. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 1992 November; 9(9): 820-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1473322&dopt=Abstract
•
High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. Author(s): Holte J, Gennarelli G, Wide L, Lithell H, Berne C. Source: The Journal of Clinical Endocrinology and Metabolism. 1998 April; 83(4): 114350. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9543131&dopt=Abstract
•
Higher carbohydrate intake is associated with decreased incidence of newborn macrosomia in women with gestational diabetes. Author(s): Romon M, Nuttens MC, Vambergue A, Verier-Mine O, Biausque S, Lemaire C, Fontaine P, Salomez JL, Beuscart R. Source: Journal of the American Dietetic Association. 2001 August; 101(8): 897-902. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11501863&dopt=Abstract
•
History of gestational diabetes leads to distinct metabolic alterations in nondiabetic African-American women with a parental history of type 2 diabetes. Author(s): Osei K, Gaillard TR, Schuster DP. Source: Diabetes Care. 1998 August; 21(8): 1250-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9702429&dopt=Abstract
•
History of gestational diabetes, insulin resistance and coronary risk. Author(s): Davis CL, Gutt M, Llabre MM, Marks JB, O'Sullivan MJ, Potter JE, Landel JL, Kumar M, Schneiderman N, Gellman M, Skyler JS. Source: Journal of Diabetes and Its Complications. 1999 July-August; 13(4): 216-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10616862&dopt=Abstract
•
HLA antigens and islet cell antibodies in gestational diabetes. Author(s): Rubinstein P, Walker M, Krassner J, Carrier C, Carpenter C, Dobersen MJ, Notkins AL, Mark EM, Nechemias C, Hausknecht RU, Ginsberg-Fellner F. Source: Human Immunology. 1981 November; 3(3): 271-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7031028&dopt=Abstract
Studies
89
•
HLA antigens in asymptomatic diabetes. A 10-year follow-up study of potential diabetes in pregnancy and gestational diabetes. Author(s): Mawhinney H, Hadden DR, Middleton D, Harley JM, Montgomery DA. Source: Ulster Med J. 1979; 48(2): 166-72. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=505670&dopt=Abstract
•
Hormonal choices after gestational diabetes. Subsequent pregnancy, contraception, and hormone replacement. Author(s): Kjos SL, Peters RK, Xiang A, Schaefer U, Buchanan TA. Source: Diabetes Care. 1998 August; 21 Suppl 2: B50-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9704227&dopt=Abstract
•
Hormonal parameters in gestational diabetes mellitus during the third trimester: high glucagon levels. Author(s): Grigorakis SI, Alevizaki M, Beis C, Anastasiou E, Alevizaki CC, Souvatzoglou A. Source: Gynecologic and Obstetric Investigation. 2000; 49(2): 106-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10671817&dopt=Abstract
•
Hypertension in women with gestational diabetes. Author(s): Roberts R. Source: Diabetes Care. 1998 August; 21 Suppl 2: B27-32. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9704224&dopt=Abstract
•
Hypertensive disorders of pregnancy and gestational diabetes mellitus in mature gravidae. Author(s): Chin RK. Source: Br J Clin Pract. 1990 December; 44(12): 560-1. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2102143&dopt=Abstract
•
Impact of different levels of carbohydrate intolerance on neonatal outcomes classically associated with gestational diabetes mellitus. Author(s): Jimenez-Moleon JJ, Bueno-Cavanillas A, Luna-del-Castillo Jde D, GarciaMartin M, Lardelli-Claret P, Galvez-Vargas R. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2002 April 10; 102(1): 36-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12039087&dopt=Abstract
90
Gestational Diabetes
•
Impact of prenatal glucose screening on the diagnosis of gestational diabetes and on pregnancy outcomes. Author(s): Wen SW, Liu S, Kramer MS, Joseph KS, Levitt C, Marcoux S, Liston RM. Source: American Journal of Epidemiology. 2000 December 1; 152(11): 1009-14; Discussion 1015-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11117609&dopt=Abstract
•
Impaired fasting glucose and impaired glucose tolerance in women with prior gestational diabetes are associated with a different cardiovascular profile. Author(s): Pallardo LF, Herranz L, Martin-Vaquero P, Garcia-Ingelmo T, Grande C, Janez M. Source: Diabetes Care. 2003 August; 26(8): 2318-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12882855&dopt=Abstract
•
Incidence and risk factors for neonatal hypoglycaemia among women with gestational diabetes mellitus in South Auckland. Author(s): Simmons D, Thompson CF, Conroy C. Source: Diabetic Medicine : a Journal of the British Diabetic Association. 2000 December; 17(12): 830-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11168324&dopt=Abstract
•
Incidence and severity of gestational diabetes in Bahrain and Australia. Author(s): el-Shafei AM, Bashmi YA, Beischer NA, Henry OA, Walstab JE. Source: The Australian & New Zealand Journal of Obstetrics & Gynaecology. 1989 August; 29(3 Pt 1): 204-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2604648&dopt=Abstract
•
Incidence of gestational hypertension in gestational diabetes mellitus. Author(s): Kvetny J, Poulsen HF. Source: Archives of Gynecology and Obstetrics. 2003 January; 267(3): 153-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12552326&dopt=Abstract
•
Increased intramyocellular lipid concentration identifies impaired glucose metabolism in women with previous gestational diabetes. Author(s): Kautzky-Willer A, Krssak M, Winzer C, Pacini G, Tura A, Farhan S, Wagner O, Brabant G, Horn R, Stingl H, Schneider B, Waldhausl W, Roden M. Source: Diabetes. 2003 February; 52(2): 244-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12540593&dopt=Abstract
Studies
91
•
Increased plasma leptin in gestational diabetes. Author(s): Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C, Schneider B, Ludvik B, Prager R, Waldhausl W. Source: Diabetologia. 2001 February; 44(2): 164-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11270672&dopt=Abstract
•
Increased retinal vascular tortuosity in gestational diabetes mellitus. Author(s): Boone MI, Farber ME, Jovanovic-Peterson L, Peterson CM. Source: Ophthalmology. 1989 February; 96(2): 251-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2704545&dopt=Abstract
•
Increased risk for gestational diabetes mellitus associated with insulin receptor and insulin-like growth factor II restriction fragment length polymorphisms. Author(s): Ober C, Xiang KS, Thisted RA, Indovina KA, Wason CJ, Dooley S. Source: Genetic Epidemiology. 1989; 6(5): 559-69. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2574127&dopt=Abstract
•
Influence of maternal and fetal glucokinase mutations in gestational diabetes. Author(s): Spyer G, Hattersley AT, Sykes JE, Sturley RH, MacLeod KM. Source: American Journal of Obstetrics and Gynecology. 2001 July; 185(1): 240-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11483936&dopt=Abstract
•
Insulin resistance and beta-cell dysfunction in normoglycaemic European women with a history of gestational diabetes. Author(s): Kousta E, Lawrence NJ, Godsland IF, Penny A, Anyaoku V, Millauer BA, Cela E, Johnston DG, Robinson S, McCarthy MI. Source: Clinical Endocrinology. 2003 September; 59(3): 289-97. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12919151&dopt=Abstract
•
Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. Author(s): Verma A, Boney CM, Tucker R, Vohr BR. Source: The Journal of Clinical Endocrinology and Metabolism. 2002 July; 87(7): 3227-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12107230&dopt=Abstract
•
Insulin response patterns contribute to different perinatal risks in gestational diabetes. Author(s): Yamada H, Hirayama Kato E, Tsuruga R, Ebina Y, Kobashi G, Sagawa T, Makita Z, Koike T, Fujimoto S. Source: Gynecologic and Obstetric Investigation. 2001; 51(2): 103-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11223703&dopt=Abstract
92
Gestational Diabetes
•
Insulin secretion during and after pregnancy in patients with gestational diabetes mellitus. Author(s): Homko C, Sivan E, Chen X, Reece EA, Boden G. Source: The Journal of Clinical Endocrinology and Metabolism. 2001 February; 86(2): 568-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11158010&dopt=Abstract
•
Insulin-meal interval and short-term glucose fluctuation in tightly controlled gestational diabetes mellitus. Author(s): Sameshima H, Kamitomo M, Kajiya S, Kai M, Ikenoue T. Source: The Journal of Maternal-Fetal Medicine. 2001 August; 10(4): 241-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11531149&dopt=Abstract
•
Insulin-sensitivity index and carbohydrate and lipid metabolism in gestational diabetes. Author(s): Bartha JL, Comino-Delgado R, Martinez-Del-Fresno P, Fernandez-Barrios M, Bethencourt I, Moreno-Corral L. Source: J Reprod Med. 2000 March; 45(3): 185-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10756494&dopt=Abstract
•
Intravenous glucose tolerance test in gestational diabetes and pregnancy: 'manual' versus computerized assessment. Author(s): Kanter Y, Kol S, Wiener F. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 1988 April; 27(4): 307-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3289981&dopt=Abstract
•
Irregular menses: an independent risk factor for gestational diabetes mellitus. Author(s): Haver MC, Locksmith GJ, Emmet E. Source: American Journal of Obstetrics and Gynecology. 2003 May; 188(5): 1189-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12748474&dopt=Abstract
•
Is a multiple birth pregnancy a risk factor for gestational diabetes? Author(s): Egeland GM, Irgens LM. Source: American Journal of Obstetrics and Gynecology. 2001 November; 185(5): 1275-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11717676&dopt=Abstract
•
Jelly beans as an alternative to a fifty-gram glucose beverage for gestational diabetes screening. Author(s): Lamar ME, Kuehl TJ, Cooney AT, Gayle LJ, Holleman S, Allen SR. Source: American Journal of Obstetrics and Gynecology. 1999 November; 181(5 Pt 1): 1154-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10561636&dopt=Abstract
Studies
93
•
John B. O'Sullivan: a pioneer in the study of gestational diabetes. Author(s): Knopp RH. Source: Diabetes Care. 2002 May; 25(5): 943-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11978704&dopt=Abstract
•
Kallmann's syndrome: pregnancy through intracytoplasmic sperm injection and complicated by gestational diabetes. Author(s): Szilagyi A, Manfai Z, Kiesel L, Szabo I. Source: Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology. 2001 October; 15(5): 325-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11727353&dopt=Abstract
•
Ketoacidosis during gestational diabetes. Case report. Author(s): Pitteloud N, Binz K, Caulfield A, Philippe J. Source: Diabetes Care. 1998 June; 21(6): 1031-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9614632&dopt=Abstract
•
Laboratory monitoring of gestational diabetes. Author(s): Narayanan S. Source: Ann Clin Lab Sci. 1991 November-December; 21(6): 392-401. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1781664&dopt=Abstract
•
Late complications of gestational diabetes--maternal effects. Author(s): Nagy G. Source: Zentralblatt Fur Gynakologie. 1993; 115(10): 450-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8273435&dopt=Abstract
•
Leptin administration prevents spontaneous gestational diabetes in heterozygous Lepr(db/+) mice: effects on placental leptin and fetal growth. Author(s): Yamashita H, Shao J, Ishizuka T, Klepcyk PJ, Muhlenkamp P, Qiao L, Hoggard N, Friedman JE. Source: Endocrinology. 2001 July; 142(7): 2888-97. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11416008&dopt=Abstract
•
Levels of advanced glycosylation end-products (AGE) in sera of pregnant diabetic women: comparison between type 1, type 2 and gestational diabetes mellitus. Author(s): Buongiorno AM, Morelli S, Sagratella E, Castaldo P, Di Virgilio A, Maroccia E, Ricciardi G, Sciullo E, Cardellini G, Fallucca F, Sensi M. Source: Ann Ist Super Sanita. 1997; 33(3): 375-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9542265&dopt=Abstract
94
Gestational Diabetes
•
Lipid metabolism alterations in patients with gestational diabetes mellitus associated fetal macrosomia. Author(s): Ersanli ZO, Damci T, Sen C, Hacibekiroglu M, Gorpe U, Ozyazar M, Ilkova H, Bagriacik N. Source: Ann Ist Super Sanita. 1997; 33(3): 411-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9542273&dopt=Abstract
•
Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Author(s): Tiikkainen M, Tamminen M, Hakkinen AM, Bergholm R, Vehkavaara S, Halavaara J, Teramo K, Rissanen A, Yki-Jarvinen H. Source: Obesity Research. 2002 September; 10(9): 859-67. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12226133&dopt=Abstract
•
Long term follow up of women who have had gestational diabetes. Author(s): Holt TA. Source: The British Journal of General Practice : the Journal of the Royal College of General Practitioners. 1992 September; 42(362): 354-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1457167&dopt=Abstract
•
Longitudinal assessment